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1 Summary 
	  The	  cancer	  anorexia-­‐cachexia	  syndrome	  (CACS)	  is	  characterized	  by	  reduced	  eating	  and	  body	  weight	   loss,	  which	   is	   the	   consequence	   of	   reduced	   fat	   and	  muscle	  mass.	   CACS	   is	  present	   in	   up	   to	  85%	  of	   cancer	  patients	   and	   represents	   the	  most	   significant	   negative	  predictor	   of	   treatment	   outcome.	   Importantly,	   it	   also	   deteriorates	   quality	   of	   life	   and	  leads	   to	   severe	   psychological	   suffering	   of	   patients	   and	   their	   families.	   The	   currently	  available	  therapeutic	  approaches	  are	  not	  sufficiently	  effective	  and	  poorly	  understood	  as	  far	  as	   the	  underlying	  mode	  of	  action	   is	   concerned.	  Therefore,	   the	   identification	  of	   the	  underlying	  pathophysiology	  and	  the	  development	  of	  new	  pharmacological	  approaches	  against	  CACS	  have	  a	  high	  clinical	  relevance.	  The	   area	   postrema	   (AP)	   and	   the	   nucleus	   tractus	   solitarii	   (NTS)	   are	   two	   important	  brainstem	  centers	   implicated	   in	   the	  mediation	  of	   anorexia,	   emesis	   and	  nausea	  during	  sickness	  conditions.	  However,	  the	  knowledge	  about	  the	  role	  of	  the	  AP	  and	  NTS	  in	  CACS	  is	  very	   limited.	  Recently	  evidence	  suggests	   that	   the	  macrophage	   inhibitory	  cytokine-­‐1	  (MIC-­‐1)	  acts	  as	   circulating	   tumor-­‐derived	   factor	  promoting	  anorexia	  and	  body	  weight	  loss.	  Using	  neurosurgical	  approaches	  we	  examined	  the	  role	  of	  the	  AP	  and	  vagal	  afferents	  projecting	  to	  the	  NTS	  in	  the	  mediation	  of	  cancer	  anorexia	  and	  body	  weight	  loss	  in	  a	  rat	  hepatoma	   tumor	   model.	   Specifically,	   we	   investigated	   whether	   a	   lesion	   of	   the	   AP	   or	  subdiaphragmatic	   vagal	   deafferentation	   attenuate	   anorexia,	   body	  weight,	   muscle	   and	  fat	   loss.	   Moreover,	   MIC-­‐1	   blood	   levels	   were	   analyzed	   at	   different	   time	   points	   during	  cancer	  progression.	  AP	  lesioned	  rats	  were	  protected	  against	  anorexia,	  body	  weight	  loss	  and	  muscle	  atrophy	  induced	  by	  tumor	  growth.	  In	  contrast,	  the	  subdiaphragmatic	  vagal	  deafferentation	  did	  not	  attenuate	  cancer-­‐induced	  anorexia	  or	  body	  weight	  loss.	  Tumor-­‐bearing	  (TB)	  rats	  had	  substantially	  increased	  MIC-­‐1	  levels,	  which	  positively	  correlated	  with	   tumor	   size	   and	   cancer	   progression,	   and	   negatively	   correlated	   with	   food	   intake.	  These	  findings	  demonstrate	  the	  importance	  of	  the	  AP	  in	  the	  central	  mediation	  of	  CACS	  in	  our	  tumor	  model	  and	  support	  a	  pathological	  role	  of	  MIC-­‐1	  as	  a	  tumor-­‐derived	  factor	  mediating	  CACS,	  possibly	  via	  an	  AP-­‐dependent	  action.	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The	   glucagon-­‐like	   peptide-­‐1	   (GLP-­‐1)	   is	   expressed	   in	   neurons	   of	   the	  NTS.	   	   GLP-­‐1ergic	  neurons	  project	   from	  the	  NTS	   to	   the	  AP	  where	   the	  GLP-­‐1	  receptor	   (GLP-­‐1R)	   is	  highly	  expressed.	   GLP-­‐1	   is	   implicated	   in	   malaise,	   nausea	   and	   aversion	   induced	   by	   different	  stimuli.	   Therefore,	   we	   hypothesized	   that	   GLP-­‐1	   signaling	   in	   the	   AP/NTS	   region	   also	  mediates	  anorexia	  following	  tumor	  growth.	  We	  first	  tested	  whether	  a	  pharmacological	  blockade	  of	  brainstem	  GLP-­‐1	  via	   chronic	  delivery	  of	   the	  GLP-­‐1R	  antagonist	  exendin-­‐9	  (Ex-­‐9)	   into	   the	   fourth	   ventricle	   attenuated	   CACS.	   Second,	   we	   investigated	   whether	   a	  genetic	  knockdown	  of	  GLP-­‐1	  expression	   in	   the	  NTS	  ameliorates	  CACS.	  Finally,	  using	  a	  two	  diets	  choice	  paradigm,	  we	  tested	  if	  tumor	  growth	  in	  our	  model	  is	  paralleled	  by	  the	  development	  of	  food	  aversion.	  Pharmacological	  or	  genetic	  blockade	  of	  brainstem	  GLP-­‐1	  signaling	   attenuated	   anorexia,	   body	   weight	   loss	   and	   fat	   depletion.	   Importantly,	   Ex-­‐9	  treatment	  was	   also	   effective	   in	   preventing	  muscle	   degradation.	   Furthermore,	   TB	   rats	  developed	   tumor-­‐induced	   food	  aversion	  because	   their	   flavor	  preference	   turned	   into	  a	  flavor	   rejection	  during	   tumor	  growth.	  Our	  study	   identifies	  brainstem	  GLP-­‐1	  as	   crucial	  mediator	  of	  CACS	  in	  hepatoma	  TB	  rats.	  In	  line	  with	  the	  function	  of	  GLP-­‐1	  as	  a	  mediator	  of	  aversion,	  emesis	  and	  nausea,	  we	  also	  demonstrated	  the	  development	  of	  food	  aversion	  during	  CACS	  in	  this	  model.	  Since	  the	  AP	  lacks	  a	  functional	  the	  blood-­‐brain-­‐barrier,	  the	  GLP-­‐1R	  located	  in	  the	  AP	  represents	  a	  promising	  target	  for	  pharmacological	  approaches	  against	  CACS.	  	  In	   addition	   to	   brainstem	   mechanisms,	   forebrain	   structures	   in	   particular	   the	   arcuate	  nucleus	   (Arc)	   seem	   to	   be	   implicated	   in	   the	  mediation	   of	   CACS.	  Hence,	   the	   underlying	  signaling	  cascades	  influencing	  Arc	  activity	  represent	  potential	  therapeutic	  targets.	  The	  gastric	  hormone	  ghrelin	  positively	  affects	  energy	  balance	  by	  increasing	  food	  intake	  and	  reducing	  energy	  expenditure.	  These	  effects	  are	  mainly	  mediated	  via	  the	  Arc.	  Therefore,	  ghrelin	   mimetics	   are	   another	   possible	   treatment	   against	   CACS.	   Using	   the	  aforementioned	  rat	  hepatoma	  model,	  the	  action	  of	  the	  non-­‐peptidergic	  ghrelin	  receptor	  agonist	  HM01	  energy	  homeostasis	  and	  muscle	  mass	  was	  evaluated.	  TB	  rats	  treated	  with	  HM01	  had	  higher	  food	  intake	  than	  TB	  controls	  and	  were	  protected	  against	  body	  weight	  loss	  and	  muscle	  degradation.	  Moreover,	  TB	  rats	  reduced	  their	  metabolic	  rate	  following	  HM01	  treatment.	  These	  results	  emphasize	  the	  possible	  therapeutic	  usefulness	  of	  ghrelin	  receptor	  agonists	  like	  HM01	  for	  the	  treatment	  of	  CACS.	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In	  conclusion,	  we	  substantiated	  the	  fundamental	  role	  of	  the	  AP	  in	  the	  mediation	  of	  CACS	  in	  our	  tumor	  model	  and	  we	  provided	  evidence	   for	  a	  role	  of	  central	  GLP-­‐1	  signaling	   in	  hepatoma	  TB	  rats.	  Furthermore,	  we	  demonstrated	  the	  therapeutic	  efficacy	  of	  the	  novel	  ghrelin	  analog	  HM01	  in	  the	  context	  of	  CACS.	  Both	  ghrelin	  and	  GLP-­‐1-­‐based	  approaches	  represent	   promising	   options	   for	   the	   treatment	   of	   CACS	   and	   possibly	   other	   forms	   of	  disease-­‐related	  anorexia.	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2 Zusammenfassung 
 Das	  krebsbedingte	  Anorexie-­‐Kachexie-­‐Syndrom	  (engl.	  CACS)	  zeichnet	  sich	  durch	  einen	  Verlust	  des	  Körpergewichts	  aus,	  welchem	  eine	  verminderte	  Nahrungsaufnahme	  und	  ein	  erhöhter	   Fett-­‐	   und	  Muskelmasseabbau	   zugrunde	   liegt.	   CACS	   tritt	   bei	   bis	   zu	   85%	   der	  Krebspatienten	   auf	   und	   ist	   der	  wichtigste	   Faktor,	  welcher	  den	  Therapieerfolg	  negativ	  beeinflusst.	  Zusätzlich	  reduziert	  CACS	  die	  Lebensqualität	  und	  kann	  schwere	  psychische	  Probleme	   bei	   Patienten	   und	   deren	   Familien	   hervorrufen.	   Leider	   sind	   die	   derzeit	  verfügbaren	   therapeutischen	   Ansätze	   nicht	   wirksam	   genug	   und	   deren	   Mechanismen	  unbekannt.	  Folglich	  ist	  die	  Erforschung	  der	  zugrundeliegenden	  Pathophysiologie	  sowie	  die	  Entwicklung	  neuer	  pharmakologischer	  Ansätze	  von	  hoher	  klinischer	  Bedeutung.	  	  Die	   Area	   postrema	   (AP)	   und	   der	   Nucleus	   tractus	   solitarii	   (NTS)	   sind	   zwei	   wichtige	  Zentren	   im	  Hirnstamm,	  die	  bei	   der	  physiologischen	  Kontrolle	  der	  Nahrungsaufnahme	  und	  der	  Vermittlung	  krankheitsbedingter	  Anorexie	   sowie	  bei	  Übelkeit	   und	  Erbrechen	  beteiligt	  sind.	  	  Ihre	  Beteiligung	  bei	  der	  Entstehung	  von	  CACS	  ist	  derzeit	  noch	  unklar.	  Als	  ein	   wichtiger	   tumor-­‐assoziierter	   Faktor	   	   wurde	   kürzlich	   das	   Macrophage	   inhibitory	  
cytokine-­‐1	   (MIC-­‐1)	   identifiziert,	   welches	   Anorexie	   und	   Körpergewichtsverlust,	  wahrscheinlich	   durch	   einen	   direkten	   zentralen	   Effekt	   auslösen	   kann.	   Mittels	  neurochirurgischer	  Ansätze	  haben	  wir	  die	  Rolle	  der	  AP	  und	  der	  vagalen	  Afferenzen,	  die	  zum	  NTS	   projizieren,	   bei	   der	   Vermittlung	   von	   CACS	   anhand	   eines	   Ratten	   Hepatoma-­‐Tumormodells	  untersucht.	  Dabei	  haben	  wir	  erforscht,	   ob	  eine	  Läsion	  der	  AP	  oder	  die	  Deafferenzierung	   der	   subdiaphragmatischen	   vagalen	   Afferenzen	   der	   krebsbedingten	  Reduktion	   von	   Futteraufnahme,	   Körpergewicht	   sowie	   Muskel-­‐	   und	   Fettmasse	  entgegenwirkt.	   Ausserdem	   haben	   wir	   die	   Plasmakonzentration	   von	   MIC-­‐1	   zu	  verschiedenen	   Zeitpunkten	  während	   des	   Tumorwachstums	   untersucht.	   Im	   Gegensatz	  zu	   der	   subdiaphragmatischen	   vagalen	   Deafferenzierung	   hob	   eine	   Läsion	   der	   AP	   die	  tumorbedingte	   Anorexie	   und	   den	   Körpergewichtsverlust	   der	   Ratten	   auf.	   Die	   MIC-­‐1	  Plasmakonzentration	  war	  bei	  tumortragenden	  Ratten	  signifikant	  erhöht	  und	  korrelierte	  positiv	  mit	  der	  Tumorgrösse	  und	  negativ	  mit	  der	  Nahrungsaufnahme.	  Diese	  Ergebnisse	  zeigen	   die	  Wichtigkeit	   der	   AP	   bei	   der	   Entwicklung	   der	   krebsbedingten	   Anorexie	   und	  Körpergewichtsreduktion	   in	   unserem	   Tumormodell	   und	   stützen	   die	   Annahme,	   dass	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MIC-­‐1	  eine	  wichtige	  Rolle	  bei	  der	  Entwicklung	  von	  CACS	  spielt	  und	  vermutlich	  über	  die	  AP	  wirkt.	  	  Das	  Peptid	  „Glucagon-­‐like	  peptide-­‐1“	  (GLP-­‐1)	  wird	  unter	  anderem	  in	  Neuronen	  des	  NTS	  exprimiert.	   Diese	   Neuronen	   projizieren	   zur	   AP,	   die	   eine	   hohe	   Expression	   des	   GLP-­‐1	  Rezeptor	   (GLP-­‐1R)	   aufweist.	   GLP-­‐1	   spielt	   eine	  wichtige	   Rolle	   bei	   der	   Entstehung	   von	  Unwohlsein,	   Übelkeit	   und	   Futteraversion,	   die	   durch	   verschiedene	   Reize	   ausgelöst	  werden	  können.	  Wir	  vermuteten,	  dass	  auch	  die	  tumorbedingte	  Anorexie	  über	  GLP-­‐1	  in	  der	  AP/NTS-­‐Region	  vermittelt	  werden	  könnte.	  Zunächst	  haben	  wir	  untersucht,	  wie	  sich	  eine	  pharmakologische	  Blockade	  vom	  GLP-­‐1R	   im	  Hirnstamm	  durch	   Infusion	  des	  GLP-­‐1R-­‐Antagonisten	   Exendin-­‐9	   (Ex-­‐9)	   in	   den	   vierten	   Ventrikel	   auf	   das	   CACS	   auswirkt.	  Zusätzlich	  haben	  wir	  getestet,	  ob	  eine	  Reduktion	  der	  GLP-­‐1	  Genexpression	  im	  NTS	  von	  Ratten	   durch	   einen	   genetischen	   GLP-­‐1	   „knockdown“	   vor	   Anorexie	   und	  Körpergewichtsverlust	  bei	  Tumoren	  schützt.	  Schlussendlich	  haben	  wir	  getestet,	  ob	  das	  Tumorwachstum	   in	   unserem	   Modell	   mit	   der	   Entstehung	   einer	   Nahrungsaversion	  assoziiert	  ist.	  Die	  pharmakologische	  sowie	  auch	  die	  genetische	  Inhibition	  von	  GLP-­‐1	  im	  Hirnstamm	   führte	   zu	   verminderter	   Anorexie	   und	   reduziertem	   Körpergewichts-­‐	   und	  Fettverlust.	  Die	  Ex-­‐9	  Behandlung	  verminderte	  zusätzlich	  den	  Muskelabbau.	  Ausserdem	  entwickelten	  tumortragende	  Ratten	  eine	  tumorinduzierte	  Nahrungsaversion	  gegen	  das	  Futter,	   das	   sie	   vor	   Beginn	   des	   Tumorwachstums	   besonders	   gern	   zu	   sich	   nahmen.	  Unsere	   Studien	   zeigen	   somit,	   dass	  GLP-­‐1	   im	  Hirnstamm	  eine	   entscheidende	  Rolle	   bei	  der	   Entwicklung	   von	   CACS	   in	   tumortragenden	   Ratten	   spielt.	   Zusätzlich	   haben	   wir	   in	  diesem	  Modell	   ebenfalls	   die	   Entwicklung	   einer	   Nahrungsaversion	   im	   Zusammenhang	  mit	  CACS	  gezeigt.	  Da	  der	  AP	  eine	  funktionelle	  Blut-­‐Hirn-­‐Schranke	  fehlt,	  sind	  die	  GLP-­‐1	  Rezeptoren	  in	  der	  AP	  ein	  möglicher	  Angriffspunkt	  für	  neuartige	  Therapien	  gegen	  CACS.	  	  Zusätzlich	   zu	   den	   Hirnstammmechanismen	   sind	   offensichtlich	   Strukturen	   im	  Vorderhirn,	   insbesondere	   der	   Nucleus	   Arcuatus	   (Arc),	   an	   der	   Vermittlung	   des	   CACS	  beteiligt.	   Daher	   stellt	   auch	   der	   Arc	   ein	   potenzielles	   therapeutisches	   Ziel	   dar.	   Das	  Hormon	   Ghrelin	   wirkt	   sich	   positiv	   auf	   die	   Energiebilanz	   aus,	   indem	   es	   die	  Nahrungsaufnahme	   erhöht	   und	   den	   Energieverbrauch	   senkt.	   Diese	   Effekte	   werden	  hauptsächlich	   über	   den	   Arc	   vermittelt.	   Deswegen	   stellen	   Ghrelin-­‐Mimetika	  grundsätzlich	   eine	   weitere	   Behandlungsmöglichkeit	   gegen	   CACS	   dar.	   Mittels	   unseres	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3 Introduction 
	  
3.1	   The	  cancer	  anorexia-­‐cachexia	  syndrome	  
	  
3.1.1 Definition 	  The	   cancer	   anorexia-­‐cachexia	   syndrome	   (CACS)	   is	   a	   complex	  multifactorial	   syndrome	  that	  is	  clinically	  characterized	  by	  reduced	  eating	  (anorexia),	  hypermetabolism	  and	  body	  weight	  loss,	  which	  is	  the	  consequence	  of	  reduced	  fat	  and	  especially	  muscle	  mass.	  Other	  symptoms	   of	   CACS	   may	   include	   anemia,	   weakness,	   nausea,	   food	   aversion	   and	  depression	  [1].	  The	  origin	  of	  the	  terms	  anorexia	  and	  cachexia	  is	  Greek.	  Anorexia	  is	  the	  combination	  of	  the	  term	  “an”	  (no)	  and	  “orexis”	  (appetite)	  while	  the	  term	  cachexia	  is	  the	  union	  of	  words	  “kakós”	  (bad)	  and	  “hexis”	  (condition	  or	  appearance).	  Although	  anorexia-­‐cachexia	  has	  been	  recognized	  as	  a	  severe	  medical	   illness	   for	  centuries,	   there	  has	  been	  no	  widely	  accepted	  definition.	  Recently	  a	  new	  definition	  of	  CACS	  based	  on	  international	  consensus	  appeared.	  CACS	  is	  defined	  as	  “a	  multifactorial	  syndrome	  characterized	  by	  an	  ongoing	  loss	  of	  skeletal	  muscle	  mass	  (with	  or	  without	   loss	  of	   fat	  mass)	  that	  cannot	  be	  fully	  reversed	  by	  conventional	  nutritional	  support	  and	   leads	   to	  progressive	   functional	  impairment.	   The	   pathophysiology	   is	   characterized	   by	   a	   negative	   protein	   and	   energy	  balance	   driven	   by	   a	   variable	   combination	   of	   reduced	   food	   intake	   and	   abnormal	  metabolism”	  [2].	  	  	  
3.1.2  Epidemiology 	  CACS	  affects	  more	  than	  a	  half	  million	  of	  cancer	  patients	  in	  the	  US	  and	  roughly	  1	  million	  in	  Europe	  [3].	  Nearly	  85%	  of	  patients	  with	  gastric	  and	  pancreatic	  cancers	  exhibit	  CACS,	  whereas	  CACS	  was	  reported	   in	  approximately	  50%	  of	   lung,	  prostate	  and	  colon	  cancer	  [4,	   5].	   On	   the	   other	   hand,	   less	   than	   one	   third	   of	   the	   patients	   suffering	   from	   acute	  leukemia	   and	   breast	   cancer	   developed	   CACS	   [6].	   Its	   severity	   is	   both	   age	   and	   cancer	  specific.	  The	  greatest	  body	  weight	  loss	  can	  be	  observed	  in	  patients	  with	  solid	  tumors,	  in	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particular	   in	   lung,	   gastric	   and	   pancreas	   cancer	   patients.	   Furthermore,	   CACS	   is	   more	  common	  in	  children	  and	  elderly	  patients	  and	  becomes	  more	  pronounced	  as	  the	  disease	  progresses	  [7].	  At	  the	  time	  of	  diagnosis	  (i.e.	  before	  any	  treatment),	  80%	  of	  patients	  with	  upper	   gastrointestinal	   cancers	   and	   60%	   of	   patients	   with	   lung	   cancer	   have	   already	  experienced	  substantial	  weight	  loss	  [5].	  	  
3.1.3  Clinical relevance 	  CACS	   is	   associated	   with	   reduced	   survival.	   Patients	   who	   show	   prolonged	   weight	   loss	  over	   time	   have	   a	   significantly	   worse	   prognosis	   [1,	   5].	   This	   is	   presumably	   the	  consequence	  of	  increased	  susceptibility	  to	  infections,	  decreased	  tolerance	  to	  anticancer	  therapies	  and	  lack	  of	  essential	  micronutrients	  (e.g.	  iron)	  [8].	  In	  particular,	  cancer	  cells	  of	  those	   patients	   are	   more	   resistant	   to	   cancer-­‐therapies,	   requiring	   higher	   doses	   of	  chemotherapeutic	   agents.	   Unfortunately,	   CACS	   is	   associated	   with	   an	   increased	  prevalence	   of	   chemotherapeutic	   side	   effects,	   leading	   to	   necessary	   dose	   reductions,	  treatment	  delays	  or	  even	  treatment	  abortion.	  Thus,	  patients	  suffering	  from	  CACS	  do	  not	  receive	  the	  full	  potential	  benefit	  of	  the	  actual	  cancer	  therapy	  [8-­‐10].	  The	  mortality	  rate	  of	  patients	  with	  CACS	  reaches	  up	  to	  80%	  per	  year	  [3].	  CACS	  accounts	  for	  20%	  of	  cancer-­‐related	  deaths	  i.e.,	  severe	  cachexia	  was	  the	  only	  symptom	  present	  at	  the	  time	  of	  death	  [11].	   It	   is	  estimated	   that	  each	  year	  CACS	  contributes	   to	  more	   than	  7	  million	  of	  deaths	  worldwide	  [12].	  Notably,	  CACS	  also	  negatively	  impacts	  quality	  of	  life.	  Independency	  and	  physical	  activity	  are	  severely	  compromised	  due	  to	  muscle	  wasting	  and	  the	  involuntary	  body	  weight	   loss	   affects	   patients’	   self-­‐esteem	   and	   identity	   [13,	   14].	   Furthermore,	   the	  loss	   of	   appetite	   and	   nausea	   causes	   psychological	   distress	   and	   is	   associated	   with	  increased	  apathy,	  which	  further	  decreases	  life	  quality	  [15].	  	  
3.1.4  Current therapeutic options 	  The	  effectiveness	  of	  both	  nutritional	  care	  and	  pharmacological	  treatments	  against	  CACS	  is	   unfortunately	   very	   limited	   and	   insufficient	   progress	   has	   been	   made	   in	   the	  development	   of	   specific	   pharmacological	   approaches	   [8].	   	   Hypercaloric	   feeding	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increases	   body	  weight	   but	   does	  not	   affect	   lean	  body	  mass	   or	   survival,	   indicating	   that	  nutritional	   counseling	  alone	   is	   an	   inadequate	   strategy	   [16].	  No	  approved	  drug	   for	   the	  treatment	  of	  CACS	   is	   currently	  available	  and,	  despite	   its	   severity,	  only	   few	   large-­‐scale	  human	   trials	   have	   been	   conducted.	   The	   most	   commonly	   used	   agent,	   the	   appetite	  stimulating	  drug	  megestrol	  acetate,	  only	  moderately	  increases	  eating	  and	  body	  weight.	  However,	   its	   body	  weight	   gaining	   effect	   is	  mainly	   due	   to	  water	   retention	   and	   not	   to	  increased	   lean	  mass	   [17].	  Corticosteroids	  are	  another	  class	  of	  pharmacological	  agents	  used	  for	  the	  treatment	  of	  CACS.	  Although	  they	  do	  not	  promote	  body	  weight	  gain,	   they	  improve	   appetite,	   decrease	   inflammation	   and	   increase	   performance	   status.	  Unfortunately,	  the	  beneficial	  effects	  of	  corticosteroids	  are	  not	  long	  lasting,	  as	  they	  seem	  to	   disappear	   after	   4	  weeks	   of	   treatment.	   Furthermore,	   long-­‐term	   use	   of	   these	   agents	  induces	  severe	  side	  effects.	  Thus,	  corticosteroids	  are	  not	  suitable	  for	  long-­‐term	  use	  and	  recommended	   to	   be	   used	   only	   during	   the	   terminal	   phase	   of	   cachexia	   [8,	   18].	   Other	  drugs	   such	   as	   cannabinoids	   and	   anti-­‐inflammatory	   agents,	   despite	   high	   expectations,	  have	   failed	   to	   show	   tangible	   benefits	   compared	   to	   megestrol	   acetate	   or	   placebo,	  respectively	   [19,	   20].	   A	   vast	   spectrum	   of	   other	   treatments,	   including	   androgens,	  serotonin	   and	   histamine	   receptor	   antagonists,	   has	   been	   studied	   in	   the	   past	   without	  much	   success	   or	   they	   have	   not	   been	   developed	   into	   effective	   therapies	   yet	   [21].	   In	  general,	  medical	  use	  of	  the	  aforementioned	  treatments	  is	  very	  limited	  due	  to	  side	  effects	  (adrenal	   insufficiency,	   thromboembolism,	   insulin	   resistance,	  neurologic	   effects,	   sexual	  dysfunction	  etc.).	  Moreover,	  these	  drugs	  do	  not	  appear	  to	  significantly	  improve	  survival	  and	  general	  quality	  of	   life	   in	  most	  of	   the	  clinical	   trials.	  Therefore,	   the	   identification	  of	  the	   pathophysiological	   mechanisms	   mediating	   CACS	   and	   the	   development	   of	   new	  pharmacological	   approaches	   that	   simultaneously	   tackle	   different	   aspects	   of	   this	  syndrome	  (i.e.	  anorexia,	  inflammation,	  hypermetabolism),	  has	  a	  high	  clinical	  relevance.	  	  	  
3.2  The regulation of energy homeostasis under physiological conditions  	  Living	   organisms	   rely	   on	   energy	   intake	   to	   fulfill	   their	   biological	   functions.	   The	  maintenance	   of	   energy	   homeostasis,	   i.e.	   the	   balance	   between	   energy	   intake	   (calories	  consumed)	  and	  energy	  expenditure,	   is	  essential	  to	  maintain	  a	  stable	  body	  weight	  over	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long	   period	   of	   time	   [22].	   An	   imbalance	   between	   these	   two	   variables	   may	   result	   in	  increased	  or	  decreased	  energy	  deposits	  (primarily	  fat).	  If	  this	  disequilibrium	  lasts	  over	  a	   long	   period	   of	   time,	   it	   may	   lead	   to	   negative	   consequences	   for	   the	   organism	   (e.g.	  cachexia,	   obesity).	   Feeding	   in	  humans	  and	   in	  many	  animals	   is	  organized	   into	  discrete	  meals.	  Meal	  initiation,	  termination,	  size	  and	  frequency	  are	  regulated	  by	  signals	  that	  are	  triggered	   in	   response	   to	   nutrient	   ingestion	   (e.g.	   satiation	   signals)	   as	   well	   as	   signals	  regarding	  the	  status	  of	  the	  energy	  stores	  (i.e.	  adiposity	  signals),	  which	  upon	  peripheral	  release,	  are	  sensed	  and	  integrated	  by	  the	  central	  nervous	  system	  (CNS)	  [22,	  23].	  	  Most	   satiation	   signals	   are	   peptides	   released	   from	   the	   gastrointestinal	   tract	   (GI)	   in	  response	  to	  nutrient	   ingestion.	  These	  signals	   include	  the	  gut	  hormone	  cholecystokinin	  (CCK)	  and	  the	  pancreatic	  hormone	  amylin.	  After	  being	  released,	   they	  can	  either	  reach	  their	  central	  site	  of	  action	  directly	  via	  the	  bloodstream	  or	  act	  in	  a	  paracrine	  manner	  on	  nerve	   afferents	   that	   innervate	   the	   GI.	   For	   instance,	   the	   anorectic	   effect	   of	   CCK	   is	  mediated	  via	   specific	   receptors	  on	  afferent	  vagal	   fibers	   that	   innervate	   the	  gut.	  On	   the	  other	  hand,	  amylin	  acts	  centrally	  by	  directly	  stimulating	  its	  receptors	  expressed	  in	  the	  
area	  postrema	  (AP)	  of	  the	  brainstem	  [24-­‐26].	  The	  satiating	  signals	  acting	  on	  the	  AP	  and	  on	   vagus	   nerve	   terminals	   are	   both	   transmitted	   to	   the	   nucleus	   tractus	   solitarii	   (NTS),	  another	  important	  brainstem	  nucleus	  involved	  the	  control	  of	  eating	  [27].	  	  Adiposity	  signals	  are	  hormones	  secreted	  in	  proportion	  to	  body	  fat	  thus	  providing	  long-­‐term	  information	  about	  the	  energy	  source	  of	  the	  body.	  The	  best-­‐characterized	  adiposity	  signals	  are	  leptin,	  which	  is	  secreted	  by	  adipocytes,	  and	  the	  pancreatic	  hormone	  insulin.	  [24-­‐26].	   Both	   leptin	   and	   insulin	   act	   via	   the	   arcuate	   nucleus	   (Arc)	   to	   control	   feeding	  behavior.	   Leptin	   and	   insulin	   exert	   their	   direct	   effects	   on	   feeding	   by	   stimulating	   pro-­‐opiomelanocortin	   (POMC)	   neurons,	   which	   express	   the	   anorexigenic	   transmitters	   α-­‐melanocyte	   stimulating	   hormone	   (αMSH)	   and	   cocaine-­‐	   and	   amphetamine-­‐regulated	  transcript	   (CART),	   and	   by	   inhibiting	   neurons	   releasing	   the	   orexigenic	   neuropeptides	  agouti-­‐related	  peptide	  (AgRP)	  and	  neuropeptide	  Y	  (NPY)	  [28-­‐31].	  	  In	   addition	   to	   adiposity	   signals,	   the	   hunger	   hormone	   ghrelin	   also	   exerts	   its	   eating-­‐promoting	   effects	   mainly	   via	   the	   Arc.	   Ghrelin	   is	   the	   best-­‐characterized	   peripheral	  orexigenic	   peptide	   [32].	   It	   is	   secreted	   by	   the	   stomach	   shortly	   before	   meals	   and	  functionally	   counteracts	   leptin	   and	   insulin	   by	   activating	   NPY	   neurons	   and	   inhibiting	  POMC	  neurons	  [28,	  30,	  31,	  33].	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3.3  The pathophysiology of CACS 
	  Tumor	   growth	   is	   associated	  with	   profound	  metabolic	   and	   neurochemical	   alterations,	  which	  can	  lead	  to	  the	  development	  of	  CACS.	  The	  severe	  loss	  of	  body	  weight	  observed	  in	  cancer	   patients	   is	   due	   to	   a	   combination	   of	   decreased	   energy	   intake	   and	   increased	  energy	   expenditure.	   In	   addition,	   increased	  muscle	   protein	   catabolism	   leads	   to	   severe	  muscle	   degradation	   [6].	   Thus,	   CACS	   fundamentally	   differs	   from	   simple	   starvation	  characterized	  by	  increased	  appetite,	  reduced	  energy	  expenditure	  and	  loss	  of	  fat	  but	  not	  lean	  mass	   [34].	  Many	  of	   the	  processes	  contributing	   to	  CACS	  are	  mediated	  by	  humoral	  factors	   acting	   centrally	   on	   brain	   areas	   involved	   in	   the	   control	   of	   energy	   balance	   and	  acting	  peripherally	  on	  muscles	  [1,	  35].	  	  Among	  other	  factors,	  inflammatory	  cytokines	  released	  by	  the	  tumor-­‐itself	  or	  by	  the	  host	  immune	  system	  play	  a	  major	  role	  in	  development	  of	  CACS	  [36].	  	  The	  role	  of	  cytokines	  as	  mediators	   of	   anorexia	   was	   established	   in	   models	   of	   acute	   inflammation,	   e.g.	   after	  treatment	   with	   the	   bacterial	   endotoxin	   lipopolysaccharide	   (LPS)	   [37].	   Furthermore,	  acute	  and	  chronic	  administration	  of	  different	  cytokines,	  such	  as	  TNF-­‐α,	  IL-­‐6,	  IL-­‐1β	  and	  INF-­‐γ,	  either	  alone	  or	  in	  combination,	  are	  capable	  of	  reducing	  food	  intake	  and	  inducing	  body	   weight	   loss	   [35-­‐38].	   In	   addition	   to	   these	   classical	   inflammatory	   cytokines,	   the	  recently	   discovered	  macrophage	   inhibitory	   cytokine-­‐1	   (MIC-­‐1)	   also	   induces	   anorexia	  and	  body	  weight	   loss	  [39].	  The	  anorectic	  effects	  of	  cytokines	  were	  also	  observed	  after	  central	  cytokine	  injections,	  suggesting	  a	  direct	  involvement	  of	  the	  brain	  [40-­‐42].	  Indeed,	  several	   cytokine	   receptors	   (including	   IL-­‐1β,	   TNF-­‐α	   and	   IFN-­‐γ)	   are	   expressed	   in	   the	  brainstem	   and	   the	   hypothalamus	   [43,	   44].	   	   Moreover,	   cytokine	   treatment	   leads	   to	  neuronal	  activation	  in	  brain	  regions	  controlling	  energy	  homeostasis,	  as	  determined	  by	  the	  detection	  of	  the	  marker	  c-­‐Fos	  [45-­‐47].	  Circulating	  cytokines	  may	  reach	  brain	  areas	  involved	   in	   the	   control	   of	   eating	   via	   active	   transport	   or	   through	   regions	   of	   the	   brain	  lacking	  a	   functional	  blood-­‐brain	  barrier	   (BBB)	   [37,	  38,	  43,	  48,	  49].	   In	   addition	   to	   this	  humoral	   pathway,	   vagal	   afferent	   signaling	   can	   also	   contribute	   to	   the	   central	  transmission	  of	  cytokines	  effects	  [50,	  51].	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The	  activation	  of	  cytokine	  receptors	  causes	  alterations	  of	  a	  wide	  range	  of	   intracellular	  signaling	  cascades	  inducing	  changes	  in	  gene	  transcription	  and	  in	  neuronal	  activity	  [51].	  For	  instance,	  the	  signal	  transduction	  of	  different	  cytokines	  involves	  the	  phosphorylation	  and	   activation	   of	   transcription	   factors	   of	   the	   STAT	   family	   (signal	   transducers	   and	  activators	  of	  transcription)	  [52].	  The	  leptin	  intracellular	  signaling	  cascade	  also	  involves	  STAT	   signaling,	   suggesting	   that	   cytokines	   induce	   effects	   on	   energy	   homeostasis	   that	  mimic	   leptin	   in	   some	   regards,	   and	   that	   the	   increased	   hypothalamic	   actions	   may	  contribute	  to	  anorexia	  and	  body	  weight	  loss	  [35,	  53].	  Moreover,	  cytokines	  interact	  with	  endothelial	   cells	   of	   the	   BBB	   to	   activate	   the	   transcription	   factor	   NF-­‐κB	   [54,	   55]	   that	  induces	   the	   expression	   of	   prostanoids	   and	   nitric	   oxide	   (NO)	   [56,	   57].	   Both	   NO	   and	  prostanoid	   signaling	   cascades	   play	   an	   important	   role	   in	   transducing	   cytokine	   actions	  into	  a	  modulation	  of	  neuronal	  activity	  [50].	   Similar	   to	   LPS	   injections,	   tumor	   growth	   induces	   peripheral	   and	   central	   expression	   of	  different	   inflammatory	  cytokines	   in	  many	  animal	  models	   for	  CACS	   [58-­‐61].	  Moreover,	  neutralization	   of	   cytokine	   actions	   with	   specific	   antibodies	   partly	   attenuates	   anorexia	  and	   body	  weight	   loss	   [60,	   62-­‐64].	   High	   serum	   levels	   of	   TNF-­‐α,	   IL-­‐6,	   IFN-­‐γ,	   IL-­‐1β	   and	  MIC-­‐1	   also	   occur	   in	   cancer	   patients,	   and	   the	   levels	   of	   these	   cytokines	   correlate	   with	  cancer	  progression	  [65-­‐70]. Cytokines	   also	   contribute	   to	   the	   etiology	   of	   CACS	   by	   direct	   peripheral	   actions	   on	  muscles	   [71,	   72].	   Increased	   inflammatory	   signaling	   negatively	   affects	   muscles	   by	  suppressing	  protein	  synthesis	  and	  increasing	  protein	  degradation	  [6,	  73].	  TNF-­‐α,	  IL-­‐1β,	  IFN-­‐γ	  and	  IL-­‐6	  have	  all	  been	  implicated	  in	  the	  mediation	  of	  muscle	  degradation	  during	  cancer	  [73].	  The	  ubiquitin-­‐proteosome	  pathway	  is	  one	  of	  the	  main	  pathways	  regulating	  muscle	   degradation	   [74].	   Cytokines	   released	   during	   tumor	   growth	   activate	   the	  ubiquitin-­‐proteosome	   pathway	   in	  many	   animal	  models	   as	  well	   as	   in	   humans	   [73,	   75,	  76].	  In	  particular,	  the	  E3	  ligases	  muscle	  atrophy	  F-­‐box	  protein	  (MAFbx/atrogin-­‐1)	  and	  muscle	   RING	   finger	   protein-­‐1	   (MURF-­‐1)	   are	   highly	   upregulated	   during	   cancer	  conditions	   [77-­‐80],	   and	   pharmacological	   blockade	   of	   ubiquitin-­‐proteosome	   pathway	  effectively	  reduces	  muscle	  atrophy	  in	  animal	  models	  for	  CACS	  [81,	  82].	  	  The	  overall	  aim	  of	  the	  thesis	  is	  to	  shed	  more	  light	  on	  the	  neuronal	  mechanisms	  involved	  in	   CACS	   and	   to	   evaluate	   possible	   therapeutic	   strategies.	   Thus,	   the	   putative	   brain	  structures,	   as	   well	   as	   the	   underlying	   neurotransmitter	   involved	   will	   be	   discussed	   in	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details	  in	  the	  following	  chapters.	  	  	  
3.4  Brainstem mechanisms contributing to sickness anorexia and nausea 
	  
3.4.1  The area postrema 	  The	   AP	   is	   a	   component	   of	   the	   dorsal	   vagal	   complex,	   a	   major	   viscerosensory	   and	  autonomic	   center	   of	   the	   brainstem.	   The	   AP	   is	   located	   on	   the	   dorsal	   surface	   of	   the	  medulla	   oblongata	   [83].	   It	   belongs	   to	   a	   group	   of	   brain	   structures	   called	   sensory	  circumventricular	   organs	   (sCVO).	   sCVO	   are	   specialized	   brain	   structures	   situated	   near	  the	   ventricular	   spaces	   in	   the	  midline	   of	   the	   brain.	   They	   are	   densely	   vascularized	   and	  lack	  a	  functional	  BBB.	  In	  mammals,	  sCVO	  include	  the	  AP,	  the	  subfornical	  organ	  and	  the	  vascular	  organ	  of	  lamina	  terminalis	  [84].	  Due	  to	  the	  fenestrated	  capillaries,	  neurons	  of	  the	  sCVO	  can	  be	  reached	  by	  humoral	   factors	   that	  cannot	  cross	   the	  BBB	   in	  other	  brain	  areas	   [85-­‐87].	   The	   AP	   is	   reciprocally	   connected	   to	   a	   variety	   of	   different	   nuclei.	   In	  particular,	  neurons	  located	  in	  the	  AP	  send	  reciprocal	  axonal	  projections	  to	  NTS,	  lateral	  lateral	  parabrachial	  nucleus	  (LPBN)	  and	  dorsal	  motor	  nucleus	  of	  the	  vagus	  (DMN)	  [83,	  88].	  Several	   studies	  demonstrated	   the	   role	  of	   the	  AP	   in	   the	  autonomic	   control	  of	  different	  physiological	   processes	   including	   feeding,	   metabolism,	   fluid	   balance	   and	   the	  cardiovascular	   system	   [87].	   The	   AP	  mediates	   the	   anorexigenic	   effect	   of	   the	   hormone	  amylin,	   which	   is	   co-­‐secreted	  with	   insulin	   by	   β	   pancreatic	   cells	   during	   and	   after	   food	  intake	  [89-­‐91].	  The	  AP	  was	  also	  functionally	  described	  as	  a	  chemoreceptor	  trigger	  zone	  mediating	   emetic	   reflexes	   (e.g.	   vomiting,	   retching	   and	   nausea)	   induced	   by	   noxious	  chemical	   stimuli	   [92,	   93].	   	   These	   effects	   appear	   to	   be	  mediated	   by	   specific	   neuronal	  subpopulations	  that	  are	  distinct	  from	  neurons	  transducing	  amylin’s	  effects	  or	  regulating	  blood	  pressure	  [94].	  Ablation	  of	  the	  AP	  prevents	  vomiting	  in	  response	  to	  many	  different	  emetic	   stimulants	   (e.g.	   radiation,	   chemotherapeutic	   agents)	   in	   different	   animals	  including	  humans	  [95,	  96].	  Different	  studies	  demonstrated	  the	  involvement	  of	  the	  AP	  in	  sickness-­‐related	  anorexia.	   In	   fact,	   neuronal	   activation	  has	  been	   shown	   in	   the	  AP	  after	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immunological	  challenge	  with	  LPS,	  IL-­‐1β	  and	  MIC-­‐1	  [97-­‐99].	  AP	  lesions	  attenuate	  TNF-­‐α	  and	  MIC-­‐1	  induced	  anorexia	  and	  body	  weight	  loss	  [100,	  101].	  	  
3.4.2  The nucleus of the solitary tract  	  The	  AP	   is	   anatomically	  and	   functionally	   linked	  with	   the	  adjacent	  NTS	   [102,	  103].	  The	  caudal	  part	  of	   the	  NTS	  receives	  and	  processes	  vagal	  afferent	   signals	   that	   control	   food	  intake,	   including	   mechanical	   (i.e.	   volumetric	   distension),	   hormonal	   (e.g.	   CCK)	   and	  chemical	  stimuli	  (e.g.	  glucose,	  amino	  acids,	  toxins)	  [27,	  104].	  In	  addition	  to	  the	  AP,	  the	  NTS	   is	   connected	   to	  other	  brain	  areas	   that	   are	   relevant	   for	   the	   control	  of	   food	   intake	  including	  the	  Arc,	  LPBN,	  DMN,	  paraventricular	  nucleus	  (PVN)	  and	  lateral	  hypothalamic	  area	   [104,	  105].	  Similar	   to	   the	  AP,	   the	  NTS	  has	  a	  crucial	   role	   in	   the	  mediation	  of	   food	  aversions	  by	   integrating	  and	  processing	  noxious-­‐related	  vagal	  afferent	  signals	  such	  as	  the	  chemotherapeutic	  agent	  cisplatin,	  the	  toxin	  lithium	  chloride	  (LiCl)	  and	  the	  mucosal	  irritant	   CuSO4	   [27,	   106-­‐110].	   Hence,	   together	   with	   the	   AP,	   the	   NTS	   represents	   an	  important	  site	  of	  convergence	  for	  humoral	  and	  neuronal	  signals	  that	  are	  transmitted	  to	  other	   rostral	   brain	   centers	   relevant	   for	   the	   physiological	   and	   pathological	   control	   of	  energy	  balance	  [102,	  103].	  	  	  
3.4.3  The role of the AP and NTS in the mediation of CACS 	  Despite	  importance	  of	  the	  AP	  and	  NTS	  in	  the	  mediation	  of	  a	  wide	  range	  of	  pathological	  and	  noxious	  stimuli,	  there	  is	  little	  experimental	  evidence	  for	  a	  role	  of	  the	  AP	  or	  NTS	  in	  cancer	   anorexia.	   AP/NTS	   neurons	   are	   activated	   in	   tumor-­‐bearing	   (TB)	   rats	   carrying	  hepatoma	  tumor	  and	  the	  degree	  of	  activation	  correlated	  positively	  with	  tumor	  growth	  and	  negatively	  with	  body	  weight	  gain	   [111];	   thus	  suggesting	  a	   role	  of	   this	  area	   in	   the	  central	  mediation	  of	  CACS.	  However,	   the	  only	  study	  specifically	  addressing	   the	  role	  of	  AP/NTS	  was	  conducted	  using	  a	  rat	  Leydig	  cell	  tumor	  model,	  which	  is	  characterized	  by	  high	  circulating	  estrogen	  levels	  [112].	  Given	  that	  estrogens	  act	  via	  the	  AP/NTS	  region	  to	  reduce	  eating	  [113],	  the	  results	  of	  that	  study	  possibly	  reflected	  the	  anorectic	  effects	  of	  estrogens	  rather	  than	  specific	   tumor-­‐dependent	  signaling	  mechanisms.	   	  Moreover,	   the	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surgical	   approach	   utilized	   to	   ablate	   the	   AP	   also	   lesioned	   major	   parts	   of	   the	   NTS	  resulting	   in	   a	   partial	   destruction	  of	   vagal	   terminal	   fields	   [114].	   Therefore,	   knowledge	  about	  the	  specific	  contribution	  of	  the	  AP	  in	  the	  mediation	  of	  CACS	  is	  very	  limited	  and	  a	  better	   dissociation	   between	   vagal	   and	   AP-­‐dependent	   mechanisms	   is	   required.	   	   In	  addition,	   the	   putative	   mechanism	   leading	   to	   AP/NTS	   activation	   needs	   deeper	  investigation.	  Given	  that	  important	  anatomical	  and	  functional	  link	  between	  the	  AP	  and	  NTS	   it	   is	   logical	   to	  assume	  that	  neuropeptide	  system	  within	  this	  region	  could	  mediate	  the	  presumed	  effects	  on	  energy	  homeostasis	  during	  cancer.	  	  	  
3.4.4  Glucagon-like peptide-1 	  Glucagon-­‐like	   peptide-­‐1	   (GLP-­‐1)	   is	   a	   peptide	   produced	   from	   the	   precursor	   pre-­‐pro-­‐glucagon	  (PPG),	  which	  is	  encoded	  by	  the	  Gcg	  gene.	  GLP-­‐1	  is	  released	  by	  L-­‐cells	  located	  in	   the	  mucosa	   of	   the	   gastrointestinal	   tract	  within	   a	   few	  minutes	   after	  meal	   initiation	  [115-­‐118].	   GLP-­‐1	   was	   initially	   identified	   as	   an	   incretin	   hormone	   for	   its	   ability	   to	  potentiate	   glucose-­‐induced	   insulin	   secretion	   [119].	   Subsequent	   studies	   demonstrated	  the	  importance	  of	  GLP-­‐1	  in	  the	  regulation	  of	  eating;	  particularly	  in	  meal	  termination	  (i.e.	  inducting	  satiation).	  Similarly	  to	  CCK,	  intestinal	  GLP-­‐1	  reduces	  meal	  size	  mainly	  acting	  in	  a	  paracrine	  fashion,	  activating	  the	  vagal	  afferent	  terminals	  located	  adjacent	  to	  the	  site	  of	   release	   [120].	   However,	   both	   central	   and	   peripheral	   GLP-­‐1	   administration	   reduce	  food	   intake	  and	  body	  weight	   [121-­‐124].	  At	   least	  when	   infused	   into	   the	  hepatic	  portal	  vein,	   pharmacological	   doses	   of	   GLP-­‐1	   inhibits	   eating	   via	   direct	   action	   on	   brain	   areas	  important	   for	   the	   control	   of	   energy	   homeostasis	   [125].	   GLP-­‐1	   activates	   the	   GLP-­‐1	  receptor	  (GLP-­‐1R),	  a	  7-­‐transmembrane	  G	  protein-­‐coupled	  receptor	  [126].	  In	  addition	  to	  vagal	   afferent	   terminals,	   GLP-­‐1R	   expression	   has	   been	   identified	   in	  many	   brain	   areas	  relevant	   for	   the	  control	  of	   food	   intake	  and	  energy	  homeostasis	   including	   the	  AP	  [119,	  127-­‐130].	  GLP-­‐1	   is	   also	   produced	   in	   the	   central	   nervous	   system,	   specifically	   in	   enteroceptive	  neurons	  located	  in	  the	  caudal	  NTS	  [127].	  Central	  GLP-­‐1	  is	  released	  from	  axon	  terminals	  of	   GLP-­‐1	   expressing	  NTS	   neurons	   and	   acts	   as	   a	   peptidergic	   neurotransmitter.	   GLP-­‐1-­‐expressing	  neurons	  project	  to	  most	  of	  the	  known	  GLP-­‐1R-­‐expressing	  brain	  areas	  [131,	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132].	   Notably,	   GLP-­‐1	   positive	   terminals	   have	   also	   been	   identified	   in	   the	   AP	   [133]	  suggesting	  that	  brain-­‐intrinsic	  GLP-­‐1	  may	  act	  on	  the	  AP.	  	  	  
3.4.5  Involvement of central GLP-1 in the mediation of sickness anorexia and 
nausea  	  Besides	   its	   presumed	   role	   in	   the	   control	   of	   eating,	   the	   central	   GLP-­‐1	   system	   is	   also	  involved	  in	  the	  mediation	  of	  malaise	  and	  in	  the	  development	  of	  food	  aversions.	  GLP-­‐1	  or	  the	  GLP-­‐1R	  agonist	   exendin-­‐4	   (Ex-­‐4)	   induce	   emesis	   and	  nausea	   in	  humans	   [134-­‐136]	  and	  conditioned	  taste	  aversion	  (CTA)	  in	  rodents	  [137-­‐139].	  Moreover,	  the	  central	  GLP-­‐1	  system	  mediates	  CTA	  and	  malaise	   induced	  by	  LiCl	  and	  cisplatin	  as	  demonstrated	  by	  a	  blockade	   of	   CTA	   and	   anorexia	   by	   fourth	   ventricular	   administration	   of	   the	   GLP-­‐1R	  antagonist	   exendin-­‐9	   (Ex-­‐9)	   [140-­‐142].	   These	   findings	   are	   consistent	   with	  immunohistological	  studies	  showing	  a	  blockade	  of	  LiCl-­‐induced	  AP	  activation	  by	  third	  ventricular	   Ex-­‐9	   treatment	   [137].	   Furthermore,	   LiCl	   and	   cisplatin	   activate	   GLP-­‐1	  expressing	  NTS	  neurons	   [142,	  143].	  There	   is	  also	  evidence	   for	  a	  role	  of	  central	  GLP-­‐1	  signaling	  in	  the	  mediation	  of	  the	  anorectic	  effect	  of	  LPS.	  LPS	  induces	  the	  expression	  of	  c-­‐Fos	   in	   the	   AP/NTS	   region	   [143].	   Similar	   to	   what	   has	   been	   described	   for	   LiCl	   and	  cisplatin	   [137,	   142],	   LPS-­‐induced	   anorexia	   is	   attenuated	   in	   rats	   receiving	   central	  injection	  of	  Ex-­‐9	  [144].	  Interestingly,	  this	  effect	  is	  only	  observed	  when	  Ex-­‐9	  was	  injected	  into	  the	  fourth	  ventricle.	  In	  contrast,	  no	  effects	  of	  Ex-­‐9	  treatment	  on	  LPS	  anorexia	  were	  noticed	  after	  third	  ventricular	  injection,	  suggesting	  that	  the	  brainstem	  GLP-­‐1	  signaling	  (i.e.	  within	  the	  AP/NTS)	  plays	  a	  predominant	  role	  in	  the	  mediation	  of	  sickness-­‐induced	  anorexia	  [144].	  However,	  the	  contribution	  of	  the	  central	  GLP-­‐1	  signaling	  in	  the	  central	  mediation	   of	   CACS	   still	   remains	   unknown.	   Furthermore,	   the	   upstream	   mediator	  responsible	  for	  the	  activation	  of	  the	  AP/NTS	  region	  still	  needs	  to	  be	  identified.	  	  
3.4.6  The macrophage inhibitory cytokine-1 as a potential peripheral mediator 
of CACS via AP/NTS signaling 
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MIC-­‐1	   also	   known	   as	   growth	   differentiation	   factor	   15	   (GDF15)	   belongs	   to	   the	   TGF-­‐β	  superfamily.	   Under	   physiological	   conditions,	   MIC-­‐1	   is	   expressed	   at	   low	   levels	   in	  different	  tissues	  and	  is	  present	  at	  low	  concentration	  in	  the	  blood	  stream	  [145].	  During	  cancer,	   tumor-­‐dependent	  expression	  of	  MIC-­‐1	  can	   increase	  serum	   levels	  by	  up	   to	  100	  fold	  [146-­‐148].	  Several	  clinical	  studies	  support	  its	  potential	  use	  as	  a	  biological	  marker	  for	  prognosis	  and	  diagnosis	  of	  certain	  types	  of	  cancer	  [39,	  70,	  149,	  150].	  Interestingly,	  circulating	  MIC-­‐1	  levels	  often	  correlate	  with	  the	  severity	  of	  CACS,	  pointing	  to	  a	  clinical	  relevance	  of	  MIC-­‐1	  as	  a	  possible	  mediator	  of	  CACS.	  Mice	  overexpressing	  MIC-­‐1	  have	  a	  leaner	   phenotype	   and	   show	   reduced	   food	   consumption	   [151].	   Conversely,	   MIC-­‐1	  knockout	  mice	  show	   increased	  adiposity	   [152].	  More	   importantly,	  MIC-­‐1	  produced	  by	  xenografted	  tumors	  and	  recombinant	  protein	  both	  reduce	  food	  intake	  and	  lead	  to	  body	  weight	  loss	  in	  mice,	  which	  can	  be	  attenuated	  by	  specific	  monoclonal	  antibodies	  against	  MIC-­‐1	   [99].	   In	   mice	   treated	   with	   MIC-­‐1,	   the	   expression	   of	   c-­‐Fos	   in	   the	   AP/NTS	   is	  increased	   [99,	   101].	   In	   line	   with	   these	   observations,	   lesion	   of	   the	   AP/NTS	   prevents	  anorexia	  and	  body	  weight	  loss	  induced	  by	  chronic	  MIC-­‐1	  treatment	  suggesting	  that	  MIC-­‐1	  may	  act	  via	  this	  brain	  region	  to	  inhibit	  food	  intake	  and	  body	  weight	  [101].	  	  
3.5  Hypothalamic and peripheral mechanisms that can be target by 
ghrelin-based anti-CACS treatments 
	  In	   addition	   to	   the	   brainstem,	   forebrain	   structures	   in	   particular	   the	   Arc	   seem	   to	   be	  implicated	   in	   the	   mediation	   of	   CACS.	   Therefore,	   the	   underlying	   signaling	   cascades	  represent	  potential	  therapeutic	  targets.	  	  
	  
3.5.1  The arcuate nucleus 	  The	   Arc	   is	   an	   important	   brain	   structure	   for	   the	   control	   of	   food	   intake	   and	   energy	  balance	   [153].	   It	   is	   located	   in	   the	   ventral	   hypothalamus	   around	   the	   basal	   part	   of	   the	  third	  ventricle,	  in	  close	  proximity	  to	  the	  median	  eminence	  [154].	  Two	  subpopulations	  of	  Arc	   neurons	   exert	   opposite	   effects	   on	   food	   intake	   and	   energy	   balance.	   Neurons	   co-­‐expressing	   NPY	   and	   AgRP	   [155]	   promote	   feeding,	   decrease	   energy	   expenditure	   and	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body	   weight	   gain,	   and	   neurons	   co-­‐expressing	   POMC	   and	   CART	   inhibit	   feeding	   and	  stimulate	  energy	  expenditure	  [156].	  POMC	  is	  a	  precursor	  of	  α-­‐MSH,	  which	  reduces	  food	  consumption	  acting	  on	  melanocortin	  4	  receptors	  (MC4R)	  [157].	  AgRP	  is	  an	  endogenous	  antagonist	  of	  MC4R	  and	  antagonizes	  the	  anorectic	  activity	  of	  POMC	  neurons	  [158].	  NPY	  promotes	  eating	  [159]	  acting	  on	  Y	  receptors	  and	  inhibiting	  POMC	  neurons	  [160].	  Both	  populations	   of	   neurons	   project	   to	   other	   hypothalamic	   areas	   such	   as	   the	   PVN	   and	   the	  lateral	  hypothalamic	  area	  [22,	  161,	  162].	  	  	  
3.5.2  The role of the Arc in the pathophysiology of CACS 	  NPY	   expression	   in	   the	   Arc	   as	   well	   as	   the	   amount	   of	   NPY	   released	   into	   the	   PVN	   are	  reduced	   in	   certain	   rodent	   models	   for	   CACS	   [163,	   164].	   Furthermore,	   the	   orexigenic	  effect	   of	   central	   intra-­‐hypothalamic	   injection	   of	   NPY	   is	   blunted	   in	   rats	   bearing	  methylcholanthrene-­‐induced	   sarcoma	   [165].	   Interestingly,	   MC4R	   knockout	   mice	   and	  rodents	  receiving	  central	  infusion	  of	  AgRP	  or	  its	  analog	  SHU9119	  are	  protected	  against	  CACS	  [166-­‐168].	  The	  effects	  on	  Arc	  NPY	  and	  POMC	  neurons	  observed	  following	  tumor	  growth	   are	   likely	   mediated	   by	   central	   direct	   cytokine	   actions.	   Indeed,	   IL-­‐1β	  administered	   into	   the	   third	   ventricle	   antagonizes	  NPY-­‐induced	   feeding	   and	  decreases	  NPY	  mRNA	  expression	   at	   doses	   that	  mimicked	   the	   cerebrospinal	   fluid	   concentrations	  observed	   in	   TB	   rats	   [42,	   169,	   170].	   Further,	   IL-­‐1β,	   MIC-­‐1	   and	   Leukaemia	   inhibitory	  factor	  stimulate	  POMC	  neurons	  causing	  increased	  α-­‐MSH	  release	  [53,	  99,	  171].	  Overall,	  these	  data	   indicate	   that,	   at	   least	   in	   some	   tumor	  models,	   cytokine	   signaling	   in	   the	  Arc	  plays	  a	  role	  in	  the	  pathophysiology	  of	  CACS,	  suggesting	  that	  substances	  that	  counteract	  or	   override	   cytokine	   actions	   in	   the	   Arc	   or	   promote	   orexigenic	   Arc	   signaling	   may	   be	  therapeutically	   useful	   as	   anti-­‐CACS	   treatment.	   A	   potential	   candidate	   is	   the	   gastric	  hormone	  ghrelin.	  	  
3.5.3  The role of ghrelin in the control of food intake and energy homeostasis 	  Ghrelin	  is	  a	  peptide	  hormone,	  which	  is	  secreted	  into	  the	  circulation	  by	  gastric	  endocrine	  cells,	   i.e.	   X/A-­‐like	   cells	   in	   rodents	   and	   P/D1	   cells	   in	   humans	   [172-­‐174].	   Ghrelin	   is	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encoded	  by	  the	  preproghrelin	  gene	  [175].	  Circulating	  ghrelin	  levels	  rise	  pre-­‐prandially	  and	   decreases	   after	   a	   meal	   [176].	   Ghrelin	   levels	   increase	   under	   food	   restriction	   and	  decrease	   in	   proportion	   to	   the	   amount	   of	   nutrients	   ingested	   [32,	   177-­‐179].	   Ghrelin	   is	  present	   in	   the	   circulation	   in	   two	  major	   forms:	   active	   (i.e.	   acylated	   at	   its	   third	   amino	  acid)	  and	  inactive	  (i.e.	  desacylated).	  Active	  ghrelin	  accounts	  for	  20%	  of	  the	  total	  ghrelin,	  while	  the	  major	  fraction	  of	  ghrelin	  circulates	  in	  its	  inactive	  form	  [172].	  The	  half-­‐life	  of	  active	  ghrelin	  is	  between	  8-­‐9	  minutes	  in	  rats	  and	  13-­‐24	  minutes	  in	  humans	  [180-­‐182].	  The	  name	  “ghrelin”	  is	  derived	  from	  the	  Proto-­‐Indo-­‐European	  “ghre”	  which	  is	  the	  root	  of	  “grow”.	   The	   name	   was	   chosen	   to	   indicate	   its	   ability	   to	   stimulate	   growth	   hormone	  release	   that	   together	   with	   the	   ability	   to	   promote	   eating,	   is	   the	   major	   and	   best-­‐characterized	  effect	  of	  ghrelin	  [172].	  	  In	  various	  electrophysiological	  and	  immunohistological	  studies,	  ghrelin	  has	  been	  shown	  to	   activate	   NPY	   neurons,	   which	   is	   considered	   the	   neuronal	   correlate	   for	   ghrelin’s	  actions	   on	   food	   intake	   and	   bodyweight.	   The	   ghrelin	   receptor,	   also	   known	   as	   growth	  hormone	  secretagogue	  receptor	  (GHSR)	  is	  highly	  expressed	  in	  the	  Arc	  [183].	  94%	  of	  the	  NPY	   neurons	   in	   the	   Arc	   co-­‐express	   GHSR	   and	   belong	   to	   the	   primary	   target	   cells	   for	  ghrelin	   in	   the	   brain	   [184,	   185].	   Peripheral	   administration	   of	   ghrelin	   induces	   c-­‐Fos	  expression	  in	  NPY	  neurons	  in	  the	  Arc	  [186].	  Moreover,	  ghrelin	  also	  increases	  the	  mRNA	  expression	  of	  NPY	  and	  AgRP	  in	  these	  neurons	  [187].	  As	  shown	  by	  electrophysiological	  studies,	  ghrelin	  directly	  activates	  leptin-­‐inhibited	  Arc	  neurons	  [188],	  while	  it	  indirectly	  (presynaptically)	   inhibits	   POMC	   neurons	   [189,	   190].	   Pharmacological	   and	   genetic	  inhibition	  of	  NPY	  neurons	  abolished	  the	  effects	  of	  ghrelin	  [191].	  Altogether	  these	  data	  substantiate	  the	  key	  role	  of	  the	  Arc	  in	  the	  mediation	  of	  ghrelin	  effects	  on	  eating.	  As	   amply	   demonstrated,	   ghrelin	   decreases	   energy	   expenditure,	   and	   increases	   fat	  accumulation	  [177].	  Chronic	  central	  ghrelin	  treatment	  increases	  fat	  deposition	  in	  pair-­‐fed	   animals	   suggesting	   that	   ghrelin	   increased	   adiposity	   independently	   of	   its	   effect	   on	  food	  intake	  [192].	  This	  lipogenic	  effect	  is	  in	  part	  mediated	  via	  the	  sympathetic	  nervous	  system	   that	   eventually	   alters	   the	   expression	   of	   various	   enzymes	   that	   promoted	   fat	  storage	   [192,	   193].	   In	   addition,	   ghrelin	   also	   suppresses	   the	   sympathetic	   outflow	   to	  brown	  adipose	  tissue	  (BAT),	  leading	  to	  a	  reduction	  in	  uncoupling	  protein-­‐1	  expression	  (UCP-­‐1)	  and	  eventually	  a	  decrease	  in	  the	  amount	  of	  energy	  invested	  in	  heat	  production	  [194,	   195].	   Ghrelin	   plays	   also	   an	   important	   role	   in	   the	   regulation	   of	   glucose	  homeostasis.	   Acute	   administration	   of	   ghrelin	   induces	   hyperglycemia	   by	   a	  mechanism	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that	  involved	  reduced	  insulin	  secretion	  by	  the	  pancreas	  and	  possibly	  increased	  hepatic	  gluconeogenesis	   [32,	  196,	  197].	  Altogether	   these	  effects	   lead	   to	  a	   reduction	  of	   energy	  expenditure	  and	  a	  higher	  carbohydrate	  vs.	   fat	  utilization,	  promoting	  a	  positive	  energy	  balance	   independently	   of	   ghrelin’s	   orexigenic	   effect.	   Due	   to	   its	   positive	   biological	  actions	   on	   short	   and	   long-­‐term	   energy	   homeostasis,	   ghrelin-­‐based	   approaches	  represent	  a	  potential	  strategy	  for	  the	  treatment	  of	  CACS.	  	  
3.5.4  The therapeutic usefulness of ghrelin and its analogs against CACS 	  In	   addition	   to	   its	   effect	   on	   energy	  homeostasis,	   ghrelin	  has	   several	   other	   actions	   that	  might	  be	  beneficial	  for	  the	  treatment	  of	  CACS.	  Ghrelin	  exerts	  anti-­‐inflammatory	  effects	  reflected	   by	   its	   ability	   to	   reduce	   LPS-­‐induced	   of	   production	   the	   pro-­‐inflammatory	  cytokines	   IL-­‐6,	   TNF-­‐α	   and	   IL-­‐1β	   [198].	   Interestingly,	   ghrelin	   also	   inhibits	   NF-­‐kB	  signaling	   in	   endothelial	   cells	   under	   in	   vitro	   conditions	   [199].	   Besides	   its	   anti-­‐inflammatory	  action,	  ghrelin	  increases	  the	  release	  of	  growth	  hormone	  (GH)	  and	  insulin-­‐like	   growth	   factor-­‐1	   (IGF-­‐1),	   which	   are	   potent	   stimulators	   of	   a	   various	   anabolic	  pathways	  leading	  to	  muscle	  growth	  [172,	  200,	  201].	  GH	  and	  IGF-­‐1	  signaling	  in	  chronic	  cachectic	  patients	  are	  often	  impaired	  mainly	  due	  to	  decreased	  circulating	  levels	  of	  both	  GH	  and	  IGF-­‐1	  [202-­‐204].	  Hence,	  ghrelin’s	  ability	  to	  increase	  GH	  and	  IGF-­‐1	  levels	  and	  to	  attenuate	   inflammation	   could	   also	   contribute	   to	   the	   positive	   effects	   of	   ghrelin-­‐based	  anti-­‐CACS	  treatments.	  Ghrelin	  and	  ghrelin	  receptor	  agonists	  have	  been	   tested	   in	  a	  number	  of	   rodent	  models	  for	   CACS.	   Most	   of	   these	   studies	   show	   positive	   effects,	   such	   as	   increased	   food	  consumption,	   attenuation	   of	   body	   weight	   loss	   and	   decreased	   muscle	   atrophy.	   A	  literature	   overview	   about	   these	   published	   studies	   is	   presented	   in	   table	   1.	   However,	  despite	  the	  positive	  outcome	  of	  these	  preclinical	  studies,	  data	  regarding	  ghrelin-­‐based	  treatment	   in	   cancer	   are	   scarce	   (see	   table	   1).	   	   In	   fact,	   there	   is	   currently	   no	   ghrelin	  mimetic	   approved	   for	   the	   treatment	   of	   CACS.	   The	   orally	   active	   ghrelin	   agonist	  anamorelin	  was	  recently	  tested	  in	  phase	  III	  clinical	  trials	  for	  the	  indication	  of	  lung	  cell	  cancer	   CACS.	   In	   patients	  with	   advanced	   non-­‐small-­‐cell	   lung,	   anamorelin	   lead	   to	   body	  mass	   increase	   and	   significantly	   improved	   appetite	   and	   quality	   of	   life,	   without	   severe	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side	  effects.	  However,	  anamorelin	  did	  not	  positively	  affect	  handgrip	  strength,	  which	  was	  one	  of	  the	  primary	  endpoints	  in	  the	  clinical	  trial	  [205].	  The	  clinical	  use	  of	  ghrelin	   is	   limited	  because	   it	  has	  a	   short	  half-­‐life	  and	   it	   can	  only	  be	  administered	   parenterally.	   Ghrelin	   mimetics	   represent	   a	   valuable	   alternative	   to	  overcome	  these	  limitations.	  The	  small	  non-­‐peptidergic	  GHSR	  agonist	  HM01	  belongs	  to	  a	  new	  generation	  of	  orally	  active	  ghrelin	  mimetics.	  It	  has	  high	  receptor	  binding	  affinity,	  a	  much	  higher	  brain	  permeability	  compared	  to	  anamorelin	  and	  a	  higher	  plasma	  half-­‐life	  compared	  to	  ghrelin	  [206].	  However,	  its	  beneficial	  effects	  on	  food	  intake,	  body	  weight,	  muscle	   and	   metabolic	   rate	   had	   not	   yet	   been	   characterized	   under	   cancer	   conditions,	  which	  is	  an	  aim	  of	  the	  current	  work.	  
	  
	  
Table	  1:	  Use	  of	  ghrelin	  and	  its	  analogs	  for	  the	  treatment	  of	  different	  diseases.	   	  b.i.d:	  twice	  a	  day;	  BW:	  
Body	  weight;	  COPD:	  chronic	  obstructive	  pulmonary	  disease;	  FI:	  food	  intake;	  GI:	  gastrointestinal;	  +:	  increase;	  
-­‐:	  decrease	  
	  
	   	  
Ghrelin Daily (b.i.d.) inj., ip. 6 days Mice Human melanoma cells FI + , BW  + Hanada et al.
Ghrelin Daily (b.i.d.) inj., ip. 10 days Mice Sarcoma FI + ,  total and fat mass + Wang et al.
Ghrelin, Chronic (minipumps), sc. 5 days Rats Sarcoma FI + , BW + DeBoer et al.
BIM-28131
Ghrelin Daily (d.i.b) inj. ip. 14 days Mice Lewis lung carcinoma muslce atrophy - , inflammation - Chen al.
Ghrelin Single dose, iv. 1 day Humans Melanoma, breast, colon cancers Calories consumption + Neary et al.
Ghrelin 2 applications, iv. 2 weeks Humans Different cancer types No differences, no side effects Strasser et al.
Ghrelin Daily, sc. 8 weeks Humans Multiple GI malignancies Appetite + , BW loss - Lundholm et al.
Anamorelin Daily, oral 12 weeks Humans Different cancer types Total and lean body mass + Garcia et al.
Anamorelin Daily, oral 12 weeks Humans Lung cancer Appetite + , BW + , Lean body mass + Takayama et al.
Anamorelin Daily, oral 12 weeks Humans Lung cancer Appetite + , BW + , Lean body mass + Temel et al.
Ghrelin Single dose (rats), 2x (mice), ip. 1 day Rats, mice Chemotherapy (cisplatin) FI + ,  gastric empting + Liu et al.
Ghrelin Single dose, icv. 1 day Ferrets Chemotherapy (cisplatin) Vomiting and retches - Rudd et al.
Ghrelin Daily inj., ip. 2 weeks Rats Chemotherapy (cisplatin) Anorexia - , BW loss - Garcia et al.
Ghrelin Daily inj., iv. 3 weeks Humans COPD FI + , BW + ,  lean body mass + Nagaya et al.
SUN11031 Daily inj., sc., (b.i.d) 3 months Humans COPD BW + ,  lean body mass + Gertner et al.
Ghrelin Daily inj., sc. 3 weeks Rats Coronary artery ligation FI + , BW loss - Nagaya et al.
Ghrelin Daily inj., iv. 3 weeks Humans Chronic heart failure Lean mass + , heart function + Nagaya et al.
Ghrelin Single dose, iv. 1 day Humans Chronic heart failure Heart function + Nagaya et al.
Ghrelin, Chronic (minipumps), sc. 2 weeks Rats Chronic kidney disease BW + , lean mass + DeBoer et al.
BIM-28131,
BIM-28125
Ghrelin Single dose, sc. 1 day Humans Dialysis dependent renal failure FI + Wynne et al.
Ghrelin Daily inj., sc. 1 week Humans Malnourished dialysis patients FI + Ashby et al.
HM01 Single dose, ip. 1 day Rats Costipation FI + , gastric empting + , + fecal output Karasawa et al.
Capromorelin Daily, oral 1 year Old adults Age-related lean mass loss Lean body mass + White et al.
MK-677 Daily, oral 6 months Old adults Hip fracture Extremity functional performance + Bach et al.
List%of%abbreviations:%b.i.d:%Twice%a%day;%BW:%Body%weight;%COPD:%Chronic%obstructive%pulmonary%disease;%FI:%Food%intake;%GI:%Gastrointestinal;%+:%Increase;%G:%Decrease,%Reduction.
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4  Aims of the thesis 
4.1  Aim 1: the role of the AP/NTS in the mediation of CACS 	  The	   AP/NTS	  may	   be	   involved	   in	   the	  mediation	   of	   CACS	   [111].	   Using	   a	   rat	   hepatoma	  tumor	  model,	  we	  examined	  the	  role	  of	  the	  AP	  and	  of	  vagal	  afferents	  in	  the	  mediation	  of	  cancer	   CACS.	   It	   was	   an	   aim	   to	   investigate	   whether	   a	   lesion	   of	   the	   AP	   (APX)	   or	  subdiaphragmatic	   vagal	   deafferentation	   (SDA)	   attenuate	   cancer	   anorexia,	   and	   body	  weight	  and	  muscle	  mass	  loss.	  The	  tumor-­‐derived	  cytokine	  MIC-­‐1	  emerged	  as	  a	  possible	  mediator	  of	  cancer	  anorexia	  [99].	  Given	  the	  recent	  evidence	  for	  a	  hindbrain-­‐dependent	  suppression	  of	  food	  intake	  by	  MIC-­‐1	  in	  CACS	  [101],	  MIC-­‐1	  blood	  levels	  were	  analyzed	  at	  different	   time	   points	   during	   cancer	   progression.	   In	   addition,	   the	   impact	   of	   tumor	  growth	  on	  metabolic	  rate,	  respiratory	  exchange	  ratio	  (RER)	  and	  locomotor	  activity	  was	  assessed.	   Finally,	   using	   pair-­‐fed	   rats	  we	   dissociated	   the	   effects	   of	   tumor	   anorexia	   on	  body	  weight,	  body	  composition	  and	  muscle	   loss	   from	  eating-­‐independent	  effects.	   	  For	  these	   experiments,	   the	   Morris-­‐7777	   hepatoma	   rat	   model	   was	   used	   for	   the	   following	  reasons:	  1)	  the	  AP/NTS	  region	  is	  activated	  following	  tumor	  induction;	  2)	  anorexia	  is	  a	  major	  contributor	  of	  CACS	  in	  this	  cancer	  model.	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4.2  Aim 2: the involvement of the central GLP-1 in the mediation of 
CACS 	  GLP-­‐1	   signaling	  within	   the	   AP/NTS	   region	   is	   an	   important	  mediator	   of	   aversion	   and	  malaise	  induced	  by	  LiCl,	  LPS	  and	  cisplatin	  [137,	  142,	  144].	  Moreover,	  GLP-­‐1	  signaling	  in	  those	  areas	  is	  required	  for	  the	  mediation	  of	  the	  LPS	  and	  cisplatin-­‐induced	  depression	  of	  food	   intake	   [142,	   144].	   Therefore,	   we	   assumed	   that	   GLP-­‐1	   signaling	   in	   the	   AP/NTS	  region	  may	  also	  mediate	  anorexia	  following	  tumor	  growth.	  By	  taking	  advantage	  of	  both	  pharmacological	  and	  genetic	  approaches,	  we	   investigated	  whether	   central	   GLP-­‐1	   signaling	   is	   required	   for	   the	  mediation	   of	   CACS.	   First,	   chronic	  fourth	  ventricular	  infusion	  of	  the	  GLP-­‐1	  antagonist	  Ex-­‐9	  was	  performed	  and	  its	  ability	  to	  attenuate	   CACS	   was	   assessed.	   Second,	   in	   order	   to	   confirm	   the	   involvement	   of	   GLP-­‐1	  expressing	   NTS	   neurons	   as	   crucial	   mediator	   of	   CACS,	   lentiviral	   vectors	   expressing	  shRNA	  directed	  against	   the	  PPG	  were	  bilaterally	   injected	   in	   the	  NTS.	  The	  effect	  of	   the	  genetic	  GLP-­‐1	  blockade	  on	   food	   intake,	  body	  weight	  was	  measured	  prior	   to	   and	  after	  tumor	  induction.	  Third,	  due	  to	  the	  role	  of	  the	  central	  GLP-­‐1	  signaling	  in	  the	  mediation	  of	  food	  aversions,	  we	  tested	  for	  the	  presence	  of	  tumor-­‐induced	  diet	  aversion	  in	  our	  model.	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4.3 Aim 3: the effects of the ghrelin analog HM01 as a treatment against 
CACS 	  Recently,	  ghrelin	  mimetics	  emerged	  as	  possible	  treatment	  against	  CACS.	  The	  usefulness	  of	  native	  ghrelin	  as	  a	  therapeutic	  agent	   is	   limited	  due	  to	   its	  peptidergic	  nature	  and	  its	  short	  half-­‐life	  time.	  The	  development	  of	  small	  synthetic	  GHSR	  agonists	  that	  have	  longer	  half-­‐life	  and	  high	  oral	  bioavailability	  is	  a	  crucial	  step	  for	  future	  clinical	  uses.	  The	  ghrelin	  mimetic	  HM01	  has	  high	  receptor	  binding	  affinity,	  high	  brain	  permeability	  and	  a	  higher	  plasma	  half-­‐life	  compared	  to	  ghrelin.	  The	  overall	  aim	  of	  this	  project	  was	  to	  evaluate	  the	  possible	  usefulness	  of	  HM01	  against	  tumor-­‐dependent	   anorexia	   and	   body	   weight	   loss.	   First,	   we	   examined	   the	   effects	   of	  chronic	  HM01	  treatment	  on	  muscle	  mass	  and	  body	  composition	  in	  healthy	  non-­‐tumor-­‐bearing	   rats.	   Second,	   the	   same	   rat	   hepatoma	  model	   was	   used	   to	   test	   whether	   HM01	  ameliorates	   tumor	   anorexia,	   body	  weight,	   fat	   and	  muscle	   loss,	   and	  whether	   it	   affects	  nutrient	  utilization	  and	  metabolic	  rate.	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5  Original Research Article: “Anorexia-cachexia syndrome in 
hepatoma tumor-bearing rats requires the area postrema but not 
vagal afferents and is paralleled by increased MIC-1/GDF15” 
	  The	   following	   section	   contains	   an	   original	   research	   article	   that	   was	   accepted	   for	  publication	  by	  the	  Journal	  of	  Cachexia,	  Sarcopenia	  and	  Muscle	  in	  October	  2016.	  	  	  My	   contribution	   to	   this	   publication	   includes:	   conception	   and	   design	   of	   research,	   data	  acquisition,	  data	  analysis,	  data	  interpretation	  and	  writing	  the	  manuscript.	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Anorexia-cachexia syndrome in hepatoma tumour-
bearing rats requires the area postrema but not vagal
afferents and is paralleled by increased MIC-1/GDF15
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Abstract
Background The cancer-anorexia-cachexia syndrome (CACS) negatively affects survival and therapy success in cancer pa-
tients. Inﬂammatory mediators and tumour-derived factors are thought to play an important role in the aetiology of CACS.
However, the central and peripheral mechanisms contributing to CACS are insufﬁciently understood. The area postrema
(AP) and the nucleus tractus solitarii are two important brainstem centres for the control of eating during acute sickness con-
ditions. Recently, the tumour-derived macrophage inhibitory cytokine-1 (MIC-1) emerged as a possible mediator of cancer an-
orexia because lesions of these brainstem areas attenuated the anorectic effect of exogenous MIC-1 in mice.
Methods Using a rat hepatoma tumour model, we examined the roles of the AP and of vagal afferents in the mediation of
CACS. Speciﬁcally, we investigated whether a lesion of the AP (APX) or subdiaphragmatic vagal deafferentation (SDA) attenu-
ate anorexia, body weight, muscle, and fat loss. Moreover, we analysed MIC-1 levels in this tumour model and their correlation
with tumour size and the severity of the anorectic response.
Results In tumour-bearing sham-operated animals mean daily food intake signiﬁcantly decreased. The anorectic response
was paralleled by a signiﬁcant loss of body weight and muscle mass. APX rats were protected against anorexia, body weight
loss, and muscle atrophy after tumour induction. In contrast, subdiaphragmatic vagal deafferentation did not attenuate
cancer-induced anorexia or body weight loss. Tumour-bearing rats had substantially increased MIC-1 levels, which positively
correlated with tumour size and cancer progression and negatively correlated with food intake.
Conclusions These ﬁndings demonstrate the importance of the AP in the mediation of cancer-dependent anorexia and body
weight loss and support a pathological role of MIC-1 as a tumour-derived factor mediating CACS, possibly via an AP-dependent
action.
Keywords Cancer; Food intake; Energy balance; Brainstem; Muscle; AP-lesion; Subdiaphragmatic vagal deafferentation
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Introduction
The anorexia-cachexia syndrome (ACS) is characterized by re-
duced eating and body weight loss, which is the consequence
of reduced fat and muscle mass.1 More than 80% of patients
with advanced cancer suffer from loss of appetite and body
weight.2 Cancer ACS (CACS) negatively affects the clinical sta-
tus, increases mortality, deteriorates treatment success, and
reduces quality of life.3,4 Inﬂammatory signalling molecules
(e.g. cytokines) that are released during malignancy by the
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host immune system or by the tumour itself are important
mediators of CACS.5,6
The area postrema (AP) is a sensory circumventricular or-
gan of the caudal hindbrain, which is anatomically linked to
and interacts in a reciprocal manner with the nucleus tractus
solitarii (NTS).7 Because of the lack of a functional blood-brain
barrier, neurons of the AP represent targets for blood-borne
hormones and pathological signalling molecules. The AP ap-
pears to be involved in pathological anorexia because lesions
of the AP and the adjacent NTS region attenuate TNF-α-
induced anorexia in rats.8 Moreover, AP neurons are activated
in tumour-bearing (TB) rats carrying hepatoma tumours.9
The NTS is an integrative relay centre for a variety of pe-
ripheral signals that control food intake.10 It is the main pro-
jection site of vagal afferents from the gastrointestinal tract
that transmits sensory visceral information to the brain. Va-
gotomy attenuated sickness-associated behaviours such as a
decrease in social exploration induced by IL-1β or by the in-
ﬂammatory endotoxin lipopolysaccharide (LPS).11,12 On the
other hand, subdiaphragmatic vagal deafferentation (SDA)
failed to inﬂuence the anorectic effects of intraperitoneally
injected LPS, muramyl dipeptide or IL-1β, indicating that vagal
afferents are not necessary for the eating inhibition by these
inﬂammatory mediators.13,14 Experimental evidence for a role
of the AP or vagal afferents in cancer anorexia is scarce. The
only study addressing this question was conducted using a
rat Leydig cell tumour model, which is characterized by endo-
crine activity of oestrogens.15 Given that oestrogens act via
the AP/NTS regions to reduce food intake,16 the outcome of
that study may reﬂect the consequences of
hyperestrogenemia rather than speciﬁc tumour-dependent
signalling mechanisms. Moreover, the lesioning approach in
this study was not speciﬁc for the AP because the lesion in-
cluded major parts of the NTS, resulting in a destruction of va-
gal terminal ﬁelds. Therefore, knowledge about the general
role of the AP in cancer anorexia is very limited, and a better
dissociation between vagal and AP-dependent mechanisms
is required.
In the present study, we used neurosurgical approaches to
examine the role of the AP and vagal afferents in the media-
tion of cancer anorexia and body weight loss in a rat hepa-
toma tumour model. A vacuum aspiration approach allowing
the speciﬁc removal of the AP without compromising the
structural integrity the NTS was used.17 Moreover, we used
the SDA technique, which is the most sophisticated deafferen-
tation method because it disrupts all subdiaphragmatic vagal
afferents while leaving about 50% of vagal efferents intact.
The remaining vagal efferents are sufﬁcient for maintaining
the control of gastrointestinal function.18 The comparison of
APX and SDA approaches allows for the dissociation of vagal
and AP mediated effects on CACS.
Despite their importance for disease-related anorexia, the
classic pro-inﬂammatory cytokines including interleukins,
TNF-α and IFN-γ do not seem to be required for the anorexia
in the hepatoma tumour model.9,19 There is cumulating evi-
dence pointing to the AP as a target site for the signalling
molecule MIC-1, also known as growth differentiation factor
15 (GDF15). Tumour cell dependent expression of MIC-1
can increase serum levels by up to 100-fold.20–23 MIC-1 pro-
duced by xenografted tumours and recombinant protein both
reduce food intake and lead to cachectic body weight loss in
mice that can be inhibited by speciﬁc monoclonal antibod-
ies.24 Additionally, systemic injection of recombinant MIC-1
leads to rapid induction of c-Fos in the AP/NTS region, and
a lesion of this brain area blocks the anorectic effect of exog-
enous MIC-1 in mice.25 Given the recent evidence for a
hindbrain-dependent suppression of food intake by MIC-1
and to further support the importance of MIC-1 signalling in
CACS, we also sought to analyse MIC-1 blood levels at differ-
ent time points during cancer progression.25
Materials and methods
Animals and housing conditions
Male Buffalo rats were used (Charles River Laboratory, USA).
The animals were housed at controlled temperature
(21! 1 °C) under a 12-h artiﬁcial light cycle with ad libitum ac-
cess to standard laboratory rat chow (890 25W16, Provimi
Kliba, AG, Kaiseraugst, Switzerland). All experiments were ap-
proved by the Veterinary Ofﬁce of the Canton Zurich.
Cell culture and tumour model
The hepatoma tumour model was described previously.9,26
Morris hepatoma 7777 cells (McA-RH7777, Catalog No. CRL-
1601, ATCC, USA) were cultured under standard conditions
in DMEM supplemented with 10% foetal bovine serum and
1% penicillin-streptomycin. Semi-conﬂuent McA-RH7777
Petri dishes were washed with DMEM repeatedly to detach
the cells from the surface. After conﬁrming viability of the
cells with trypan blue, 107 cells were inoculated subcutane-
ously between the scapulae in 250μL PBS under short
isoﬂurane anaesthesia. Control animals were also anaesthe-
tized and injected with PBS.
Area postrema lesion
The APX was conducted as described.27 Brieﬂy, animals (200–
230 g) were placed in a stereotactic frame with the head
ﬂexed ventrally in order to visualize the crista occipitalis.
The atlanto-occipital membrane was dissected, and the me-
ninges were carefully incised under surgical microscope con-
trol. The AP was then visualized and removed by vacuum
aspiration using a blunted 26G cannula connected to a water
2 T. Borner et al.
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vacuum pump. The animals were allowed 2weeks for recov-
ery before the start of the behavioural trials.
A histological veriﬁcation of successful AP lesion was per-
formed post-mortem. Microscopic coronal sections of the
AP/NTS region were analysed. Only those animals in which
the AP was removed without visible damage of the adjacent
NTS were included in the study. Photomicrographs were
taken at 20× magniﬁcation, using a Zeiss Imager Z2 micro-
scope ﬁtted with a digital camera system (Zeiss Axiocam).
Subdiaphragmatic vagal deafferentation
This surgical technique consists in a left-side intracranial tran-
section of the vagal afferent rootlets and an ipsilateral tran-
section of the dorsal subdiaphragmatic trunk of the vagus
nerve resulting in complete SDA as previously described.18
Rats (210–250 g) were pretreated with ip injections of
50μg/kg atropine, antibiotics, and then anaesthetized with
isoﬂurane. For sham-SDA surgery, the vagal rootlets and the
dorsal subdiaphragmatic vagus trunk were exposed without
disrupting them. Five millitre of warm saline and an analgesic
were injected ip after suturing the abdomen. Post-surgical
treatment with antibiotics and the analgesic continued for
the following 2 days.
Two histological tests aimed to verify the completeness of
SDA. These tests were based on published techniques for ret-
rograde labelling of vagal motor neurons in the dorsal motor
nucleus of the vagus (DMN) and anterograde labelling of va-
gal afferents in the NTS.28–30 Rats were anaesthetized with
isoﬂurane, and a midline incision at the level of the throat
was made to expose the left nodose ganglion. A glass micro-
pipette was inserted into the ganglion using a micromanipu-
lator. A water solution (1.5μL) containing the anterograde
tracer biotinylated dextran amine (BDA, 5%) and 1% blue
food colouring (Trawosa AG, St. Gallen, Switzerland) was
pressure injected (PicoSpritzer 3; Parker Instrumentation,
Fairﬁeld, NJ) during 3–5min. Three days after surgery the an-
imals were shortly anaesthetized with isoﬂurane and 2mg of
the retrograde tracer ﬂuorogold (FG) in 1mL saline (Fluoro-
chrome, Denver, CO) were injected intraperitoneally. After
2 days of tracer migration, the rats were perfused and the
brains were removed as described below. The procedure for
visualizing BDA-positive vagal projections in the NTS involved
an incubation with the avidin-biotin-peroxidase complex
followed by an incubation in 3,3′-diaminobenzidine solution
(0.05% 3,3′-diaminobenzidine, 0.009% H2O2, 0.04% NiCl2,
0.08% CoCl2 in 0.05M Tris-HCl). Absence of labelling was
interpreted as successful transection of vagal afferents. To
conﬁrm completeness of unilateral subdiaphragmatic trunk
vagotomy, an observer who was blind to the rat’s surgery,
counted the number of ﬂuorogold-labelled neurons in the left
and right DMN at the level of the AP. If the number of la-
belled cells found in the right DMN was less than 3% of the
number found in the left DMN, and if vagal afferent ﬁbres
were absent in the NTS, the SDA surgery was considered suc-
cessful. Sham-SDA rats were only included if FG-positive
DMN neurons were labelled bilaterally and dense vagal affer-
ent terminals were detected histologically. Photomicrographs
were taken as described earlier.
Behavioural and metabolic studies
Using non-operated TB rats, we ﬁrst sought to dissociate the
effects of tumour anorexia on body weight and muscle loss
from eating-independent effects. Non-tumour-bearing
(NTB), pair-fed (PF), and TB rats (220–250 g) were single-
housed in BIODAQ cages (Research Diets, NJ, USA) equipped
with an external food hopper allowing precise 24-h food in-
take measurements. Rats were adapted to the housing condi-
tions for 14 days before tumour cell injection. Daily food
intake and body weight were measured shortly before dark-
onset. Nine days after tumour induction, PF animals received
the same amount of food as was consumed the previous day
by the TB group. At the end of the experiment, the animals
were euthanized for blood and tissue collection.
We then assessed the impact of tumour growth on meta-
bolic rate and locomotor activity in this model. This experi-
ment, which involved TB and NTB rats (130–150 g), was
conducted in an open-circuit indirect calorimetric system
(TSE Phenomaster, Bad Homburg, Germany) equipped with
internal food hoppers and water bottles connected to scales,
which allow for continuous recording of food and water
consumption. The animals were single-housed in metabolic
cages and adapted to the housing conditions for 7 days be-
fore the start of the experiment. Body weight was measured
daily before dark onset. Food intake and respiratory gas ex-
change (O2 and CO2) were recorded automatically at 17-min
intervals throughout the entire experiment. Locomotor activ-
ity (i.e. number of horizontal movements) was recorded using
a frame of horizontal infrared beams (Accuscan, Columbus,
Ohio).
Behavioural and metabolic studies with APX and SDA rats
were also conducted in the same open-circuit indirect calori-
metric system. In both studies, the animals were kept and
adapted to the experimental conditions as described earlier.
Food intake and body weight were recorded daily.
Terminal tissue and blood collection
Rats were anaesthetized shortly before dark onset after injec-
tion of pentobarbital (100mg/kg ip). The thorax was opened
and blood was collected from the right ventricle for subse-
quent MIC-1 measurements. Immediately afterwards, the rats
were transcardially perfused with 0.1MPB followed by 4%
phosphate-buffered paraformaldehyde. The brains were
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removed, post-ﬁxed for 4 h in 4% phosphate-buffered parafor-
maldehyde and then cryoprotected for 2 days in 20% sucrose
in 0.1MPB at 4°C. Brains were subsequently frozen in hexane.
Three series of coronal brainstem sections containing the
AP/NTS region (20μm) were cut with a cryomicrotome
(CM3050S, Leica Microsystems, Germany), thaw-mounted on
glass slides and then stored at !20°C until further processing.
MIC-1 measurements
Rats were single-housed in BIODAQ cages as described earlier.
Food intake and body weight were measured daily and tu-
mour growth was induced in all animals. Blood was obtained
by puncturing the sublingual vein under mild isoﬂurane an-
aesthesia. Sampling was conducted 3 days before tumour in-
duction (baseline) and 11 days and 17 days after induction,
that is, shortly after the onset of anorexia and during fully de-
veloped anorexia, respectively. Blood was collected in EDTA
containing tubes (Sarstedt, Nümbrecht, Germany) and centri-
fuged at 7000 × g (4°C, 7min) to obtain plasma, which was
stored in aliquots at!80°C for subsequent analysis. The levels
MIC-1 were measured with using an ELISA (R&D Systems,
USA) according to the manufacturers’ instructions.
Body composition analysis and muscle and tumour
weight measurements
After euthanizing the rats, tumours were resected and
weighed. Total carcass lean and fat mass were measured by
magnetic resonance imaging (EchoMRI, Echo Medical Sys-
tems, Texas, USA). Two consecutive measurements were
taken to ensure instrument precision and averaged for the
subsequent statistical analysis. The left gastrocnemius,
tibialis, and soleus muscles were dissected at the level of
their upper to lower tendons and weighed.
Data evaluation and statistical analysis
Mean daily food intake, body weight, body composition (lean
and fat mass), and MIC-1 levels were expressed as
mean" SEM. In the pair-feeding experiment, body weight
changes were calculated by subtracting the weight of the an-
imal at the day of tumour induction from the ﬁnal body
weight. In the experiments involving AP-lesioned and
vagotomized animals, food intake was corrected for body
weight because at least in the APX study, the surgery had
an effect on body weight. This effect is in line with previous
studies in which APX animals tended to gain less weight than
sham-APX because of moderately decreased total food in-
take.17 Weekly body weight change after tumour-induction
was calculated by subtracting the body weight at the
beginning of each week from the body weight at the end of
same week. Food intake and body weight changes were quan-
tiﬁed across a 3-week period starting one week before the on-
set of anorexia. Presumably, because of general biological
variability, anorexia in the APX study started a week later than
in the SDA study, that is, 3 instead of 2weeks after tumour in-
duction. Metabolic rate was calculated from O2 consumption
and CO2 production as described previously.
31 Metabolic rate
data were normalized for body weight. The calculation was
based on the following equation: total EE (kcal/kg/h) =
(3.9 ×VO2 + 1.1 × VCO2) / 1000. The average values obtained
between Days 1 and 3 after tumour inoculation were used
as baseline (i.e. prior to the onset of anorexia) and compared
with the average values during three consecutive days in each
week after tumour induction. The number of horizontal move-
ments (i.e. locomotor activity) was monitored across continu-
ous 5-min intervals over 24 h and expressed as average of
three consecutive days.
Statistical comparisons between multiple groups were per-
formed using one-way ANOVA followed by Tukey’s post-hoc
test. Unpaired Student’s t-test (two-sided) was used for com-
parison between two groups. Linear regression analysis was
used to examine the correlation between MIC-1 levels, tu-
mour weight and food intake. For all statistical tests, a P-
value less than 0.05 was considered signiﬁcant. Data were
analysed using Prism GraphPad 5.0.
Results
Effects of tumour growth on food intake, body
weight and muscle, fat and lean mass
Tumours became palpable between Days 9 and 11, which co-
incided with the onset of the anorectic response. TB rats
showed signiﬁcantly lower food intake than NTB animals from
Day 11 after tumour cell inoculation. Daily food intake stabi-
lized at a lower level with an average reduction of 45% in com-
parison to NTB animals (Figure 1A). While NTB animals
displayed constant body weight gain during the experimental
period, TB animals showed a marked loss of body weight,
which became signiﬁcant 12 days after tumour induction.
Pair-feeding reduced body weight gain, which led to a signiﬁ-
cantly lower body weight compared with NTB on Days 18–
19. Pair-feeding did not, however, lower body weight to the
level of the TB animals; these animals were signiﬁcantly
heavier than the TB rats on Day 13 (Figure 1B–C). TB animals
had lower lean carcass mass in comparison with healthy con-
trols and PF animals (Figure 1D). TB rats also had lower fat
mass than controls and PF rats. Furthermore,TB rats had lower
gastrocnemius and tibialis muscle mass than NTB animals
(Figure 1E), while muscle weight of the PF group did not differ
from NTB controls. The tumour weight was 13.2" 1.5 g at the
end of experiment.
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Effects of tumour growth on metabolism and
locomotor activity
Energy expenditure and activity were analysed in a separate
cohort of TB and NTB rats. The food intake of these animals
following tumour induction decreased, leading to signiﬁcantly
lower body weight in TB rats compared to NTB controls
(Figure 2A–B). While the metabolic rate of the NTB controls
did not signiﬁcantly change during the experiment, TB animals
showed a slight but signiﬁcant reduction in metabolic rate
during the third week after tumour induction (Figure 2C).
Daily locomotor activity was similar between the two experi-
mental groups (Figure 2D) and there were no differences in
the diurnal and nocturnal activity pattern (data not shown).
Area postrema lesion blocked anorexia and
attenuated tumour-induced body weight loss and
muscle degradation
Body weight before tumour induction was lower in the APX
animals compared with sham-APX rats (APX: 225! 9 vs.
sham-APX 262! 8.5 g). However, no signiﬁcant differences
in food intake between the experimental groups occurred
prior to tumour anorexia when food intake was corrected
for body weight (APX: 7.2! 0.2 vs. sham-APX: 7.6! 0.2 g/
100 g BW). The food intake of the sham-APX rats decreased
following tumour induction, resulting in a signiﬁcant reduc-
tion of 40! 3% between Weeks 2 and 4 (Figure 3A). This ef-
fect was accompanied by a decline in body weight gain,
leading to net body weight loss in Week 4 (Figure 3B). Strik-
ingly, and in contrast to its effect in sham-APX rats, tumour
growth did not affect food intake in APX animals (Figure 3A).
The weekly body weight gain of the APX rats only signiﬁcantly
decreased in Week 4. In contrast to sham-APX rats, however,
APX animals did not lose body weight following tumour
growth (Figure 3B). Furthermore, APX rats had higher gastroc-
nemius and soleus muscle weights than controls (Figure 3C).
The metabolic rate was similar between APX and sham-APX
animals. Tumour growth decreased metabolic rate in both
surgical groups similarly with a signiﬁcant reduction between
Weeks 2 and 3. No further decrease occurred between Weeks
3 and 4 (APX vs. sham-APX, wk2: 185.8! 10.3 vs. 186.1! 5.4;
wk3: 160.6! 2.6, 160.0! 1.3; wk4: 162.2! 4.8 vs.
159.6! 3.4 kcal/kg/d). Locomotor activity was similar in APX
and sham-APX animals and no signiﬁcant changes occurred
between the two groups following tumour induction (APX
vs. sham-APX, wk2: 5.5! 0.5 vs. 5.6! 0.4; wk3: 6.6! 0.4 vs.
Figure 1 Tumour-induced body weight loss and muscle degradation are partly independent of anorexia. (A–C) Tumour-bearing rats developed an-
orexia and lost body weight. Pair-feeding only led to an attenuation of body weight gain that was calculated by subtracting the body weight at the
time of tumour induction from the body weight at the end of the experiment. (D) Tumour-bearing animals had lower lean and fat carcass mass com-
pared with both control groups. (E) Tumour-bearing rats had lower gastrocnemius and tibialis muscle mass compared with Non-Tumour-bearing an-
imals and lower gastrocnemius muscle mass compared with the pair-fed group. Data analysed with Student’s t-test (A) or with one-way ANOVA
followed by Tukey’s post-hoc test (B–E). Means with different letter or symbols are signiﬁcantly different from each other; * P< 0.05, ** P< 0.01,
*** P< 0.001, same for # and §).
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6.7! 0.5; wk4: 6.0! 0.5 vs. 6.7! 0.3 arbitrary units). Impor-
tantly, tumour weight did not differ signiﬁcantly between
APX and sham-APX rats at the end of the experiment
(9.6! 0.7 vs. 7.7! 2.3 g). Representative histological sections
of the AP/NTS region from a sham-APX and an APX animal are
shown in Figure 3D.
Subdiaphragmatic vagal deafferentation did not
prevent tumour-induced anorexia and body weight
loss
In line with previous reports, daily food intake did not differ
between SDA and sham-SDA animals prior to tumour induc-
tion (21.8! 0.9 SDA vs. 22.3! 0.5 g sham-SDA).32,33 More-
over, body weight did not differ between the two groups
before the surgery (SDA: 253! 4 vs. sham-SDA: 246! 3 g)
and prior to tumour induction (SDA: 252! 5 vs. sham-SDA:
248! 4 g). In contrast to APX, SDA did not affect tumour-
induced anorexia. Tumour growth reduced food intake in
SDA and sham-SDA rats similarly, leading to a food intake re-
duction of 39! 3 and 41! 2% between Weeks 1 and 3 in
SDA and sham-SDA rats, respectively (Figure 4A). Likewise,
tumour growth attenuated body weight gain in both groups
during Week 2 similarly, resulting in body weight loss in Week
3 (Figure 4B). No differences in lean and fat mass, metabolic
rate, and locomotor activity were observed between the two
groups (data not shown). The tumour weight of the SDA and
sham-SDA animals did not differ at the end of the experiment
(17.6! 2.6 vs. 21.8! 1.9 g). Figure 4C shows representative
histological sections of animals in both groups. Unilateral an-
terograde labelling of vagal afferents in the NTS was visible in
sham-SDA but absent in SDA rats. Furthermore, sham-SDA
rats showed bilateral retrograde labelling of vagal motor neu-
rons in the DMN, whereas only unilateral staining of the DMN
was present in SDA animals.
Tumour growth and anorexia correlated with
MIC-1 blood levels
MIC-1 plasma levels in TB rats were signiﬁcantly higher than
in NTB and PF controls at the end of the experiment, showing
a 42-fold increase (Figure 5A). MIC-1 levels did not differ be-
tween PF and NTB rats. In a separate group of animals, MIC-1
Figure 2 Tumour growth reduced metabolic rate without affecting locomotor activity. Tumour-bearing rats developed anorexia (A) and showed re-
duced body weight gain (B), but did not show differences in metabolic rate (C) or locomotor activity (D), except during Week 3 in which tumour-bear-
ing rats showed reduced metabolic rate. Data analysed with Student’s t-test (A–B), * P< 0.05, ** P< 0.01, *** P< 0.001. Data analysed with one-way
ANOVA followed by Tukey’s post-hoc test (C–D). Means with different letters are signiﬁcantly different from each other (P< 0.05).
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levels were also measured before tumour induction, shortly
after the onset of anorexia and at the end of the experiment
(11 and 17 days after tumour induction, respectively). MIC-1
plasma levels were already elevated 11 days after tumour in-
duction compared with baseline conditions and increased
further until Day 17 (Figure 5B). MIC-1 levels positively corre-
lated with tumour size (Figure 5C) and with the severity of
anorexia during tumour growth (Figure 5D).
Discussion
The role of the AP and of vagal afferents in chronic cancer an-
orexia and body weight loss has neither been critically exam-
ined nor conclusively dissociated. Using the speciﬁc APX and
SDA approaches, we now provide evidence that the AP is re-
quired for cancer anorexia and body weight loss in hepatoma
TB rats. Lesion of the AP also attenuated cancer-dependent
muscle loss. In contrast to APX, SDA did not affect cancer-
induced anorexia and body weight loss, indicating that vagal
afferents are not necessary for the mediation of CACS in this
model. We also identiﬁed MIC-1 as a possible mediator of
CACS in hepatoma TB rats because MIC-1 levels correlated
with tumour progression and tumour size, and correlated
negatively with food intake.
As demonstrated in previous studies, hepatoma TB rats
showed an activation of the AP/NTS region that was caused
by tumour growth but not as a consequence of anorexia be-
cause it did not occur in pair-fed NTB controls.9 Our studies
extend this observation by demonstrating clear differences
between TB and pair-fed NTB rats with respect to body
weight, body composition, and muscle mass. TB rats lost con-
siderably more body weight than NTB pair-fed rats and
showed a reduction in total lean mass and hind limb muscle
mass. These ﬁndings are consistent with the notion that
Figure 3 Lesion of the area postrema attenuated anorexia, body weight loss and muscle degradation induced by tumour growth. (A–B) Area postrema
lesioned (APX) animals were protected against tumour-induced anorexia and showed markedly attenuated body weight loss following tumour induc-
tion. (C) Area postrema lesioned rats show higher gastrocnemius and soleus mass compared to area postrema-sham lesioned (sham-APX)
tumour-bearing animals. (D) Coronal sections of the area postrema/nucleus tractus solitarii of a sham-lesioned control (upper image) and an area
postrema lesioned animal (lower image). AP, area postrema; NTS, nucleus tractus solitarii; DMN, dorsal motor nucleus of the vagus; Gr, gracile nucleus;
CC, central canal. Data analysed with one-way ANOVA followed by Tukey’s post-hoc test (A–B), means with different letters are signiﬁcantly different
from each other (P< 0.05). Changes in food intake, differences in body weight change between Weeks 2 and 4, and muscle weights were analysed
using the Student’s t-test (A-C), * P< 0.05, ** P< 0.01, *** P< 0.001.
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tumour-dependent body weight loss and muscle degradation
is not only due to reduced energy intake.
Differences in metabolic rate and locomotor activity be-
tween TB and NTB were small or absent, respectively. The
only signiﬁcant difference consisted of a reduced metabolic
rate of TB rats during Week 3 after tumour induction. The
consequences of cancer growth for energy expenditure vary
among tumour models depending on the status of inﬂamma-
tion and effects caused by changes in food intake or physical
activity.34,35 In our studies, the moderately reduced meta-
bolic rate of TB rats might be related to the reduced food
intake.
Notably, indirect calorimetry does not reﬂect possible
changes in energy expenditure because of anaerobic metab-
olism, which particularly occurs in tumour tissues, including
the hepatoma cells used in these studies.36,37 The consider-
ably greater body weight loss in TB vs. pair-fed NTB rats in
the absence of marked differences in aerobic metabolic rate
and locomotor activity suggests a role of anaerobic hyperme-
tabolism in this tumour model. Another possible reason for
the difference in body weight between TB and PF animals
could be related to a maladaptation of energy expenditure,
following reduced caloric intake. Reduction in metabolic rate
during food-restriction is a well-known adaptive mechanism
Figure 4 Subdiaphragmatic vagal deafferentation did not attenuate cancer-anorexia-cachexia syndrome. (A) Tumour growth induced a strong anorec-
tic response in both subdiaphragmatic vagal deafferentation (SDA) and sham-operated (sham-SDA) animals. (B) In both groups anorexia was paralleled
by a similar reduction of body weight gain in Week 2 and a net body weight loss in Week 3. (C) Schematic illustration of afferent and efferent vagal
ﬁbres targeted by the subdiaphragmatic vagal deafferentation and of the procedures used to verify its completeness. The subdiaphragmatic vagal de-
afferentation consists in a left intracranial rhizotomy of all dorsal vagal ﬁbres (i.e. afferent) (1) and a complete subdiaphragmatic dissection (afferent
and efferent ﬁbers) of the left trunk of the vagus nerve (2). With this surgical procedure all vagal afferents are dissected, leaving 50% of the vagal
efferents intact. Biotinylated dextran amine (BDA) was applied directly into the nodose ganglion of the vagus nerve 5 days prior to sacriﬁce (3).
Fluorogold (FG) was injected intraperitoneally 48 h prior to sacriﬁce (4). D–E) Coronal sections of the area postrema/nucleus tractus solitarii region
of a sham-lesioned control and a subdiaphragmatic vagal deafferentation animal. (D) While biotinylated dextran amine-positive ﬁbers were present
in the nucleus tractus solitarii of sham rats, no labelling was observed in the nucleus tractus solitarii of subdiaphragmatic vagal deafferentation
animals. (E) While bilateral Fluorogold staining in the dorsal motor nucleus (DMN) of sham rats was observed, only unilateral staining of the dorsal
motor nucleus occurred in subdiaphragmatic vagal deafferentation animals. CC, central canal. One-way ANOVA followed by Tukey’s post-hoc test,
means with different letters are signiﬁcantly different from each other (P< 0.05).
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preventing excessive body weight loss. While this mechanism
might have partially protected PF animals from body weight
loss, an adaptive reduction in metabolic rate might have been
negligible in TB rats.38,39 We did not directly compare meta-
bolic rate of PF and TB rats, but the small reduction in meta-
bolic rate of TB rats compared with NTB animals is in line with
this assumption.
In contrast to earlier studies using AP/NTS lesions, the NTS
was not lesioned in our study.15 This is important because it
means that the neuroanatomy conveying vagal afferent sig-
nalling to the hindbrain was still intact in our APX study. Fur-
thermore, by using SDA, we minimized the severe
impairment of gastrointestinal function that usually occurs
in other experimental approaches (e.g. complete
subdiaphragmatic vagotomy). Although lesion of the AP mod-
erately reduces food intake and body weight compared with
controls,17,27 APX animals are still sensitive to anorectic stim-
uli such as LPS or CCK.40,41 Therefore, lesion of the AP does
not create a state of general unresponsiveness to anorectic
stimuli. While APX rats did not develop cancer anorexia or
body weight loss, body weight gain signiﬁcantly decreased in
the last week of the experiments. As discussed earlier, anaer-
obic hypermetabolism might have contributed to reduced
body weight gain. Furthermore, mean daily food intake
tended to decrease during the last week leading to a non-
signiﬁcant reduction of cumulative food intake by about 10 g
compared with the week before. We did not attempt to con-
ﬁrm or exclude the possible reasons for the reduced body
weight gain toward the end of the experiment because the
different effects mentioned earlier are likely to act in concert.
Most importantly, however, our studies clearly demon-
strate an amelioration of CACS in APX rats including an atten-
uation of muscle loss. Differences in tumour growth did not
account for decreased loss of muscle mass, because APX did
not affect the tumour size. The lesion of the AP per se is also
unlikely to increase muscle mass because APX rats generally
tend to have lower body weights compared with sham-APX
rats. The pathological mechanisms leading to muscle wasting
in the present tumour model have not yet been explored. In
general, pro-inﬂammatory cytokines are important mediators
of cancer-dependent muscle wasting acting via muscle degra-
dation pathways.42 So far, no increased levels of TNF-α, IL-1β,
IL-6, or IFN-γ have been identiﬁed in this tumour model.9 TB
APX rats might be able to partially preserve muscle mass be-
cause of higher energy intake than TB sham-APX rats, but
pair-feeding experiments would be required to conﬁrm this.
The persistence of CACS in SDA rats may seem surprising
given the presumed role of vagal afferents for the transmis-
sion of sickness-related signals to the brain.43 While the
SDA approach is the most appropriate surgical technique to
disrupt vagal afferent signalling, we cannot exclude that af-
ferent signals originating from the right nodose ganglion
could be transmitted to the brainstem. However, the effects
of anorectic stimuli such as CCK are blocked by SDA, suggest-
ing that an intact nodose ganglion is not sufﬁcient for the
suppression of food intake induced by vagus-dependent ano-
rectic stimuli.44 Based on almost identical anorexia and body
weight loss in SDA compared with sham-SDA animals, it ap-
pears unlikely that the full CACS response is mediated via a
unilateral supradiaphragmatic vagal mechanism.
Whereas in some studies, complete subdiaphragmatic va-
gotomy has been shown to reduce different sickness-related
symptoms including LPS and IL-1β-induced anorexia,45 the
more speciﬁc SDA procedure that we employed here did
not attenuate the anorectic response to immunomodula-
tors.13,14 Moreover, all these studies investigated the involve-
ment of the vagus nerve in sickness anorexia accompanying
acute models of inﬂammation, for example, treatment with
endotoxins such as LPS or muramyl dipeptide or acute injec-
tion of pro-inﬂammatory cytokines. To our knowledge, the
only study exploring the role of the vagus in cancer anorexia
was conducted in Leydig cell TB rats. Both total vagotomy
and capsaicin-induced vagal damage attenuated tumour an-
orexia in this tumour model.46 Whether the vagal mediation
Figure 5 Macrophage inhibitory cytokine-1 levels increased with tumour progression and correlated with tumour size and the severity of anorexia (A)
macrophage inhibitory cytokine-1 plasma levels were signiﬁcantly higher in tumour-bearing rats compared to controls at the end of the experiment.
(B) macrophage inhibitory cytokine-1 levels were elevated 11 days after tumour induction (i.e. 3 days after anorexia onset) and further increased with
cancer progression. (C) Macrophage inhibitory cytokine-1 levels correlated with tumour weight. (D) Macrophage inhibitory cytokine-1 levels negatively
correlated with food intake during tumour growth. Data analysed with one-way ANOVA followed by Tukey’s post-hoc test (A–B), means with different
letters are signiﬁcantly different from each other (P< 0.05).
Anorexia-cachexia syndrome 9
Journal of Cachexia, Sarcopenia and Muscle 2016
DOI: 10.1002/jcsm.12169
	   40	  
of cancer anorexia in this model is related to oestrogen pro-
duced by the tumour remains unclear but represents a plau-
sible explanation.
Overall, the heterogeneity of ﬁndings regarding the in-
volvement of vagal afferent signalling in disease-related an-
orexia may reﬂect differences in pathological characteristics
of the pertinent disease models. Although we cannot gener-
alize our ﬁnding that vagal afferents did not contribute to
cancer anorexia, the clear-cut dissociation of vagal vs. AP-
dependent mechanisms helps to narrow down possible
pathomechanisms and therapeutic targets.
There is much evidence for the pivotal role of pro-
inﬂammatory cytokines in the development of CACS.47 In
contrast to other tumour models,48 no increases in circulating
cytokines such as IL-1β, IFN-γ, IL-6, and TNF-α have been ob-
served in hepatoma TB rats.9 We therefore hypothesized that
other cytokines or tumour-derived factors might contribute
to CACS in this tumour model. Consistent with this hypothe-
sis, we identiﬁed clearly elevated levels of MIC-1 in TB rats,
which positively correlated with tumour size and anorexia.
The increase in circulating MIC-1 was not secondary to an-
orexia because pair-fed NTB rats had basal MIC-1 levels com-
parable with ad libitum fed controls. This ﬁnding parallels
recent observations in humans demonstrating that MIC-1
levels do not seem to be determined by the amount of food
intake.49 Different types of tumours express high levels of
MIC-1.21–23 Under inﬂammatory conditions, MIC-1 can also
be expressed by host tissue.50 While we have not identiﬁed
the origin of MIC-1 in TB rats, the lack of a general elevation
in pro-inﬂammatory cytokines and the strong correlation be-
tween tumour size and MIC-1 levels suggest the tumour as a
likely source of MIC-1 in hepatoma TB rats.
Our studies complement previous ﬁndings suggesting that
MIC-1 contributes to CACS via an AP/NTS-dependent action
as MIC-1-induced anorexia and body weight loss was attenu-
ated in mice with AP/NTS lesion.25 While only a combined
AP/NTS lesion completely blunted the effect of MIC-1
treatment on body weight, mice with speciﬁc lesions of the
AP showed reduced body weight gain but were protected
against body weight loss.
The clinical relevance of MIC-1 as a possible mediator of
CACS in humans has primarily been evaluated based on cor-
relations of MIC-1 blood levels with tumour and disease pa-
rameters (e.g. body weight loss). While in many clinical
studies MIC-1 levels correlated with the severity of body
weight loss in cancer patients,24,51 other studies did not ob-
serve such a correlation.52,53 Several clinical studies
highlighted the potential use of MIC-1 as a biological marker
for prognosis and diagnosis of certain types of cancer52,54,55
(see Fairlie et al.56 for review). It is important to highlight that
the clinical relevance of MIC-1 in human cancer patients ap-
pears to vary depending on the type of cancer.
Collectively, our studies substantiate the role of the AP in
CACS. We also identiﬁed MIC-1 as a possible humoral media-
tor of anorexia and body weight loss in hepatoma TB rats.
Both MIC-1 and local signalling processes in the AP/NTS re-
gion (e.g. GLP-1) represent promising therapeutic targets
for the treatment of CACS.
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signaling is involved in the mediation of CACS in hepatoma tumor-
bearing rats” 	  The	  following	  section	  contains	  an	  original	  research	  article	  that	  is	  in	  preparation	  and	  will	  be	  submitted	  to	  the	  Journal	  of	  Cachexia,	  Sarcopenia	  and	  Muscle	  for	  publication.	  	  	  	  My	   contribution	   to	   this	  manuscript	   includes:	   conception	   and	   design	   of	   research,	   data	  acquisition,	  data	  analysis,	  data	  interpretation	  and	  writing	  the	  manuscript.	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Abstract	  	  Background	  The	   cancer	   anorexia-­‐cachexia	   syndrome	   (CACS)	   is	   frequent	   in	   cancer	   patients.	   CACS	  increases	  morbidity,	  mortality	  and	  psychological	  suffering,	  and	  compromises	  treatment	  success.	  Currently,	  no	  pharmacological	  treatment	  is	  specifically	  approved	  and	  available	  for	  the	  therapy	  of	  CACS.	  Using	  a	  rat	  hepatoma	  tumour	  model,	  we	  recently	  demonstrated	  a	   role	   of	   the	   area	   postrema	   (AP)	   in	   the	   mediation	   of	   CACS,	   but	   the	   underlying	  mechanism	  and	  possible	  therapeutic	  targets	  still	  remain	  to	  be	  identified.	  Glucagon-­‐like	  peptide-­‐1	   (GLP-­‐1)	   is	  expressed	   in	  neurons	  of	   the	  nucleus	  tractus	  solitarii	   (NTS)	  and	   is	  implicated	   in	  malaise,	  nausea	  and	   food	  aversion.	  GLP-­‐1ergic	  neurons	  project	   from	  the	  NTS	  to	  the	  AP	  where	  the	  GLP-­‐1	  receptor	  (GLP-­‐1R)	  is	  highly	  expressed.	  We	  hypothesized	  that	  NTS/AP	  dependent	  GLP-­‐1	  signalling	  might	  play	  a	  role	  in	  the	  mediation	  of	  CACS.	  Methods	  Using	   hepatoma	   tumour-­‐bearing	   (TB)	   and	   healthy	   rats,	   we	   first	   tested	   whether	   a	  pharmacological	  blockade	  of	  brainstem	  GLP-­‐1	  receptors	  (GLP-­‐1R)	  via	  chronic	  delivery	  of	   the	   GLP-­‐1R	   antagonist	   exendin-­‐9	   (Ex-­‐9;	   100	   μg/day)	   into	   the	   fourth	   ventricle	  attenuated	   CACS.	   Second,	   we	   investigated	   whether	   a	   genetic	   knockdown	   of	   GLP-­‐1	  expression	   in	   the	   NTS	   ameliorates	   CACS.	   We	   used	   a	   lentiviral	   short-­‐harpin	   RNA	  approach	   to	   silence	   the	   pre-­‐proglucagon	   gene	   (PPG)	   encoding	   GLP-­‐1.	   Finally,	   using	   a	  two	  diets	  choice	  paradigm,	  we	  tested	  if	  tumour	  growth	  in	  our	  model	  is	  paralleled	  by	  the	  development	  of	  food	  aversion.	  	  Results	  In	  healthy	  animals,	  pharmacological	  and	  genetic	  blockade	  of	  brainstem	  GLP-­‐1	  signalling	  did	  not	  affect	   food	   intake	  or	  body	  weight.	   In	  contrast,	  Ex-­‐9	  attenuated	  anorexia,	  body	  weight	   loss	   and	   fat	   depletion	   compared	   to	   TB	   controls.	   Importantly,	   Ex-­‐9	   also	  ameliorated	   tumour-­‐induced	   loss	   of	   muscle	   mass.	   Similarly,	   TB	   animals	   with	   a	  knockdown	   of	   GLP-­‐1	   expression	   in	   the	   NTS	   had	   higher	   food	   intake,	   reduced	   body	  weight	  loss,	  and	  higher	  lean	  and	  fat	  mass	  compared	  to	  NTB	  controls.	  TB	  rats	  developed	  tumour-­‐induced	   food	   aversion	   because	   their	   flavour	   preference	   turned	   into	   a	   flavour	  rejection	  during	  tumour	  growth.	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  Conclusions	  Our	  study	  identifies	  brainstem	  GLP-­‐1	  as	  crucial	  mediator	  of	  CACS	  in	  hepatoma	  TB	  rats.	  In	  line	  with	  the	  function	  of	  GLP-­‐1	  as	  a	  mediator	  of	  aversion,	  emesis	  and	  nausea,	  we	  also	  demonstrated	  the	  development	  of	   food	  aversion	  during	  CACS	  in	  this	  model.	   	  Based	  on	  our	  current	  and	  recent	  findings,	  a	  local	  release	  of	  GLP-­‐1	  in	  the	  AP	  appears	  to	  contribute	  to	  CACS.	  Since	  the	  AP	  lacks	  a	  functional	  the	  blood-­‐brain-­‐barrier,	  the	  GLP-­‐1R	  represents	  a	   promising	   target	   for	   pharmacological	   approaches	   against	   CACS	   and	   possibly	   other	  forms	  of	  disease-­‐related	  anorexia/cachexia.	  	  
	  
Key	  terms:	  cancer,	  food	  intake,	  energy	  balance,	  hindbrain,	  food	  aversion,	  muscle.  
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INTRODUCTION	  	  The	  cancer	  anorexia-­‐cachexia	  syndrome	  (CACS)	  causes	  a	  decline	  of	  the	  clinical	  status	  of	  cancer	   patients	   and	   often	   becomes	   a	   life-­‐threatening	   condition	   [1].	   CACS	   increases	  mortality,	   reduces	   treatment	   success	   and	   produces	   severe	   psychological	   suffering	   of	  patients	   and	   their	   families	   [34,	   207].	   Its	   prevalence	   can	   reach	   up	   to	   85%	   in	   cancer	  patients	  [208].	  We	  recently	  demonstrated	  the	  importance	  of	  the	  area	  postrema	  (AP)	  of	  the	  brainstem	  for	  the	  mediation	  of	  CACS	  in	  hepatoma	  tumour-­‐bearing	  (TB)	  rats	  [209].	  In	  order	  to	  identify	  a	  possible	  therapeutic	  target,	  our	  current	  study	  aims	  to	  explore	  the	  role	  of	  the	  neuropeptide	  glucagon-­‐like	  peptide-­‐1	  (GLP-­‐1)	  in	  the	  brainstem	  as	  a	  mediator	  of	  CACS.	  	  GLP-­‐1	   is	   a	   posttranslational	   product	   of	   the	   peptide	   preproglucagon	   (PPG),	   which	   is	  expressed	   in	  enteroendocrine	  L-­‐cells	  of	   the	  small	   intestine	   [115,	  210,	  211]	  and	   in	   the	  
nucleus	   tractus	   solitarii	   (NTS)	   [127],	   which	   is	   an	   integrative	   and	   relay	   center	   for	  enteroceptive	   signals	   controlling	   food	   intake	   [27,	   106,	   212].	   GLP-­‐1-­‐expressing	   NTS	  neurons	  project	  to	  the	  AP	  [131,	  133],	  which	  is	  implicated	  in	  the	  physiological	  control	  of	  food	   intake,	  pathological	  anorexia,	  nausea,	  and	  emesis	  [87].	  The	  GLP-­‐1	  receptor	  (GLP-­‐1R)	  is	  highly	  expressed	  in	  the	  AP	  [127,	  129,	  130].	  	  Systemic	   as	  well	   as	   central	   administration	   of	   GLP-­‐1	   or	   the	   GLP-­‐1R	   agonist	   exendin-­‐4	  reduce	   food	   intake	   and	   body	  weight	   [121-­‐124].	  While	   the	   possible	   role	   of	   brainstem	  GLP-­‐1	   in	   the	   physiological	   control	   of	   energy	   balance	   is	   unclear,	   GLP-­‐1	   signalling	   is	  known	  to	  induce	  anorexia,	  nausea	  and	  food	  aversion	  in	  rodents	  and	  humans	  [134-­‐139].	  The	  AP/NTS	  region	  is	  activated	  in	  TB	  rodents	  [99,	  213],	  by	  the	  inflammatory	  endotoxin	  LPS,	   by	   the	   emetic	   agent	   LiCl,	   and	  by	   the	   chemotherapeutic	   drug	   cisplatin	   [143,	   214,	  215].	  These	  and	  other	  toxic	  agents	  lead	  to	  anorexia	  or	  malaise,	  which	  is	  reflected	  by	  the	  development	   of	   conditioned	   food	   aversion	   (CTA)	   [106,	   216,	   217].	   LPS	   and	   cisplatin-­‐induced	   anorexia	   are	   attenuated	   in	   rats	   receiving	   fourth	   ventricular	   injection	   of	   the	  GLP-­‐1R	   antagonist	   exendin-­‐9	   (Ex-­‐9)	   [142,	   144].	   Central	   administration	   of	   Ex-­‐9	   also	  prevents	  CTA	   induced	  by	  LiCl	   [140,	  141]	  and	  blunts	  LiCl-­‐induced	  AP	  activation	   [137].	  We	  hypothesize	  that	  GLP-­‐1	  might	  also	  contribute	  to	  anorexia	  and	  cachectic	  body	  weight	  loss	  under	  chronic	  cancer	  conditions.	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  We	   first	   examined	   whether	   a	   pharmacological	   blockade	   of	   brainstem	   GLP-­‐1R	   by	  chronic	  fourth	  ventricular	  infusion	  of	  Ex-­‐9	  blunts	  CACS.	  Second,	  in	  order	  to	  confirm	  the	  involvement	   of	   local	   brainstem	  GLP-­‐1	   as	   a	  mediator	   of	   CACS,	  we	   knocked	   down	  PPG	  gene	  expression	  in	  the	  NTS	  by	  a	  lentiviral	  short-­‐hairpin	  RNA	  (shRNA)	  approach.	  Third,	  we	  also	   tested	   if	   the	  development	  of	  CACS	   is	  paralleled	  by	  CTA	   in	  our	   tumour	  model.	  Although	   sickness-­‐related	   food	   aversion	   and	   anorexia	   are	   conceptualized	   as	   different	  phenomena,	   they	   often	   occur	   together	   and	   might	   act	   in	   concert	   to	   negatively	   affect	  appetite	  and	  energy	  intake.	  	  
	  
	  
MATERIALS	  AND	  METHODS	  
	  
Animals	  and	  housing	  conditions	  
	  Male	   Buffalo	   rats	   (Charles	   River	   Laboratory,	   USA)	   were	   housed	   at	   controlled	  temperature	   (21±1°C)	   under	   a	   12-­‐hour	   artificial	   light	   cycle	  with	   ad	   libitum	   access	   to	  standard	   laboratory	   rat	   chow	   (890	   25	   W16,	   Provimi	   Kliba,	   AG,	   Kaiseraugst,	  Switzerland)	  except	  for	  the	  CTA	  studies	  (see	  below).	  All	  experiments	  were	  approved	  by	  the	  Veterinary	  Office	  of	  the	  Canton	  Zurich	  (95/2013).	  	  
Cell	  culture	  and	  tumour	  model	  
	  The	  hepatoma	   tumour	  model	  was	  described	  previously	   [209].	  Morris	  hepatoma	  7777	  cells	   (McA-­‐RH7777,	  Catalog	  No.	  CRL-­‐1601,	  ATCC,	  USA)	  were	   cultured	  under	   standard	  conditions	   in	   DMEM	   supplemented	   with	   10%	   fetal	   bovine	   serum	   and	   1%	   penicillin-­‐streptomycin.	  A	  trypan	  blue	  staining	  was	  performed	  to	  confirm	  the	  viability	  of	  tumour	  cells.	   	   For	   tumour	   induction,	   107	   cells	   (dissolved	   in	   250	   μl	   PBS)	   were	   inoculated	  subcutaneously	   between	   the	   scapulae	   under	   short	   isoflurane	   anaesthesia.	   Control	  animals	  were	  anesthetized	  and	  injected	  with	  PBS	  only.	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Fourth	  ventricular	  cannulation	  for	  infusion	  of	  Ex-­‐9	  Rats	   (250-­‐280	   g)	  were	  placed	   in	   a	   stereotactic	   frame	  under	   isoflurane	   anaesthesia.	  A	  guide	   cannula	   (9mm	   326OPG/Spc,	   Plastics	   One,	   USA)	   was	   implanted	   into	   the	   4th	  ventricle	   and	   anchored	   by	   dental	   cement	   and	   stainless	   screws.	   The	   coordinates	   for	  cannula	   placement	   (bregma	   -­‐11.6	   mm,	   lateral	   0.0	  mm,	   dorsoventral	   -­‐7.2	   mm)	   were	  chosen	   according	   to	   the	   rat	   brain	   atlas	   of	   Paxinos	   and	  Watson	   [218].	   The	   rats	   were	  treated	   with	   antibiotics	   (7.5	   mg/kg,	   BaytrilR),	   prednisolone	   (25	   μg/kg,	   PrednisolutR)	  and	   analgesic	   (1	   mg/kg,	   NorocarpR).	   After	   recovery,	   the	   correct	   placement	   of	   the	  cannula	  was	  verified	  by	  measuring	   the	  hyperglycaemic	  response	   to	   fourth	  ventricular	  infusion	  of	  5-­‐thio-­‐D-­‐glucose	  (5TG,	  210	  μg	  5TG	  dissolved	  in	  3	  μl	  of	  saline).	  Only	  animals	  with	  a	  correct	  cannula	  placement	  display	  elevated	  plasma	  glucose	  levels	  [219].	  Animals	  that	  did	  not	  show	  an	  increase	  of	  at	  least	  100%	  in	  their	  plasma	  glucose	  concentration	  30	  min	  after	  5TG	  injection	  were	  excluded	  from	  the	  experiment. 
 
Measurement	  of	  energy	  expenditure	  	  The	  experiments	  were	  conducted	   in	  an	  open-­‐circuit	   indirect	  calorimetric	  system	  (TSE	  Phenomaster,	   Bad	   Homburg,	   Germany)	   equipped	   with	   internal	   food	   hoppers	   for	  continuous	   recording	   of	   food	   consumption.	   The	   animals	   were	   single-­‐housed	   in	  metabolic	  cages	  and	  adapted	  to	  the	  housing	  conditions	  for	  7	  days	  before	  the	  start	  of	  the	  experiment.	   Body	   weight	   was	   measured	   daily	   before	   dark	   onset.	   Food	   intake	   and	  respiratory	  gas	  exchange	  (O2	  and	  CO2)	  were	  recorded	  automatically	  at	  17-­‐min	  intervals	  throughout	  the	  entire	  experiment.	  	  
First,	  we	  investigated	  the	  effect	  of	  chronic	  central	  Ex-­‐9	  treatment	  on	  food	  intake,	  body	  weight,	   metabolic	   rate	   and	   respiratory	   exchange	   ratio	   (RER)	   in	   non-­‐tumour-­‐bearing	  (NTB)	   rats.	   After	   baseline	   measurements,	   primed	   osmotic	   minipumps	   (model	   2ML2,	  ALZET,	  DURECT	   corporation,	  USA)	  were	   implanted	   subcutaneously	   into	   the	   left	   flank	  between	  the	  chest	  and	  the	  hind	  limbs	  and	  connected	  to	  the	  forth	  ventricular	  cannula	  via	  a	  subcutaneous	  vinyl	  catheter	  (C312VT,	  Plastics	  One,	  USA).	  Minipumps	  were	  filled	  with	  Ex-­‐9	   or	   saline	   for	   controls.	   The	  minipumps	   released	   a	   constant	   amount	   of	   Ex-­‐9	   (100	  μg/day)	   directly	   into	   the	   4th	   ventricle.	   Similar	   experiments	   were	   conducted	   in	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hepatoma	   tumour-­‐bearing	   rats.	   After	   baseline	   measurements,	   tumour	   cells	   were	  inoculated	  in	  two	  groups	  of	  TB	  animals	  receiving	  Ex-­‐9	  or	  saline	  treatment	  as	  described	  above.	  Minipumps	  were	  implanted	  on	  day	  9	  after	  tumour	  inoculation,	  i.e.	  at	  the	  typical	  onset	  of	  the	  anorectic	  response	  [209,	  220].	  The	  minimump	  infusion	  lasted	  for	  11	  days	  until	  the	  animals	  were	  euthanized	  according	  to	  the	  ethical	  criteria	  for	  the	  termination	  of	  the	   experiments.	   Animals	   were	   euthanized	   for	   tissue	   collection	   and	   carcass	   analysis	  with	  a	  lethal	  intraperitoneal	  dose	  of	  pentobarbital	  (100	  mg/kg)	  injected	  shortly	  before	  dark	  onset	  (see	  below).	  
	  
Lentiviral	  vectors	  
High-­‐titer	  (>109	  IU/ml)	  lentiviral	  vectors	  dissolved	  in	  PBS,	  produced	  by	  Sigma-­‐Aldrich,	  were	   gently	   provided	   by	  Dr.	   Shin	   Lee,	   ETHZ,	   Zurich,	   Switzerland.	   These	   viral	   vectors	  expressed	   either	   a	   non-­‐target	   sequence	   (control)	   shRNA	  or	   a	   shRNA	  directed	   against	  the	  rat	  PPG	  mRNA	  under	  the	  control	  of	  the	  human	  U6	  promoter.	  In	  addition,	  the	  vectors	  contained	  an	  independent	  enhanced	  green	  fluorescent	  protein	  (turboGFP)	  cassette	  for	  the	   detection	   of	   transduced	   neurons.	   The	   PPG	   shRNA	   oligonucleotide	   sequence	   was	  
tgccaaacgtcatgatgaatt. 	  
Lentiviral	  shRNA	  knockdown	  of	  PPG	  gene	  expression	  in	  the	  NTS	  	  Rats	   (260-­‐320	   g)	   were	   anesthetized	   with	   an	   ip	   injection	   of	   50mg/kg	   ketamine	   and	  6mg/kg	   xylazine	   and	   placed	   in	   a	   stereotactic	   frame	   with	   the	   head	   in	   a	   ventroflexed	  position.	   A	   2	   cm	   midline	   incision	   was	   made	   above	   the	   occipito-­‐atlantal	   joint,	   the	  muscles	   were	   retracted	   and	   the	   joint	   capsule	   was	   opened.	   For	   the	   injections,	   a	   10μl	  glass-­‐syringe	  (Nanofil,	  World	  Precision	  Instrument,	  USA)	  equipped	  with	  a	  35G	  bevelled	  needle	  (World	  Precision	   Instrument,	  USA)	  was	  attached	  to	  a	  stereotactic	  arm.	  Using	  a	  microinfusion	  pump	   (World	  Precision	   Instrument,	  USA),	   2.0	   μl	   of	   virus	   solution	  were	  infused	  bilaterally	  under	  visual	  control	   into	   the	  NTS	  over	  20	  min	  (400	  μm	  lateral	  and	  100	   μm	   caudal	   to	   the	   obex,	   and	   600	   μm	   below	   the	   surface	   of	   the	   brain).	   These	  coordinates	  were	  chosen	  to	  target	  the	  area	  of	  the	  NTS	  with	  the	  highest	  density	  of	  PPG	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neurons	  [221,	  222].	  To	  prevent	  reflux	  of	  virus	  solution,	  the	  needle	  was	  left	   in	  position	  for	  10	  min	  after	  the	  infusion.	  The	  needle	  was	  then	  removed	  and	  the	  skin	  sutured.	  Post-­‐surgical	  treatments	  were	  the	  same	  as	  described	  above.	  
Three	  weeks	  after	  the	   lentivirus	   injection,	  rats	  were	  single-­‐housed	  and	  adapted	  to	  the	  housing	  conditions	  for	  14	  days	  before	  tumour	  cell	  injection.	  PPG	  knockdown	  (PPG-­‐KD)	  and	  control	  animals	  were	  kept	  in	  cages	  equipped	  with	  external	  food	  hoppers	  for	  manual	  measurement	   of	   food	   intake	   (Research	   Diets,	   NJ,	   USA).	   Daily	   food	   intake	   and	   body	  weight	  were	  measured	  daily	   shortly	   before	  dark-­‐onset.	  At	   the	   end	  of	   the	   experiment,	  animals	  were	  euthanized	  for	  tissue	  collection	  and	  carcass	  analysis	  with	  a	  lethal	  dose	  of	  pentobarbital	  (see	  above).	  
	  
Tissue	  collection,	  qPCR,	  and	  confirmation	  of	  PPG	  knockdown	  	  After	   sacrifice,	   the	   caudal	   medulla	   was	   dissected	   and	   snap-­‐frozen	   in	   liquid	   nitrogen.	  Samples	  were	  stored	  at	  -­‐80°C	  until	  processing.	  Micro-­‐punch	  samples	  (2	  mm	  diameter)	  containing	   the	   AP/NTS	   region	   were	   obtained	   under	   a	   dissecting	   microscope	   on	   3	  consecutive	   250	   μm-­‐thick	   coronal	   sections	   previously	   cut	   on	   a	   cryostat	   (Leica	  microsystem,	  Germany)	  and	  pooled	   together.	  Sections	  were	  collected	  starting	  250	  μm	  caudal	   to	   the	   obex.	   RNA	  was	   extracted	   and	   purified	   according	   to	   the	  manufacturer’s	  instructions	   (ReliaPrep,	   Promega,	  USA).	  The	   concentration	   and	   integrity	   of	  RNA	  were	  measured	   using	   a	   nanodrop	   system	   (NanoDrop	   1000	   Spectrophotometer,	   Thermo	  Scientific).	  cDNA	  was	  generated	  from	  the	  extracted	  RNA	  using	  the	  high	  capacity	  cDNA	  reverse	   transcription	   kit	   (Applied	   Biosystems,	   USA).	   Quantitative	   polymerase	   chain	  reaction	   was	   performed	   using	   the	   7500	   Fast	   system	   (Applied	   Biosystem/Life	  technologies)	  with	  pre-­‐designed	  Taqman	  probes	   (Thermoscientific).	   	  Rat	  S18	  (Ref.	  nr.	  Rn01428913)	  was	  used	  as	  housekeeping	  reference	  gene	  and	  the	  following	  probes	  were	  used	  to	  amplify	  PPG	  (Ref.	  nr.	  Rn00562293),	  GLP-­‐1R	  (Ref.	  nr.	  Rn00562406),	  IL-­‐1β	  (Ref.	  nr.	   Rn00580432),	   TNF-­‐α	   (Ref.	   nr.	   Rn01525860),	   and	   IFN-­‐γ	   (Ref.	   nr.	   Rn00594078)	  transcripts.	  The	  relative	  expression	  of	  PPG,	  GLP-­‐1R,	  TNF-­‐α,	  IL-­‐1β,	  and	  IFN-­‐γ	  mRNA	  was	  calculated	  using	  the	  comparative	  delta-­‐delta	  Ct	  method	  [223].	  Each	  sample	  was	  run	  in	  duplicates.	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Measurements	  of	  brainstem	  PPG	  and	  GLP-­‐1R	  expressions,	  and	  circulating	  GLP-­‐1	  levels	  	  	  PPG	  and	  GLP-­‐1R	  mRNA	  expression	  levels	  were	  analysed	  in	  non-­‐operated	  TB,	  NTB,	  and	  NTB/pair-­‐fed	   (PF)	   rats	   (220-­‐250	   g).	  Moreover,	   to	   evaluate	   a	   possible	   contribution	   of	  peripheral	  GLP-­‐1	  signalling	  in	  the	  mediation	  of	  CACS,	  circulating	  GLP-­‐1	  levels	  were	  also	  measured.	  	  For	  this	  experiment	  rats	  were	  single-­‐housed	  as	  described	  above.	  Daily	  food	  intake	  and	  body	  weight	  were	  measured	   shortly	  before	  dark-­‐onset.	   Starting	   from	  nine	  days	  after	  tumour	  induction	  of	  the	  TB	  group,	  PF	  animals	  received	  the	  same	  amount	  of	  food	  that	  was	  consumed	  the	  previous	  day	  by	  the	  TB	  rats.	  At	  the	  end	  of	  the	  experiment	  (i.e.	   19	   days	   after	   tumour-­‐induction)	   all	   animals	   were	   euthanized	   and	   brains	   were	  immediately	  dissected	  and	  processed	  for	  gene	  expression	  analysis	  as	  described	  above.	  Blood	   was	   collected	   from	   the	   right	   ventricle	   of	   the	   heart	   in	   EDTA-­‐coated	   tubes	  (Sarstedt,	   Germany)	   containing	   a	   DPP-­‐IV	   inhibitor	   (1:100,	   Millipore,	   USA)	   and	  centrifuged	  at	  7’000	  x	  g	  (4°C,	  7	  min)	  to	  obtain	  plasma	  which	  was	  stored	  in	  aliquots	  at	  -­‐80°C	   for	   subsequent	   GLP-­‐1	   measurements.	   The	   levels	   of	   GLP-­‐1	   were	   measured	   in	  triplicates	   using	   a	   commercial	   kit	   (Meso	   Scale	   Discovery,	   USA)	   according	   to	   the	  manufacturer	  instructions.	  	  
Computed	  tomography	  (CT)	  scanning	  and	  muscle	  weight	  measurements	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Food	  aversion	  study	  
	  A	  two	  diets	  choice	  paradigm	  was	  used.	  The	  diets	  had	  identical	  nutrient	  composition	  and	  caloric	   content,	   but	   different	   flavours	   (AIN-­‐76A-­‐modified	   diets	   with	   either	   0.4%	  chocolate	  or	  0.4%	  vanilla	   flavour,	   respectively,	  Research	  Diets,	  US).	  Buffalo	   rats	   (300-­‐340	  g)	  were	  single-­‐housed	  in	  BIODAQ	  cages	  equipped	  with	  2	  external	  food	  hoppers	  for	  the	  parallel	  measurement	  of	  diet	  consumption.	  First,	  taste	  preference	  for	  the	  two	  diets	  was	  determined	  before	   tumour	   induction	  by	  measuring	   the	   relative	   daily	   food	   intake	  over	  a	  4-­‐days	  period.	  For	  the	  following	  7	  days,	  the	  animals	  received	  standard	  chow	  only	  (AIN-­‐76A,	   Research	   Diet,	   US).	   Two	   days	   after	   the	   food	   preference	   test,	   in	   half	   of	   the	  animals,	  tumour	  growth	  was	  induced,	  while	  in	  control	  animals	  PBS	  was	  injected.	  Before	  the	   expected	   onset	   of	   the	   anorectic	   response	   (i.e.	   5	   days	   after	   tumour	   induction	   [the	  anorectic	  response	  typically	  starts	  around	  day	  9;	  [209,	  220]]),	  all	  animals	  received	  their	  individually	   preferred	   flavoured	   diet	   (i.e.	  mean	   relative	   consumption	   during	   the	   food	  preference	  test	  >50%)	  ad	  libitum	  for	  8	  days.	  During	  the	  anorectic	  phase	  (14	  days	  after	  tumour	   induction),	   the	   standard	   diet	   was	   presented	   again	   for	   2	   days	   before	   a	   final	  preference	   test	  was	   conducted	  by	  presenting	  both	   flavoured	  diets	   over	  5	   consecutive	  days.	  	  	  
Data	  evaluation	  and	  statistical	  analysis	  	  All	  data	  were	  expressed	  as	  mean	  ±	  SEM.	  In	  the	  Ex-­‐9	  studies,	  body	  weight	  changes	  were	  calculated	  by	  subtracting	  the	  weight	  of	  the	  animal	  at	  the	  day	  of	  minipump	  implantation	  from	   the	   final	   body	   weight.	   These	   values	   were	   corrected	   for	   the	   weight	   of	   the	  minipumps.	   In	   the	   experiments	   involving	   PPG-­‐KD	   animals,	   body	   weight	   change	   was	  calculated	   by	   subtracting	   the	   body	  weight	   before	   the	   onset	   of	   the	   anorectic	   response	  (day	   8	   after	   tumour	   induction)	   from	   the	   body	   weight	   at	   the	   end	   of	   the	   experiment.	  Metabolic	   rate	   and	  RER	  were	   calculated	   from	  O2	   consumption	   and	  CO2	  production	   as	  described	  previously	  [220].	  Metabolic	  rate	  data	  were	  normalized	  for	  body	  weight.	  The	  calculation	  was	  based	  on	  the	  following	  equation:	  total	  EE	  (kcal/kg/h)	  =	  (3.9	  x	  VO2	  +	  1.1	  x	   VCO2)	   /	   1000.	   For	   the	   experiment	   involving	   Ex-­‐9	   treatment	   in	   healthy	   rats,	   the	  average	  values	  obtained	  from	  2	  consecutive	  days	  prior	  to	  minipump	  implantation	  were	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used	  as	  baseline	  and	  compared	  to	  the	  average	  values	  of	  treatment	  days	  3	  and	  4.	  In	  the	  experiment	  involving	  TB	  animals	  treated	  with	  Ex-­‐9,	  the	  values	  obtained	  between	  days	  2-­‐3	  after	  tumour	  inoculation	  were	  used	  as	  baseline	  (i.e.,	  prior	  to	  the	  onset	  of	  anorexia)	  and	   compared	   to	   the	   average	   values	   on	   days	   12-­‐13	   after	   tumour	   induction	   (i.e.	  treatment	  days	  3-­‐4).	  In	  the	  food	  aversion	  study,	  diet	  preference	  was	  calculated	  for	  each	  animal	  by	  dividing	  the	  consumption	  of	  the	  preferred	  diet	  by	  total	  daily	  food	  intake.	  	  Unpaired	   Student’s	   t-­‐test	   was	   used	   for	   comparison	   between	   two	   groups.	   Statistical	  comparisons	  between	  multiple	  groups	  were	  performed	  using	  one-­‐way	  ANOVA	  followed	  by	  Tukey’s	  post-­‐hoc	  test.	  For	  all	  statistical	  tests,	  a	  p-­‐value	  less	  than	  0.05	  was	  considered	  significant.	  Data	  were	  analysed	  using	  Prism	  GraphPad	  5.0.	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RESULTS	  	  	  
Chronic	   fourth	  ventricular	   infusion	  of	  Ex-­‐9	  did	  not	  affect	  energy	  balance	   in	  non-­‐tumour-­‐
bearing	  rats	  	  Chronic	  12-­‐day	  infusion	  of	  Ex-­‐9	  into	  the	  fourth	  ventricle	  did	  not	  affect	  daily	  food	  intake	  (Fig.	  1A-­‐B),	  body	  weight	  and	  body	  weight	  gain	  (Fig.	  1	  C-­‐D)	  compared	  to	  control	  animals.	  Similarly,	  no	  change	  in	  body	  composition	  occurred	  between	  Ex-­‐9	  treated	  rats	  compared	  to	   controls,	   and	   Ex-­‐9	   treated	   and	   control	   animals	   did	   not	   differ	   in	   body	   composition	  (data	  not	  shown).	  Moreover,	  metabolic	  rate	  and	  RER	  were	  similar	  in	  both	  groups	  and	  no	  significant	  changes	  occurred	  during	  treatment	  (Fig.	  1E-­‐F).	  	  
Chronic	  fourth	  ventricular	  infusion	  of	  Ex-­‐9	  attenuated	  CACS	  in	  hepatoma	  tumour-­‐bearing	  
rats	  	  No	  significant	  difference	  in	  food	  intake	  between	  the	  experimental	  groups	  occurred	  prior	  to	   minipump	   implantation.	   Tumours	   became	   palpable	   around	   day	   9	   after	   tumour	  induction,	   which	   typically	   coincides	   with	   the	   approximate	   onset	   of	   the	   anorectic	  response	  in	  this	  tumour	  model.	  Vehicle-­‐treated	  TB	  (Vehicle/TB)	  animals	  showed	  a	  clear	  anorectic	   response.	   In	   Ex-­‐9-­‐treated	   TB	   (Ex-­‐9/TB)	   rats,	   anorexia	   was	   markedly	  attenuated	  compared	  to	  controls	  (Figure	  2A).	  On	  average,	  daily	  food	  intake	  during	  the	  treatment	  period	  (i.e.	  from	  day	  10	  to	  day	  20	  after	  tumour	  induction)	  was	  16.3±0.4	  g	  vs.	  13.9±0.6	  g	  (Ex-­‐9/TB	  vs.	  Vehicle/TB;	  p	  <	  0.01),	  which	  corresponds	  to	  17%	  higher	  food	  intake	  of	  Ex-­‐9/TB	  rats	  compared	  to	  controls	  (Figure	  2B).	  Tumour-­‐induced	  body	  weight	  loss	  was	  attenuated	  in	  rats	  receiving	  Ex-­‐9.	  While	  the	  difference	  in	  absolute	  body	  weight	  did	   not	   reach	   statistical	   significance,	   the	   change	   in	   body	   weight	   was	   significantly	  different	  between	   treatment	  groups	   (Figure	  2C).	  This	  appeared	   to	  be	  mainly	  due	   to	  a	  preservation	  of	  fat	  mass	  because	  Ex-­‐9/TB	  rats	  had	  higher	  fat	  mass	  but	  similar	  total	  lean	  mass	  compared	  to	  Vehicle/TB	  animals	  (Figure	  2D).	  However,	  Ex-­‐9/TB	  rats	  had	  higher	  gastrocnemius	   and	   total	   hind	   limb	  muscle	  weights	   (i.e.	   sum	  of	   gastrocnemius,	   tibialis	  and	  soleus	  muscle	  mass)	  than	  TB	  controls	  (Fig.	  2E).	  Relative	  to	  baseline	  conditions,	  i.e.	  before	   the	   onset	   of	   anorexia	   on	   days	   2-­‐3	   after	   tumour	   induction,	   control	   rats	   had	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significantly	  lower	  RER	  values	  on	  days	  12-­‐13	  reflecting	  an	  increased	  lipid	  metabolism.	  While	  the	  tumour-­‐dependent	  reduction	  in	  RER	  was	  not	  observed	  in	  the	  Ex-­‐9/TB	  group,	  the	  RER	  of	  these	  animals	  did	  not	  significantly	  differ	  from	  the	  vehicle	  treated	  group	  (Fig.	  3A).	  The	  metabolic	   rate	  was	   similar	  between	  Ex-­‐9/TB	  and	  Vehicle/TB	  animals	  before	  and	   during	   the	   treatment	   period	   (Fig.	   3B).	   Importantly,	   tumour	  weight	   did	   not	   differ	  significantly	   between	   Ex-­‐9/TB	   and	   Vehicle/TB	   rats	   at	   the	   end	   of	   the	   experiment	  (17.5±1.1	  vs.	  14.2±1.2	  g).	  	  	  
Knockdown	  of	  PPG	  expression	  in	  the	  NTS	  attenuated	  CACS	  	  Fig.	   4A	   shows	   a	   representative	   histological	   photomicrograph	   of	   the	   right	   caudal	   NTS	  displaying	  GFP	  fluorescence	  7	  weeks	  after	  the	  lentiviral	  vector	  injection.	  The	  indicated	  target	   region	   (Fig.	   4B)	   corresponds	   to	   the	   caudal	   NTS	   area	   where	   PPG	   neurons	   are	  located	   [222].	   Seven	   weeks	   after	   the	   lentivirus	   injection,	   PPG-­‐KD	   rats	   expressed	  significantly	   (-­‐47%)	   less	  PPG	  mRNA	   in	   the	  AP/NTS	   region	   than	   controls	   (Fig.	  4C).	  No	  change	   in	   GLP-­‐1R	   expression	   occurred	   between	   the	   experimental	   groups	   (Fig.	   4D).	  Furthermore,	   mRNA	   levels	   of	   TNF-­‐α,	   IL-­‐1β,	   and	   IFN-­‐γ	   in	   the	   AP/NTS	   did	   not	   differ	  between	  PPG-­‐KD	  and	  controls.	  The	  relative	  expression	  values	  were	  comparable	  to	  non-­‐operated	  TB	  and	  NTB	  rats	   indicating	   the	  absence	  of	   local	   virus-­‐induced	   inflammation	  (data	  not	  shown).	  Both	  experimental	  groups	  showed	  similar	  food	  intake	  in	  the	  week	  prior	  to	  tumour	  cell	  inoculation	  (PPG-­‐KD:	  23.0±1.0	  g/day	  vs.	  controls	  23.5±1.0	  g/day)	  and	  prior	  to	  tumour	  anorexia	   (Fig	   5A).	   Food	   intake	   of	   control	   animals	   decreased	   10	   days	   after	   tumour	  induction	   leading	   to	   a	   30%	   reduction	   on	   the	   last	   day	   of	   the	   experiment	   compared	   to	  baseline	   (i.e.	   days	   1-­‐2	   after	   tumour	   induction,	   Fig.	   5A).	   On	   average,	   mean	   daily	   food	  intake	  was	  26%	  higher	  in	  PPG-­‐KD	  than	  controls	  from	  day	  8	  to	  the	  end	  of	  the	  experiment	  (Fig.	  5C).	  Anorexia	  in	  control	  animals	  was	  associated	  with	  marked	  loss	  of	  body	  weight.	  This	  effect	  was	  significantly	  attenuated	  in	  PPG-­‐KD	  animals	  beginning	  at	  day	  13	  (Fig.	  5B-­‐D).	  The	  body	  weight	  change	  between	  day	  8	  after	  tumour	  induction	  and	  the	  end	  of	  the	  experiment	  was	  -­‐6.4±2.7	  g	  vs.	  -­‐23.9±4.7	  g	  (PPG-­‐KD	  vs.	  controls).	  The	  differences	  in	  body	  weight	  were	  due	  to	  both	  higher	  lean	  and	  fat	  volumes	  (Fig.	  5E).	  Despite	  the	  higher	  lean	  mass	  of	  the	  PPG-­‐KD	  group,	  differences	  in	  hind	  limb	  muscle	  mass	  did	  not	  reach	  statistical	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significance	   (not	   shown).	  Tumour	  weight	  did	  not	  differ	   significantly	  between	   the	   two	  groups	  (PPG-­‐KD:	  11.9±1.1	  vs.	  controls:	  12.1±0.9	  g).	  	  	  
Tumour	  growth	  decreased	  PPG	  expression	  without	  affecting	  circulating	  GLP-­‐1	  and	  GLP-­‐1R	  
expression	  in	  the	  AP/NTS.	  	  Circulating	  active	  GLP-­‐1	  levels	  were	  not	  significantly	  different	  between	  NTB,	  PF	  and	  TB	  rats	   (Fig.	   6A).	   Tumour-­‐bearing	   animals	   had	   lower	   PPG	   expression	   compared	   to	   NTB	  rats.	  However,	  pair-­‐feeding	  also	  reduced	  PPG	  expression	  to	  the	  level	  of	  the	  TB	  animals	  (Fig.	   6B).	  No	   significant	   difference	   in	  GLP-­‐1R	   expression	   levels	   occurred	  between	   the	  experimental	  groups.	  	  	  
Hepatoma	   tumour-­‐bearing	   rats	   developed	   a	   conditioned	   taste	   aversion	   during	   cancer	  
anorexia	  	  TB	   rats	   showed	   lower	   food	   intake	   than	   NTB	   animals	   from	   day	   8	   after	   tumour	   cell	  inoculation.	  Daily	   food	   intake	   stabilized	  at	   a	   lower	   level	  with	   an	  average	   reduction	  of	  30%	  in	  comparison	  to	  NTB	  animals	  (Fig.	  7B).	  In	  both	  experimental	  groups,	  alteration	  of	  the	  diet’s	  flavour	  properties	  did	  not	  affected	  total	  food	  consumption.	  In	  the	  first	  diet	  choice	  test	  (i.e.	  prior	  to	  tumour	  induction),	  animals	  exhibited	  a	  bimodal	  pattern	   of	   preference	   (i.e.,	   8	   animals	   preferred	   the	   vanilla	   flavour	   diet	   and	   7	   the	  chocolate	   flavour	   diet	   (87%	   and	   80%	   of	   total	   intake	   over	   the	   4	   testing	   days;	  respectively).	   The	   relative	   flavour	   preference	   values	   remained	   constant	   during	   4	  consecutive	  testing	  days	  (Fig.	  7C).	  Vanilla	  and	  chocolate	  preferring	  rats	  were	  allocated	  in	   similar	   numbers	   to	   both	   experimental	   groups	   (TB	   and	  NTB).	  NTB	  animals	   showed	  constant	   food	   intake	   and	  a	   constant	  body	  weight	   gain	  during	   the	   entire	   experimental	  period.	   In	   TB	   rats,	   food	   intake	   decreased	   8	   days	   after	   tumour	   induction	   (Fig.	   7B),	  leading	  to	  significant	  body	  weight	  loss	  compared	  to	  NTB	  (data	  not	  shown).	  During	  the	  second	  preference	  test,	  healthy	  controls	  had	  a	  similar	  flavour	  preference	  as	  in	  the	  first	  trial	   before	   tumour	   induction.	   TB	   rats	   clearly	   avoided	   the	   flavour	   that	  was	   preferred	  before	  tumour	  growth	  and	  presented	  during	  the	  conditioning	  phase	  (Fig.	  7D).	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DISCUSSION	  	  The	  present	  study	  extends	  our	  previous	  work	  that	  established	  a	  role	  of	  the	  AP	  in	  a	  rat	  hepatoma	   tumour	   model	   of	   CACS	   [209].	   We	   identified	   GLP-­‐1	   as	   a	   neurochemical	  mediator	  of	  brainstem-­‐dependent	  CACS	  providing	  first	  evidence	  that	  the	  central	  GLP-­‐1	  system	  mediates	  cancer	  anorexia	  and	  subsequent	  body	  weight	  loss.	  A	  pharmacological	  and	   genetic	   blockade	   of	   GLP-­‐1R	   signalling	   in	   the	   brainstem	   attenuated	   anorexia	   and	  body	  weight	   loss	   induced	  by	  tumour	  growth.	  Notably,	   the	  blockade	  of	  brainstem	  GLP-­‐1R	   by	   Ex-­‐9	   also	   ameliorated	  muscle	  wasting.	   In	   line	  with	   the	   function	   of	   GLP-­‐1	   as	   a	  mediator	   of	   aversion,	   emesis	   and	   nausea,	   we	   also	   demonstrated	   the	   development	   of	  food	  aversion	  during	  CACS	  in	  hepatoma	  TB	  rats.	  	  In	  several	  studies,	  endogenous	  GLP-­‐1	  signalling	  was	  inhibited	  in	  the	  brainstem	  to	  study	  its	  involvement	  in	  energy	  balance.	  At	  least	  in	  freely	  feeding	  rats	  a	  blockade	  of	  brainstem	  GLP-­‐1R	  does	  not	  affect	  energy	  intake	  or	  body	  weight	  development	  [144,	  224,	  225].	  Our	  findings	  are	  consistent	  with	  these	  studies	  because	  neither	  GLP-­‐1R	  blockade	  nor	  PPG-­‐KD	  affected	  food	  intake	  or	  body	  weight	  in	  NTB	  rats.	  Hence,	  brainstem	  GLP-­‐1	  does	  not	  seem	  to	   be	   required	   for	   the	   maintenance	   of	   energy	   balance	   under	   standard	   experimental	  conditions	   in	   healthy	   animals.	   Consequently,	   the	   anti-­‐CACS	   effects	   described	   in	   our	  experiments	   are	   due	   to	   a	   specific	   blockade	   of	   a	   pathological	   activation	   of	   the	   GLP-­‐1	  system,	  but	  not	  secondary	  to	  a	  change	  in	  basal	  energy	  balance.	  	  	  	  	  	  Although	  peripherally	  administered	  GLP-­‐1	  reduces	   food	   intake	  and	  body	  weight	   [125,	  226-­‐228],	   our	   findings	   do	   not	   suggest	   a	   role	   of	   peripheral	   GLP-­‐1	   in	   the	  mediation	   of	  CACS.	  There	  was	  only	  a	  tendency	  of	  increased	  circulating	  GLP-­‐1	  in	  TB	  rats	  but	  the	  levels	  were	   not	   significantly	   different	   from	  NTB	   or	   pair-­‐fed	   animals.	   Intestinal	   GLP-­‐1	  might	  also	  act	  locally	  on	  GLP-­‐1R	  on	  terminals	  of	  intestinal	  vagal	  afferents	  [226,	  229].	  However,	  according	  to	  our	  recent	  studies,	  vagal	  afferents	  are	  not	  required	  for	  CACS	  in	  this	  tumour	  model	   [209].	   Our	   current	   study	   rather	   supports	   a	   role	   of	   brainstem	   GLP-­‐1	   and	   local	  GLP-­‐1R	  in	  the	  mediation	  of	  CACS.	  	  The	  AP	  and	  the	  lateral	  parabrachial	  nucleus	  (LPBN)	  are	  important	  first	  order	  projection	  sites	  of	  NTS	  GLP-­‐1	  neurons	  in	  the	  brainstem	  [131].	  Fourth	  ventricular	  Ex-­‐9	  is	  unlikely	  to	  block	  GLP-­‐1R	  in	  the	  LPBN	  or	  in	  the	  forebrain	  because	  of	  the	  rostral-­‐to-­‐caudal	  flow	  of	  the	  cerebrospinal	   fluid	   [144,	   230].	   Therefore,	   CACS	   appears	   to	   be	   driven	   by	   GLP-­‐1-­‐ergic	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projections	   from	   the	  NTS	   to	   the	  AP.	   This	   is	   also	   consistent	  with	   the	   similarity	   of	   our	  current	  findings	  and	  the	  outcome	  of	  our	  recent	  AP	  lesion	  studies	  [209].	  The	  results	  of	  our	  pharmacological	  and	  genetic	  blockade	  of	  brainstem	  GLP-­‐1	  signalling	  were	  similar.	  In	  both	  approaches,	  we	  observed	  either	  a	  positive	  treatment	  effect	  on	  lean	  mass	  or	  muscle	  mass	  in	  addition	  to	  a	  preservation	  of	  fat	  mass	  that	  occurred	  under	  both	  experimental	   conditions.	   It	   might	   appear	   surprising	   that	   the	   positive	   effect	   of	   Ex-­‐9	  treatment	  on	  hind	  limb	  muscle	  mass	  was	  not	  paralleled	  by	  increased	  whole	  body	  lean	  mass.	   Vice	   versa,	   PPG-­‐KD	   rats	   had	  higher	   total	   lean	  mass	   but	   no	   increased	  hind	   limb	  muscle	  mass.	  Apparently,	  these	  parameters	  do	  not	  necessarily	  correspond,	  at	  least	  not	  in	   the	   time	   frame	  of	   our	   experiments.	   It	   should	  be	  mentioned,	   however,	   that	  PPG-­‐KD	  animals	  were	  sacrificed	  4	  days	  earlier	  than	  those	  in	  the	  Ex-­‐9	  experiment.	  Hence,	  muscle	  atrophy	  might	  not	  have	  been	  advanced	  at	  that	  stage,	  which	  could	  account	  for	  the	  lack	  of	  a	   statistically	   significant	   treatment	   effect	   on	   muscle	   mass.	   Additionally,	   CACS	   is	  associated	   with	   sarcopenic	   obesity	   during	   which	   lipids	   are	   stored	   in	   inappropriate	  depots	   (e.g.	   in	   muscle).	   Whether	   abnormal	   intramuscular	   fat	   deposition	   (i.e.	  myosteatosis)	   occurred	   in	   our	  model	  was	   not	   evaluated.	   However,	   one	   can	   speculate	  that	   a	   reduction	   of	   tumour-­‐induced	   intramuscular	   fat	   deposition	   following	   Ex-­‐9	  treatment	  might	  mask	  the	  protective	  effects	  of	  Ex-­‐9	  on	  muscle	  fibers.	  A	  functional	  test	  (e.g.	  grip	  strength)	  in	  these	  animals	  could	  be	  used	  to	  determine	  whether	  Ex-­‐9	  treatment	  results	   in	   changes	   in	   muscle	   function.	   Nonetheless,	   our	   findings	   are	   in	   principle	  consistent	   with	   our	   recent	   demonstration	   that	   brainstem-­‐dependent	   mechanisms	  contribute	  to	  cancer	  anorexia,	  muscle	  wasting	  and	  loss	  of	  fat	  and	  lean	  body	  mass	  [209].	  	  We	   have	   not	   yet	   explored	   the	   possible	   anti-­‐CACS	   effect	   of	   peripheral	   Ex-­‐9	  administration	   in	   TB	   rats.	   Due	   to	   the	   absence	   of	   a	   functional	   blood-­‐brain	   barrier	   AP	  neurons	  are	  accessible	  by	  blood-­‐borne	  substances	   [83]	   that	   typically	  do	  not	  cross	   the	  blood-­‐brain	  barrier.	  This	   favours	  pharmacological	  approaches	  targeting	  GLP-­‐1R	  in	  the	  AP.	  While	   GLP-­‐1R	   agonists	   are	   therapeutically	   approved	   for	   the	   treatment	   of	   obesity	  and	  diabetes	  [231],	  we	  are	  not	  aware	  of	  a	  therapeutic	  GLP-­‐1R	  antagonist.	  	  Under	   our	   current	   experimental	   conditions,	   the	   anti-­‐CACS	   effect	   of	   GLP-­‐1	   blockade	  appears	   to	   be	   mainly	   based	   on	   an	   improvement	   of	   energy	   intake,	   leading	   to	   a	  preservation	  of	  fat	  mass	  and	  ultimately	  also	  lean	  mass.	  A	  blockade	  of	  brainstem	  GLP-­‐1	  signalling	  did	  not	  affect	  the	  metabolic	  rate.	  The	  cachectic	  effect	  in	  hepatoma	  TB	  rats	  is	  partly	   independent	  of	  reduced	  energy	  intake	  because	  TB	  rats	   loose	  more	  body	  weight	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and	   muscle	   mass	   than	   pair-­‐fed	   NTB	   animals	   [209].	   Therefore,	   impaired	   energy	  expenditure	   appears	   to	   contribute	   to	   CACS	   in	   this	   tumour	   model.	   While	   we	   did	   not	  explore	   the	   effects	   of	   peripheral	   Ex-­‐9	   administration	   on	   CACS,	   additional	   beneficial	  effects	  might	  occur	  in	  the	  periphery	  also	  with	  respect	  to	  energy	  balance.	  At	  least	  in	  diet-­‐induced	  obese	  mice,	  peripheral	  treatment	  with	  a	  GLP-­‐1R	  agonist	  increased	  basal	  energy	  expenditure	   presumably	   via	   increased	   expression	   of	   uncoupling	   proteins	   in	   different	  tissues	   including	   muscle	   [232].	   Moreover	   the	   GLP-­‐1R	   agonist	   exendin-­‐4	   increased	  oxygen	   consumption	   and	   thermogenic	   gene	   expression	   in	  muscle	   cells,	   which	   can	   be	  blocked	   by	   Ex-­‐9	   [233].	   Antagonism	   of	   these	   effects	   might	   be	   beneficial	   to	   preserve	  energy	  and	  muscle	  mass	   in	  parallel	   to	   the	  centrally	  mediated	  attenuation	  of	  anorexia.	  Whether	   peripheral	   treatment	   with	   a	   GLP-­‐1R	   antagonist	   such	   as	   Ex-­‐9	   counteracts	  hypermetabolism	  via	  such	  peripheral	  mechanisms	  under	  cancer	  conditions	  remains	  to	  be	  elucidated.	  	  	  GLP-­‐1R	   expression	   levels	   in	   the	   AP/NTS	  were	   unaffected	   by	   tumour	   growth	   or	   pair-­‐feeding.	  Quite	  surprisingly,	  tumour	  growth	  decreased	  PPG	  expression	  levels	  in	  the	  NTS.	  However,	   no	   difference	   was	   found	   between	   PF	   and	   TB	   animals,	   indicating	   that	   the	  decrease	   in	   PPG	   expression	   during	   tumour	   growth	   is	   likely	   due	   to	   change	   in	   eating	  rather	  than	  specific	  tumour	  -­‐dependent	  effects.	  	  Despite	   the	   lower	   NTS	   GLP-­‐1	   expression	   levels	   following	   tumour	   growth,	   GLP-­‐1	  blockade	  was	  effective	  in	  attenuating	  CACS.	  Changes	  in	  PPG	  mRNA	  expression	  may	  not	  necessarily	  correlate	  with	  GLP-­‐1	  abundance	  or	  GLP-­‐1	  synaptic	  release.	  Further	  studies	  are	  required	  to	  investigate	  this	  interesting	  aspect.	  The	  brainstem	  GLP-­‐1	  system	  mediates	  acute	  behavioural	  sickness	  responses	  induced	  by	  LPS,	  LiCl	  und	  cisplatin	  [141,	  142,	  144].	  Food	  aversion	  following	  malaise	  is	  a	  commonly	  known	  phenomenon,	  which	   not	   only	   occurs	   under	   these	   experimental	   conditions	   but	  also	  in	  cancer	  patients	  [106,	  234].	  The	  development	  of	  CTA	  can	  be	  a	  consequence	  of	  the	  cancer	   itself	   but	   also	   secondary	   to	   anti-­‐cancer	   treatment	   such	   as	   chemotherapy	   and	  irradiation	   [234-­‐239].	   The	   mechanisms	   contributing	   to	   taste	   abnormalities	   are	  multifactorial	   and	   involve	   direct	   alterations	   in	   taste	   sensing	   and	   perception	   or	  conditioned	  avoidance	  food	  properties	  unrelated	  to	  impaired	  taste	  responses	  [106,	  238,	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240-­‐242].	  Irrespective	  of	  their	  cause,	  taste	  abnormalities	  and	  aversions	  may	  contribute	  to	  and	  worsen	  the	  loss	  of	  appetite	  and	  anorexia	  in	  cancer	  patients.	  	  	  	  	  	  	  	  	  Our	  findings	  may	  suggest	  a	  GLP-­‐1	  dependent	  mediation	  of	  CTA,	  which	  could	  be	  assessed	  by	  combining	  a	  CTA	  study	  with	  GLP-­‐1	  blockade.	  Whether	  tumour-­‐dependent	  aversion	  contributes	   to	  anorexia	   is	  difficult	   to	  address	  under	  our	  experimental	   conditions.	  The	  development	  of	  anorexia	  during	  our	  CTA	  experiment	  was	  not	  affected	  by	  changing	  the	  diet	   or	   by	   giving	   the	   choice	   between	   two	   flavours	   during	   the	   final	   preference	   test.	  Hence,	   at	   least	   in	   our	   studies,	   alteration	   of	   the	   diet’s	   flavour	   properties	   did	   not	  counteract	  anorexia.	   It	  remains	  to	  be	  determined	  whether	  the	  attenuation	  of	  anorexia	  and	  body	  weight	  loss	  by	  a	  blockade	  of	  brainstem	  GLP-­‐1	  signalling	  is	  partly	  secondary	  to	  a	  suppression	  of	  aversive	  mechanisms.	  	  Although	  we	   identified	  GLP-­‐1	   as	   neuronal	  mediator	   of	   CACS	   in	   the	  AP/NTS	   region,	   it	  remains	   unknown	   how	   NTS	   GLP-­‐1	   neurons	   are	   activated	   under	   tumour	   conditions.	  Recent	  studies	  suggest	  a	  role	  of	  the	  macrophage	  inhibitory	  cytokine-­‐1	  (MIC-­‐1)	  in	  CACS,	  which	  acts	  via	  the	  AP/NTS	  region	  to	  reduce	  food	  intake	  and	  body	  weight	  [99,	  101].	  Our	  model	   is	   characterized	   by	   increased	   levels	   of	   MIC-­‐1	   in	   the	   absence	   of	   other	  inflammatory	   circulating	   cytokines	   [209,	   213].	   MIC-­‐1	   primarily	   activates	   non-­‐catecholaminergic	   neurons	   in	   the	   NTS	   [101].	   GLP-­‐1-­‐expressing	   neurons	   are	   not	  catecholaminergic	   [222],	   but	   it	   is	   currently	   unknown	  whether	  MIC-­‐1	   activates	   GLP-­‐1	  expressing	  NTS	  neurons.	  The	  dendrites	  of	  NTS	  PPG	  neurons	  extend	  into	  the	  AP	  and	  to	  the	   border	   of	   the	   fourth	   ventricle.	   Therefore,	   NTS	   neurons	   could	   directly	   respond	   to	  factors	  in	  the	  blood	  and	  cerebrospinal	  fluid	  [131].	  This	  may	  lead	  to	  GLP-­‐1	  release	  in	  the	  AP	  and	  a	  subsequent	  activation	  of	  GLP-­‐1R	  expressing	  neurons	  (Fig.	  8).	  	  In	  summary,	  we	  found	  GLP-­‐1/GLP-­‐1R	  signalling	  in	  the	  brainstem	  to	  be	  required	  for	  the	  central	  mediation	  of	  CACS	  in	  hepatoma	  TB	  rats.	  A	  blockade	  of	  brainstem	  GLP-­‐1	  not	  only	  attenuated	   anorexia,	   but	   also	   body	   weight	   loss	   and	   muscle	   wasting.	   Future	   studies	  should	   address	   the	   question	   whether	   brainstem	   GLP-­‐1	   might	   mediate	   anorexia	   and	  cachexia	   in	   other	   cancer	   or	   chronic	   disease	   models.	   	   Moreover,	   it	   remains	   to	   be	  established	   which	   stimuli	   activate	   the	   brainstem	   GLP-­‐1	   system	   under	   these	   sickness	  conditions.	  Based	  on	  our	  findings	  GLP-­‐1R	  antagonists	  may	  be	  therapeutically	  useful	  for	  the	  treatment	  of	  CACS	  and	  possibly	  other	  form	  of	  sickness-­‐anorexia.	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Fig.	  1	  Chronic	  central	  Ex-­‐9	  treatment	  did	  not	  affect	  energy	  balance	  in	  healthy	  rats	  	  Chronic	   fourth	   ventricular	   infusion	   of	   Ex-­‐9	   infusion	   (100	   μg/day)	   did	   not	   affect	   food	  intake	  (A-­‐B),	  body	  weight	  or	  body	  weight	  gain	  (C-­‐D)	   in	  non-­‐tumour-­‐bearing	  rats.	  (E-­‐F)	  Ex-­‐9	   treatment	   did	   not	   alter	   respiratory	   exchange	   ratio	   and	  metabolic	   rate.	   Baseline	  data	   were	   collected	   for	   two	   consecutive	   days	   prior	   to	   minipump	   implantation.	   Data	  analysed	  with	  Student’s	  t-­‐test	  (A-­‐D)	  or	  with	  one-­‐way	  ANOVA	  followed	  by	  Tukey’s	  post-­‐hoc	  test	  (E-­‐F).	  Different	  letters	  indicate	  significant	  differences	  (p<0.05).	  	  	  
Fig.	  2	  Chronic	   central	  Ex-­‐9	   treatment	  attenuated	  anorexia,	  body	  weight	   loss,	   fat	  
and	  muscle	  wasting	  induced	  by	  tumour	  growth	  A-­‐B)	  Ex-­‐9	  (100	  μg/day)	  administered	  chronically	  into	  the	  fourth	  ventricle	  significantly	  attenuated	   the	   anorectic	   response	   induced	   by	   tumour	   growth.	   C)	   Ex-­‐9	   treated	   rats	  showed	   attenuated	   tumour-­‐dependent	   body	   weight	   loss	   following	   treatment.	   Ex-­‐9	  treated	  animals	  had	  higher	   fat	  mass	   than	   controls	   (D)	   and	  higher	  gastrocnemius,	   and	  total	  muscle	  mass	  (sum	  of	  gastrocnemius,	  tibialis	  and	  soleus	  muscle	  mass)	  compared	  to	  tumour-­‐bearing	  controls	  (E).	  Data	  analysed	  using	  the	  Student’s	  t-­‐test,	  *	  p	  <	  0.05,	  **	  p	  <	  0.01.	  	  	  
Fig.	  3	  Chronic	  central	  Ex-­‐9	  treatment	  did	  not	  affect	  respiratory	  exchange	  ratio	  and	  
metabolic	  rate	  in	  hepatoma	  tumour-­‐bearing	  rats	  A)	  Following	  tumour	  induction,	  control	  rats	  had	  significantly	  lower	  RER	  values	  relative	  to	   baseline	   conditions,	   reflecting	   a	   shift	   towards	   lipid	   metabolism.	   Ex-­‐9	   treatment	  (100μg/day)	  did	  not	  prevent	  this	  tumour-­‐induced	  reduction.	  B)	  Metabolic	  rate	  did	  not	  significantly	   differ	   between	   groups.	   Data	   analysed	  with	   one-­‐way	   ANOVA	   followed	   by	  Tukey’s	  post-­‐hoc	   test.	  Means	  with	  different	   letter	  are	  significantly	  different	   from	  each	  other	  (p<0.05).	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Fig.	  4	  Lentiviral	  PPG-­‐specific	  shRNA	  injection	  into	  the	  NTS	  significantly	  decreased	  
PPG	  mRNA	  expression	  	  A)	  Representative	   image	   of	  GFP	   fluorescence	   in	   the	  NTS	   seven	  weeks	   after	   lentivirus	  infusion,	   indicating	  successful	  transfection.	  Scale	  bar	  50	  μm.	  B)	  Location	  of	  NTS	  target	  area	   for	   lentiviral	   PPG	   knockdown.	   Bregma	   level	   -­‐14.64.	   Gr,	   gracile	   nucleus;	   SolC,	  commissural	  nucleus	  of	   the	   solitary	   tract;	   Sol,	   nucleus	  of	   the	   solitary	   tract;	   10,	   dorsal	  motor	   nucleus	   of	   the	   vagus;	   CC,	   central	   canal.	  Modified	   image	   from	  The	   Rat	   Brain	   in	  Stereotaxic	  Coordinates,	  Paxinos,	  G.	  and	  Watson,	  C.,	  Copyright	  Paxinos,	  G.	  and	  Watson,	  C.	  (1998),	  with	  permission	  from	  Elsevier.	  C-­‐D)	  Quantification	  of	  PPG	  and	  GLP-­‐1R	  mRNA	  levels	  in	  the	  AP/NTS	  of	  rats	  injected	  with	  lentivirus	  encoding	  for	  a	  PPG-­‐specific	  shRNA	  or	  control	  lentivirus.	  
	  
	  
Fig.	  5	  Knockdown	  of	  PPG	  mRNA	  expression	  in	  the	  NTS	  attenuated	  anorexia,	  and	  
loss	  of	  body	  weight	  by	  preservation	  of	  lean	  and	  fat	  mass	  	  A-­‐B)	   PPG	   knockdown	   in	   the	   NTS	   strongly	   attenuated	   anorexia	   and	   body	  weight	   loss	  induced	   by	   tumour	   growth	   without	   affecting	   baseline	   food	   intake	   before	   tumour	  induction.	   C-­‐D)	   From	  day	  8	   onwards,	   PPG	  KD	   animals	   showed	   significantly	   increased	  food	  intake	  and	  lost	  significantly	  less	  body	  weight	  compared	  to	  controls.	  E)	  The	  higher	  body	  weight	  of	  PPG	  KD	  animals	  was	  due	  to	  by	  higher	  lean	  and	  fat	  volumes	  compared	  to	  tumour-­‐bearing	  controls.	  Data	  analysed	  using	  the	  Student’s	  t-­‐test,	  *	  p	  <	  0.05,	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001.	  
	  
	  
Fig.	   6	   Tumour	   growth	   did	   not	   affect	   circulating	   GLP-­‐1,	   and	   PPG	   and	   GLP-­‐1R	  
expressions	  levels	  in	  the	  AP/NTS	  A)	   Circulating	   GLP-­‐1	   did	   not	   significantly	   differ	   between	   groups.	   B)	   Tumour-­‐bearing	  rats	  (TB)	  and	  pair-­‐fed	  animals	  (PF)	  had	  lower	  PPG	  expression	  levels	  compared	  to	  non-­‐tumour-­‐bearing	   controls	   (NTB).	   C)	   GLP-­‐1R	   expression	  was	   similar	   among	   all	   groups.	  Data	   analysed	   with	   one-­‐way	   ANOVA	   followed	   by	   Tukey’s	   post-­‐hoc	   test.	   Means	   with	  different	  letter	  are	  significantly	  different	  from	  each	  other	  (p<0.05).	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Fig.	  7	  Tumour	  growth	  induced	  food	  aversion	  	  A)	  Experimental	  paradigm	  used	  to	  evaluate	  the	  role	  of	  food	  aversion	  following	  tumour	  growth.	   B)	   Tumour-­‐bearing	   (TB)	   rats	   developed	   anorexia	   8	   days	   after	   tumour	  induction.	  In	  both	  tumour-­‐bearing	  and	  non-­‐tumour-­‐bearing	  (NTB)	  animals,	  alteration	  of	  the	  diet’s	  flavour	  properties	  did	  not	  affected	  total	  food	  consumption.	  C)	  Prior	  to	  tumour	  induction	   the	   two	  groups	  displayed	   similar	   preference	   values	   that	   remained	   constant	  during	   consecutive	   testing	   days.	   C)	   After	   tumour	   induction,	   tumour-­‐bearing	   animals	  displayed	   a	   marked	   reduction	   in	   preference	   for	   the	   diet	   that	   was	   presented	   during	  tumour	   growth	   compared	   to	   non-­‐tumour-­‐bearing	   rats.	   This	   food	   avoidance	   persisted	  for	  the	  entire	  experimental	  period.	  Data	  analysed	  using	  the	  Student’s	  t-­‐test,	  	  *	  p	  <	  0.05,	  
**	  p	  <	  0.01,	  ***	  p	  <	  0.001.	  	  	  
Fig.	   8	   Model	   of	   GLP-­‐1-­‐dependent	   mediation	   of	   CACS	   during	   tumour	   growth	  Humoral	  mediators	  such	  as	  MIC-­‐1	  may	  directly	  or	  indirectly	  activate	  GLP-­‐1	  expressing	  neurons	  located	  in	  the	  NTS	  leading	  to	  GLP-­‐1	  release	  in	  the	  AP	  and	  activation	  of	  GLP-­‐1R	  expressing	   neurons.	   Neuronal	   efferents	   of	   the	   AP	   activate	   neurons	   in	   downstream	  projection	  sites	  involved	  in	  the	  control	  of	  energy	  balance.	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7  Original Research Article: “ The ghrelin receptor agonist HM01 
mimics the neuronal effects of ghrelin in the arcuate nucleus and 
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Borner T, Loi L, Pietra C, Giuliano C, Lutz TA, Riediger T.
The ghrelin receptor agonist HM01 mimics the neuronal effects of
ghrelin in the arcuate nucleus and attenuates anorexia-cachexia
syndrome in tumor-bearing rats. Am J Physiol Regul Integr Comp
Physiol 311: R89 –R96, 2016. First published May 4, 2016;
doi:10.1152/ajpregu.00044.2016.—The gastric hormone ghrelin
positively affects energy balance by increasing food intake and
reducing energy expenditure. Ghrelin mimetics are a possible
treatment against cancer anorexia-cachexia syndrome (CACS).
This study aimed to characterize the action of the nonpeptidergic
ghrelin receptor agonist HM01 on neuronal function, energy ho-
meostasis and muscle mass in healthy rats and to evaluate its
possible usefulness for the treatment of CACS in a rat tumor
model. Using extracellular single-unit recordings, we tested
whether HM01 mimics the effects of ghrelin on neuronal activity
in the arcuate nucleus (Arc). Furthermore, we assessed the effect of
chronic HM01 treatment on food intake (FI), body weight (BW),
lean and fat volumes, and muscle mass in healthy rats. Using a
hepatoma model, we investigated the possible beneficial effects of
HM01 on tumor-induced anorexia, BW loss, muscle wasting, and
metabolic rate. HM01 (10!7–10!6 M) mimicked the effect of
ghrelin (10!8 M) by increasing the firing rate in 76% of Arc
neurons. HM01 delivered chronically for 12 days via osmotic
minipumps (50 "g/h) increased FI in healthy rats by 24%, paral-
leled by increased BW, higher fat and lean volumes, and higher
muscle mass. Tumor-bearing rats treated with HM01 had 30%
higher FI than tumor-bearing controls and were protected against
BW loss. HM01 treatment resulted in higher muscle mass and fat
mass. Moreover, tumor-bearing rats reduced their metabolic rate
following HM01 treatment. Our studies substantiate the possible
therapeutic usefulness of ghrelin receptor agonists like HM01 for
the treatment of CACS and possibly other forms of disease-related
anorexia and cachexia.
cancer; malnutrition; food intake; metabolism; hypothalamus
THE CANCER ANOREXIA-CACHEXIA syndrome (CACS) is character-
ized by reduced eating, increased catabolism, and body weight
loss. CACS is a major cause for the decline in the clinical
status of affected patients and is associated with increased
mortality. CACS is present in up to 80% of cancer patients at
death and represents the most significant negative predictor of
treatment outcome (12, 23, 41). Affected cancer patients show
a poor responsiveness to anticancer therapies, irrespective of
the type of malignancy (1, 9). The effectiveness of nutritional
care as a therapeutic option against CACS is limited, and
insufficient progress has been made in the development of
specific pharmacological approaches (21).
Because of positive effects on energy balance, the gastroin-
testinal hormone ghrelin or ghrelin analogs are considered as a
possible treatment option for CACS. Ghrelin is mainly secreted
from the stomach, and it has been identified as a high-affinity
ligand for the growth hormone secretagogue receptor (GHS-R)
(20). Plasma levels of ghrelin rise during fasting and shortly
before meals. Pharmacological doses of ghrelin stimulate food
intake and promote body weight gain in rodents (36, 42). These
effects are thought to be mediated via the hypothalamic arcuate
nucleus (Arc), which is of high importance for the control of
food intake and energy homeostasis (32). The GHS-R is highly
expressed in the Arc and ghrelin’s effects on neuronal activity
of Arc neurons have been characterized in various electrophys-
iological and immunohistological studies (13, 16, 17). Ghrelin
activates neuropeptide Y-expressing neurons in the Arc, which
is widely considered as the neuronal correlate for ghrelin’s
actions on food intake and body weight (5, 34, 45). Moreover,
ghrelin also promotes muscle cell differentiation in vitro and
ameliorates skeletal muscle atrophy in mice, suggesting that
ghrelin may also exert direct effects on muscle that are inde-
pendent of its central actions (10, 31).
Ghrelin has been tested as anti-CACS treatment in clinical
human trials and rodent cancer models (4, 8, 15, 25–27, 39,
46). Most of these studies support a beneficial effect of ghrelin
on food intake and body weight. However, because of its
peptidergic nature and its short half-life time of 15–20 min, the
usefulness of native ghrelin as a therapeutic agent is limited
(44). HM01 is a synthetic small-molecule compound that acts
as a GHS-R agonist. It has high receptor binding affinity, high
brain permeability, and a higher plasma half-life compared
with ghrelin (19). Besides other possible therapeutic indica-
tions, it might, therefore, be used as an anti-CACS treatment.
It was the overall aim of our studies to evaluate the possible
usefulness of HM01 against tumor-dependent anorexia and
body weight loss. First, we sought to confirm the ghrelin-like
excitatory action of HM01 in electrophysiological recordings
of the Arc of rats. Second, we investigated the effect of chronic
HM01 treatment on food intake, body weight, muscle mass,
and body composition in healthy non-tumor-bearing rats.
Third, we used a rat Morris-7777 hepatoma model to test
whether HM01 ameliorates tumor anorexia, body weight loss,
and muscle wasting, and whether HM01 affects nutrient utili-
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zation and metabolic rate. The Morris-7777 hepatoma model is
well established and characterized by a clear anorectic re-
sponse and body weight loss (35). Since an attenuation of
anorexia is one important mode of action for ghrelin-based
approaches, we chose a tumor model in which anorexia is a
major contributor to body weight loss. Another advantage of
this tumor model is that anorexia and body weight loss are less
severe than in other tumor models. A very rapid deterioration
of the health status caused by aggressive tumors often limits
the usefulness of such tumor models for chronic treatment
paradigms.
METHODS
Animals. Adult male Wistar rats (Elevage Janvier, France), weigh-
ing between 230 and 270 g, were used for all electrophysiological and
behavioral experiments involving non-tumor-bearing animals. Ani-
mals were kept in a temperature-controlled room (21 ! 1°C) on a
12:12-h light-dark cycle with ad libitum access to standard chow (890
25 W16, Provimi Kliba) and tap water. For the in vivo testing of the
GHS-R agonist HM01, rats were single-housed in wire-mesh cages.
Before the experiments, rats were handled daily and kept in the cages
for an adaptation period of at least 1 wk.
For the behavioral and metabolic studies involving tumor-bearing
animals, adult male Buffalo rats (Charles River) weighing around
280 g were used. The animals were single-housed in metabolic cages
(TSE Phenomaster, TSE Systems) and were adapted to the housing
conditions for 7 days before the start of the experiment. To evaluate
the effects of tumor growth on muscle mass, Buffalo rats were
single-housed in wire-mesh cages. All animal procedures were ap-
proved by the Veterinary Office of the Canton of Zurich, Switzerland.
Electrophysiology. The electrophysiological recording technique
was the same as described previously (3). The rats were decapitated
using a guillotine at the same time point in the middle of the light
phase to minimize differences in the circadian and prandial state of the
animals. After decapitation, the brain was quickly removed and
superfused with ice-cold artificial cerebrospinal fluid (aCSF) that was
oxygenated and pH-equilibrated with oxycarbon (pH 7.4; 290
mosmol/kg H2O). Coronal brain slices (700 "m) were cut at the
mid-rostro-caudal level of the Arc using a vibratome (Leica VT1000S,
Leica Microsystems). A rectangular 3 # 3-mm slice preparation
containing the Arc was manually dissected under a dissection micro-
scope and transferred to a temperature-controlled (37°C) incubation
chamber filled with constantly oxygenated aCSF. For recordings, the
Arc preparations were transferred to a temperature-controlled (37°C)
recording chamber that was constantly perfused with oxygenated and
prewarmed aCSF at a rate of 1.6 ml/min. Extracellular single-unit
recordings were obtained using home-made glass-coated platinum-
iridium electrodes. Recordings were conducted in the medial arcuate
nucleus, in which the majority of neurons are excited by ghrelin (34).
HM01 (provided by Helsinn Healthcare, Lugano, Switzerland) was
superfused at a concentration of 10$6 or 10$7 M. The cosensitivity of
the recorded neurons to ghrelin was tested by stimulation with rat
ghrelin (10$8 M; Bachem).
Effects of HM01 in non-tumor-bearing rats. Osmotic minipumps
(model 2ML2, ALZET osmotic pumps; DURECT) were implanted
subcutaneously into the left flank at the lower level of the abdomen
between the chest and the hind limbs. Minipumps were filled with
HM01 (10 "g/"l) or saline for controls. The minipumps released a
constant amount of HM01 (50 "g/h at a pump rate of 5 "l/h). The
capacity of the minipumps (2 ml) allowed a constant compound
release for 14 days. Body weight and food intake were measured
daily. At the end of the experiment, animals were euthanized for the
measurement of body composition by computed tomography (CT)
scanning and muscle mass.
Effects of HM01 in tumor-bearing rats. The hepatoma tumor model
was used in our experiments, as previously described (35). Morris
hepatoma 7777 cells (McA-RH7777, cat. no. CRL-1601, American
Type Culture Collection) were cultured under standard conditions in
DMEM supplemented with 10% FBS and 1% penicillin-streptomycin.
Semiconfluent McA-RH7777 Petri dishes were washed with DMEM
repeatedly to detach the cells from the surface. After confirming
vitality of the cells with Trypan blue, 107 cells were inoculated
subcutaneously in 250 "l PBS under short isoflurane anesthesia
between the scapulas.
HM01 or saline treatment was applied as described above. Mini-
pumps were implanted on day 11 after tumor inoculation, shortly after
the onset of the anorectic response. Treatments continued for 6 days
until the animals had to be euthanized for ethical reasons, according
to our criteria for the termination of experiments. Food intake and
respiratory gas exchange (O2 and CO2) were recorded automatically
at 17-min intervals throughout the entire experiment. Body weight
was measured daily. After euthanizing the rats, tumors and limb
muscles were resected and weighed, and body composition was
determined by CT scan (see Computed tomography scanning and
muscle weight measurements).
To examine the effects of tumor growth on muscle mass, tumor-
bearing and non-tumor-bearing rats were used. After adaptation,
tumor growth was induced as described above; control animals
received the same volume of PBS without tumor cells. Rats were
euthanized 16 days after tumor induction, and limb muscles were
dissected and weighed.
Computed tomography scanning and muscle weight measurements.
Total carcass lean and fat volumes were measured by quantitative
microcomputed tomography (La Theta LCT-100A scanner, Hitachi-
Aloka Medical). Sequential 2-mm slice images with a pixel size of
Fig. 1. Recording of a ghrelin-excited Arc neuron, which
was also reversibly stimulated by superfusion of HM01.
Horizontal bars indicate time of superfusion.
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250 ! 250 "m were used for calculations using LaTheta software
(version 2.10). Head, lungs, and tail were excluded from the analysis
of tissue volumes. After the CT scanning, the left gastrocnemius,
tibialis, and soleus muscles were dissected at the level of their upper
to lower tendons and were weighed.
Quantification and statistical analysis. Electrophysiological pa-
rameters were quantified as previously described (3). The mean
spontaneous baseline activity of each single neuron was evaluated for
60 s before the stimulus (spontaneous activity). This value was used
to normalize changes in the firing rate expressed as absolute mean
response change (Hz) and as a percentage of mean response
change. If both the absolute and the percentage of discharge rate
changes during the response were larger than # 0.5 Hz and # 20%,
respectively, the neuron was considered sensitive to the applied
substance. Furthermore, the latency, the duration, and the peak
response (Hz) were also measured. The effect parameters of the
electrophysiological responses were averaged and expressed as
means # SE. Values were compared using one-way ANOVA
followed by Tukey’s post hoc test.
For the behavioral experiments, daily and cumulative food intake,
body weight, and body composition volumes were expressed as
means # SE. Body weight change following treatment was calcu-
lated by subtracting the body weight at the time of minipump
implantation from the body weight at the end of the treatment
period. These values were corrected for the weight of the mini-
pumps and the tumor mass that was determined by tumor resection.
Data were expressed as means # SE and statistically compared
using Student’s t-test (two-sided).
In tumor-bearing rats, the respiratory exchange ratio (RER) and
energy expenditure (EE) were calculated from O2 consumption and
CO2 production, as described previously (33). EE data were normal-
ized for body weight. The calculation was based on the following
equation: total EE (kcal·kg$1·h$1) % (3.9 ! VO2 & 1.1 !
VCO2)/1,000; RER % VCO2 / VO2. The average of days 1 and 2 after
tumor inoculation was used as baseline (i.e., prior to the onset of
anorexia) and compared with the values obtained on days 14 and
15 during the treatment period (i.e., during the anorectic phase).
Group means were analyzed with one-way ANOVA followed by
the Tukey post hoc test. After tumor resection, tumor weights were
compared between control animals and HM01-treated rats by
Student’s t-test (two-sided). For all statistical analyses, P ' 0.05
was considered significant.
RESULTS
Electrophysiology. Seventeen Arc neurons were recorded.
Similar to previous studies, the majority (13/17; 76%) of
neurons recorded in the medial Arc was reversibly excited by
ghrelin (10$8 M) (34). All ghrelin-excited cells were also
activated by superfusion of HM01 at a concentration of 10$7–
10$6 M (see example in Fig. 1). Interestingly, neurons that
were insensitive (3/17; 18%) or inhibited (1/17; 6%) by ghrelin
showed the same type of responses to HM01, resulting in
100% concordant responses. The average response latency was
significantly longer for the lower concentration of HM01
(10$7 M) compared with ghrelin or HM01 at 10$6 M. The
absolute changes in firing rate and the peak responses were not
significantly different between the stimuli. However, HM01
tended to induce longer-lasting responses compared with ghre-
lin, which reached statistical significance for the higher con-
centration of HM01 (Table 1).
Effects of HM01 in non-tumor-bearing rats. HM01 signifi-
cantly stimulated food intake starting on the first day after
minipump implantation. This effect remained stable during the
12 days of measurements. On average HM01-treated rats
consumed 6.0 # 0.3 g (24 # 1%) more food per day than
controls (Fig. 2A). Over the 12-day treatment period, this
resulted in a significantly higher cumulative food intake
(HM01, 405 # 6 g; saline, 329 # 7 g; P ' 0.001). This
orexigenic effect of HM01 was paralleled by an increase in
body weight relative to controls, which became significant
on day 5 after minipump implantation (Fig. 2B). At the end
of the experiments, the difference in body weight was 35 g
Table 1. Effect parameters of the excitatory responses after




M (n % 13)
HM01 10$6
M (n % 8)
HM01 10$7
M (n % 5)
Mean spontaneous activity, Hz 2.7# 0.5 2.5# 0.7 1.7# 0.7
Mean latency, s 53 # 7.9a 63 # 13.7a 128 # 36.3b
Absolute response, Hz 2.5# 0.6 2.7# 0.6 3.9# 1.1
Absolute peak response, Hz 5.2# 1 4.5 # 1 6.1 # 1.7
Mean response duration, s 899# 76.2a 2103 # 552b 1952 # 537a
Values are expressed as means # SE. Data were analyzed with one-way
ANOVA followed by Tukey post hoc test. Means with different letters are
significantly different.
Fig. 2. Daily food intake and body weight of HM01-treated (50 "g/h) and vehicle-treated animals. A: HM01-stimulated food intake starting from the day after
minipump implantation. This effect remained stable during the 12-day treatment period. B: HM01-induced increase in food intake was paralleled by an increase
in body weight relative to controls, which became significant from day 5 after minipump implantation. Data analyzed using the Student’s t-test (*P ' 0.05,
**P ' 0.01, ***P ' 0.001).
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(369 ! 6 g vs. 334 ! 8 g; P " 0.05). HM01 significantly
increased lean and fat body mass after the 12-day treatment
period (229.7 ! 4.3 vs. 209.5 ! 4.3; P " 0.05 and 51.6 !
6.1 cm3; vs. 32.2 ! 3.5 cm3; P " 0.05; respectively, Fig.
3A). Moreover, rats treated with HM01 had a higher gas-
trocnemius weight compared with saline controls (HM01:
1.795 ! 0.052 g vs. control: 1.508 ! 0.076 g; P " 0.05,
Fig. 3B).
Effects of HM01 in tumor-bearing rats. In tumor-bearing
animals food intake started to decline around day 7 after tumor
induction. After implantation of minipumps on day 11, HM01
prevented a further decrease in eating, and HM01-treated rats
consumed significantly more food than control animals (Fig.
4A). On average, daily food intake during the treatment period
(i.e., from day 12 to day 17 after tumor induction) was 18.5 !
0.6 g vs. 14.3 ! 0.5 g (saline controls), which corresponds to
a 30% higher food intake of HM01-treated rats compared
with controls (Fig. 4B). While tumor-bearing controls
showed a loss of body weight during the treatment period,
rats receiving HM01 stabilized their body weight. The
difference in absolute body weight did not reach statistical
significance; however, the change in body weight was
highly significant between the treatment groups (HM01: 1.1
! 2.0 g vs. control: #10.4 ! 1.7 g; P " 0.001; Fig. 4C).
This difference in body weight change appeared to be
mainly due to lower fat mass in tumor-bearing control rats
because HM01-treated rats showed significantly higher fat
mass but similar lean mass compared with control animals
(Fig. 5A). Tumor-bearing rats had lower gastrocnemius, tibialis,
and soleus muscle mass compared with controls (1.077 ! 0.018
vs. 1.208 ! 0.038, 0.342 ! 0.012 vs. 0.397 ! 0.022, 0.059 !
0.002 g vs. 0.067 ! 0.001 g; P " 0.05; in all cases, Fig. 5B).
HM01 led to a higher gastrocnemius and soleus mass compared
with tumor-bearing controls (1.422 ! 0.050 vs. 1.253 ! 0.054,
0.091 ! 0.005 g vs. 0.072 ! 0.005 g; P " 0.05; respectively,
Fig. 5C).
Relative to baseline conditions before the onset of anorexia
(days 1 and 2), control rats had significantly lower RER values
on days 14 and 15 reflecting a shift toward lipid metabolism.
This tumor-dependent reduction in RER was partly prevented
by HM01 treatment (Fig. 6A). Interestingly, energy expendi-
ture was significantly lower in HM01-treated compared with
control rats during the treatment period (days 14 and 15) and
also lower relative to baseline conditions on days 1 and 2 (Fig.
6B). Chronic HM01 treatment did not affect tumor growth
Fig. 3. Computed tomography-based assessment of lean and total fat volumes, and weights of gastrocnemius, tibialis, and soleus muscle. A: rats treated with
HM01 (50 $g/h) displayed higher lean and fat volumes than vehicle-treated animals. B: HM01 treatment also resulted in higher gastrocnemius and total muscle
mass (sum of gastrocnemius, tibialis, and soleus mass) compared with controls. Data were analyzed using the Student’s t-test (*P " 0.05; ns, not significant).
Fig. 4. Daily food intake, mean daily food intake during treatment, and body weight development of HM01-treated (50 $g/h) and vehicle-treated tumor-bearing
(TB) rats following minipump implantation. A: HM01 significantly attenuated the anorectic response induced by tumor growth. B: on average, HM01-treated
TB rats had a 30% higher daily food intake compared with TB controls. C: chronic HM01 administration prevented tumor-induced body weight loss. Data
analyzed using the Student’s t-test (*P " 0.05, **P " 0.01, ***P " 0.001).
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because average tumor weight was not significantly different
between treatment groups (8.9 ! 1.0 g vs. 8.2 ! 0.7 g, Fig. 7).
DISCUSSION
We provide in vitro and in vivo characterization of the
synthetic GHS-R agonist HM01 under nonpathological condi-
tions and in the context of cancer anorexia and body weight
loss. In particular, we showed that HM01 acts as a ghrelin
analog in the Arc, increases food intake and body weight in
healthy rats, and prevents the tumor-induced body weight loss
by attenuating anorexia and by reducing energy expenditure. In
the electrophysiological experiments, HM01 and ghrelin
showed a concordant response profile in all tested neurons.
Hence, HM01 mimicked the effects of ghrelin on neuronal
activity of Arc neurons.
We performed recordings using two concentrations of
HM01 (10"7 M and 10"6 M), and we observed a significantly
longer response duration after superfusion of the higher con-
centration of HM01 (10"6 M) compared with ghrelin. How-
ever, no difference was seen in the absolute response and the
peak response. It was not the aim of this study to establish a
complete dose-response characteristic for the excitatory effects
of HM01, but only to provide proof of concept that HM01 and
ghrelin exert concordant actions on Arc neurons. To use
effective stimuli, we used concentrations that are clearly above
the EC50 of 1–2 nM for HM01 (19). Therefore, a possible
ceiling effect might be the reason why the absolute and peak
responses caused by the two concentrations were similar. We
cannot exclude differences in the dynamics of receptor activa-
tion by ghrelin and HM01, respectively, which might be
reflected by the longer latency of HM01 (10"7 M) compared
with ghrelin (10"8 M). In addition to the direct excitatory
effect of ghrelin on NPY neurons, ghrelin indirectly inhibits
POMC neurons in the Arc (5). It was not our aim to charac-
terize the effect of HM01 on second-order neurons. Neverthe-
less, an indirect inhibition of POMC neurons is a likely
downstream effect of HM01.
The ghrelin-like action of HM01 on neuronal activity in the
Arc is in line with the orexigenic effect of HM01 observed in
the current study. HM01 treatment in healthy rats was associ-
ated with increased body weight gain and increased lean and
fat mass. These effects were similar to the action induced by
chronic treatment with the ghrelin analog BIM-28131, which
has been considered as one of the most potent GHS-R agonists
(28, 29, 38). Interestingly, we observed an increase in both
absolute fat and lean volumes and in gastrocnemius muscle
mass in HM01-treated rats. While most studies using ghrelin or
GHS-R agonists demonstrate increased adiposity in healthy
rodents, treatment effects on lean and muscle mass appear to be
less robust (22, 24, 38, 42). Ghrelin or BIM-28131-induced
positive effects on lean body mass in healthy rats, although
most of these effects only occurred after longer treatment
periods compared with the current study (4, 28, 29, 38).
On the basis of previous studies, a possible feeding-inde-
pendent adipogenic action of HM01 could be due to an up-
regulation of lipogenic enzymes and a reduction of lipid export
in adipose tissue (7, 30). Another factor promoting adiposity
may be a reduction of metabolic rate, which is a well-docu-
mented effect of ghrelin. This effect is mediated via reduced
sympathetic outflow to brown adipose tissue that leads to
decreased uncoupling protein-1 expression (43, 48). It was
beyond the scope of our study to reconfirm the aforementioned
mechanisms. On the basis of the similarity between the action
of ghrelin and HM01, it appears plausible that similar adipo-
genic and metabolic processes might also be engaged by
HM01.
Similar to its orexigenic action, ghrelin’s effect on GH
release depends on the GHS-R, although both effects occur
Fig. 5. Computed tomography-based assessment of lean and total fat volumes
and limb muscle weights. A: compared with tumor-bearing (TB) control
animals, HM01-treated rats (50 #g/h,) had higher fat volumes. B: tumor
growth was associated with reduced gastrocnemius, tibialis, soleus, and total
muscle mass (sum of gastrocnemius, tibialis, and soleus muscle mass), sug-
gesting the development of tumor-induced muscle atrophy (NTB: non-tumor-
bearing controls). C: HM01 treatment led to higher gastrocnemius, soleus, and
total muscle mass compared with tumor-bearing controls. Data analyzed using
the Student’s t-test (*P $ 0.05, **P $ 0.01).
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independently (40). Hence, the effect of HM01 on lean body
mass might at least be partly mediated by HM01-dependent
growth hormone/insulin-like growth factor 1 (GH/IGF-1) sig-
naling (20). IGF-1 is a well-known mediator of GH-dependent
muscle growth acting via the Akt protein kinase pathway to
promote muscle protein synthesis (37). HM01 is a potent
stimulator of GH release (Pietra C, unpublished findings).
Therefore, a stimulation of GH/IGF-1 signaling is likely to
contribute to the HM01-dependent increase in lean mass.
A major aim of our study was to evaluate the ability of
HM01 to counteract tumor anorexia and body weight loss. In
line with its potent action on food intake in healthy non-tumor-
bearing animals, HM01 prevented the progression of the ano-
rectic response and the loss of body weight in tumor-bearing
rats. Moreover, HM01 reduced metabolic rate, lipid metabo-
lism, and muscle wasting.
The relative increase in food intake of HM01-treated ani-
mals was similar in tumor-bearing and in non-tumor-bearing
rats (30% and 24%, respectively). The magnitude of the pos-
itive effects of HM01 on food intake and body weight in
tumor-bearing animals was also similar to the actions of
ghrelin analogs used in previous studies (8). However, direct
comparisons between the effectiveness of HM01 and ghrelin
analogs used in other studies are limited due to different tumor
models and treatment paradigms, as well as potential differ-
ences in dose-response relationships and pharmacokinetics of
the substances used.
Hepatoma tumor-bearing rats had lower muscle mass com-
pared with non-tumor-bearing controls, indicating tumor-in-
duced muscle degradation. HM01 not only stimulated muscle
growth in healthy animals, but it also increased muscle mass in
tumor-bearing rats. Muscle atrophy during cancer is associated
with decreased expression of different markers for muscle
formation such as myoD, myogenin, and mTOR, and increased
proteolytic markers like myostatin, activin A, FOXO,
MURF-1, and atrogin-1/MAFbx (two muscle-specific ubiqui-
tin ligases) (2). Chronic ghrelin treatment prevented the can-
cer-induced increase of myostatin, MURF-1, and atrogin-1/
MAFbx in Lewis lung carcinoma-bearing mice. In parallel, it
increased myoD and myogenin signaling (4). Whether similar
mechanisms contribute to the HM01-mediated attenuation of
cancer-induced muscle loss in our hepatoma tumor model
remains to be elucidated.
Although we did not measure locomotor activity in the
present study, we did not detect a tumor-dependent alteration
of physical activity in hepatoma tumor-bearing rats in previous
experiments. Hence, reduced physical activity does not appear
to be a major determinant of muscle mass loss under our
experimental conditions. Although our studies were not de-
signed to test the influence of activity on muscle mass, it
appears plausible that enhanced physical activity might further
improve the therapeutic action of HM01.
Notably, HM01 treatment reduced energy expenditure. This
is the first study showing a beneficial effect of a ghrelin-based
therapy on energy expenditure during CACS. Therefore, not
only the higher food consumption induced by HM01 but also
the reduction in energy expenditure might have contributed to
the preservation of body weight under our conditions. The
reduction of RER following tumor induction reflects a shift
from glucose to increased fat utilization. Chronic administra-
tion of HM01 attenuated the suppressive effect of tumor
growth on RER, which indicates decreased fat metabolism in
HM01-treated rats compared with controls. The latter effect is
consistent with the preservation of fat depots by HM01 treat-
ment.
Although an activation of GH/IGF-1 axis might have bene-
ficial effects on lean and fat mass, it also raises concerns of
potentially stimulating tumor proliferation. Nevertheless, ex-
periments conducted in different rodent models and clinical
studies have so far demonstrated the safety of ghrelin-based
therapeutic approaches without indications of increased tumor
growth or cancer progression (8, 15, 25, 27, 39, 46). Our
Fig. 7. Tumor weight of HM01-treated and control rats at the end of the 12-day
treatment period. Tumor weight did not differ between the two groups,
indicating that chronic HM01 treatment did not affect tumor growth.
Fig. 6. Respiratory exchange ratio and en-
ergy expenditure of HM01-treated (50 !g/h)
and vehicle-treated tumor-bearing (TB) rats.
A: during treatment, TB control rats had
significantly lower RER values compared
with baseline conditions, reflecting a shift
toward lipid metabolism. HM01 treatment pre-
vented this tumor-induced reduction in RER.
B: energy expenditure of the tumor-bearing
HM01-treated group was significantly lower
compared with the control group and to base-
line conditions. Data analyzed using the one-
way ANOVA followed by the Tukey post hoc
test. Bars with different letters are significantly
different, P " 0.05.
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observation that HM01 does not promote tumor growth is
consistent with these findings. The lack of difference in the
tumor weight between the HM01-treated animals and the
control group is an important finding that is relevant for future
long-term clinical applications.
In the context of CACS, the role of endogenous ghrelin is
controversial. Ghrelin has been found increased, unchanged, or
decreased in different rodent tumor models and among patients
with different types of cancers (6, 11, 14, 18). We did not
detect any changes in total or active ghrelin circulating level in
our animals at the end of experiment (data not shown). Hence,
a reduction in endogenous ghrelin levels does not appear to
mediate the observed reduction in food intake in this rat tumor
model.
Some studies postulated that CACS could lead to partial
ghrelin resistance, which might eventually limit the effective-
ness of ghrelin-based therapy (11, 47). This might be the
reason why some ghrelin-based clinical trials have failed to
attenuate CACS (39). However, under our experimental con-
ditions, the antianorectic action of HM01 and its positive effect
on body weight were still significant at the end of the treatment
period. Moreover, the relative difference in food intake be-
tween HM01-treated rats and controls was similar in tumor-
bearing and non-tumor-bearing rats, suggesting the absence of
profound ghrelin resistance. In our studies, the effect of HM01
on food intake became more variable toward the end of the
experiment, that is, just before our criteria for the termination
of the experiment were reached. It is a general and expected
phenomenon that the increasing tumor burden overrides anti-
CACS treatment effects at late disease stages in experimental
cancer models (15). Notably, an important purpose of anti-
CACS treatments is to positively influence the health status and
the anti-cancer treatment success before the patients undergo
end-stage disease. For these reasons, we did not attempt to
characterize the effectiveness of HM01 to counteract CACS at
later time points.
In addition to the direct effect of HM01 on energy homeo-
stasis, there might be beneficial effects resulting from anti-
inflammatory actions. Ghrelin has been shown to attenuate the
inflammatory cytokine response in tumor-bearing mice (4). In
contrast to other tumor models, the possible inflammatory or
cytokine-dependent mechanisms that contribute to CACS in
our hepatoma tumor model have not yet been identified.
Systemic levels of IL-1!, IFN-", IL-6, and TNF-# have been
reported to be unaltered in this tumor model (35). Although
this does not exclude that other cytokines contribute to CACS
in hepatoma tumor-bearing rats, other tumor models appear to
be more appropriate to investigate anti-inflammatory effects of
HM01 (4). An attenuation of the inflammatory response might
not only indirectly attenuate anorexia, but also cytokine-medi-
ated effects on muscle wasting.
Perspectives and Significance
We demonstrated that HM01 mimicked the actions of ghre-
lin on Arc neurons in vitro and stimulated food intake and body
weight gain in healthy rats. More importantly, HM01 attenu-
ated cancer anorexia in a rat hepatoma model, and it positively
affected metabolism, body weight development, and muscle
wasting. Thus, ghrelin agonists, such as HM01, may be a
useful therapeutic approach for the treatment of CACS and
possibly other forms of pathological anorexia, malnutrition,
and muscle wasting.
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8  Final Discussion and perspectives 	  
8.1  Summary of the major findings 
	  The	   current	   studies	  provided	  new	   insight	   into	   the	  pathophysiology	  of	  CACS	  and	   shed	  light	  on	  different	  strategies	  for	  its	  treatment.	  The	  first	  set	  of	  studies	  showed	  that	  the	  AP	  is	   involved	   in	   the	   central	  mediation	   of	   CACS	   in	   hepatoma	   TB	   rats.	  We	   also	   proposed	  MIC-­‐1	   as	   a	   potential	   tumor-­‐released	   factor	   involved	   in	   the	   peripheral	   to	   central	  mediation	   of	   CACS	   in	   hepatoma	   TB	   rats.	   	   Moreover,	   we	   were	   able	   to	   provide	   first	  evidence	   of	   the	   central	   GLP-­‐1	   signaling	   within	   the	   AP/NTS	   region	   in	   the	   central	  mediation	  of	  CACS	  in	  this	  model.	  Furthermore,	  we	  provided	  a	  better	  characterization	  of	  the	  hepatoma	  tumor	  model	  by	  showing	  the	  presence	  of	  eating-­‐independent	  effects	  on	  muscle	   and	   fat	   mass,	   as	   well	   as	   the	   development	   of	   tumor-­‐induced	   food	   aversion.	  Finally,	   we	   highlighted	   the	   therapeutic	   efficacy	   of	   ghrelin-­‐based	   approaches	   in	   the	  context	   of	   CACS	   by	   demonstrating	   the	   anti-­‐CACS	   effects	   of	   the	   novel	   ghrelin	   analog	  HM01.	  	  
8.2  The relevance of brainstem and central GLP-1 signaling in CACS 	  
8.2.1  The AP but not vagal afferents mediate CACS 	  The	  major	   goal	   of	   the	   first	   publication	   (i.e.	   chapter	  5)	  presented	   in	   this	   thesis	  was	   to	  explore	   the	  relative	  contribution	  of	  AP	  and	  vagal	  afferents	   in	   the	  central	  mediation	  of	  CACS	   in	   hepatoma	   TB	   rats.	   By	   using	   advanced	   surgical	   approaches,	   we	   provided	  evidence	   that	   the	   AP	   is	   required	   for	   the	   central	   mediation	   of	   CACS	   in	   this	   model.	  Although	   changes	   in	   metabolic	   rate	   were	   not	   detected,	   the	   surgical	   lesion	   of	   the	   AP	  markedly	   attenuated	   cancer-­‐dependent	   muscle	   degradation.	   This	   result	   is	   clinically	  relevant	   as	   loss	   of	   muscle	   mass	   is	   one	   of	   the	   most	   severe	   consequences	   of	   CACS.	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Excessive	   muscle	   wasting	   compromises	   daily	   activities	   by	   increasing	   fatigue	   and	  weakness,	  which	  reduce	  quality	  of	  life	  [7].	  In	  addition	  to	  its	  physical	  impact,	  muscle	  loss	  is	   also	   linked	   with	   an	   increase	   in	   chemotherapy-­‐related	   side-­‐effects	   and	   decreased	  survival	   rates	   [243].	  The	  attenuation	  of	  anorexia	   induced	  by	   the	   lesion	  of	   the	  AP	  may	  contribute	  to	  the	  observed	  effects	  on	  muscles,	  suggesting	  that	  increased	  energy	  intake	  is	  able	  to	  partly	  counteract	  the	  tumor-­‐induced	  muscle	  loss	  in	  this	  model.	  In	  contrast,	  SDA	  did	  not	  affect	  CACS,	  indicating	  that	  the	  central	  mediation	  of	  CACS	  does	  not	  require	  vagal	  afferents	  signaling	  in	  this	  model.	  This	  is	  rather	  surprisingly	  given	  the	  importance	  of	  the	  vagus	  in	  the	  transmission	  of	  acute	  sickness,	  toxic	  and	  noxious	  signals	  to	   the	  brain.	  However,	  most	  of	   the	   studies	   investigating	   the	   involvement	  of	   the	  vagus	  nerve	  in	  this	  context	  were	  conducted	  in	  acute	  models	  of	  sickness,	  e.g.,	  LPS,	  and	  cisplatin	  treatments	  or	  injection	  of	  pro-­‐inflammatory	  cytokines	  [244-­‐248].	  Only	  two	  previous	  studies	  investigating	  the	  role	  of	  AP	  and	  vagal	  afferent	  signaling	  in	  the	  context	  of	  CACS	  were	  conducted	   in	   the	  past.	  However,	   the	   lesioning	  approach	  used	   in	  these	  studies	  (i.e.	  thermal	  lesion)	  was	  not	  specific	  for	  the	  AP	  because	  the	  lesion	  included	  major	  parts	  of	  the	  NTS	  [249].	  Furthermore,	  the	  experimental	  procedures	  used	  to	  block	  vagal	   afferent	   signaling	   (i.e.	   perivagal	   capsaicin	   injection	   and	   total	   subdiaphragmatic	  vagotomy)	  were	  also	  not	   specific	   and	   selective	   [250].	   In	   addition,	   the	   results	  of	   these	  studies	  are	  probably	  the	  consequences	  of	  increased	  estrogen	  levels	  rather	  than	  specific	  tumor-­‐dependent	  signaling	  mechanisms.	  In	  our	  studies,	  the	  AP	  was	  removed	  via	  vacuum	  aspiration,	  allowing	  the	  specific	  removal	  of	   the	   AP	   without	   damaging	   the	   NTS	   and	   thus	   compromising	   its	   structural	   integrity	  [114].	   In	   addition,	   to	   surgically	   disrupt	   vagal	   afferent	   signaling,	   we	   used	   the	   SDA	  technique.	   SDA	   is	   the	   most	   specific	   surgical	   deafferentation	   method	   available	   and	  consists	   in	   a	   unilateral	   intracranial	   transection	   of	   the	   vagal	   afferent	   rootlets	   and	   an	  ipsilateral	  transection	  of	  the	  dorsal	  subdiaphragmatic	  trunk	  of	  the	  vagus	  nerve.	  Hence,	  this	  procedure	  disrupts	  all	  subdiaphragmatic	  vagal	  afferents	  while	  leaving	  half	  of	  vagal	  efferents	   intact,	   minimizing	   the	   impairment	   of	   gastrointestinal	   motor	   function	   that	  usually	   occurs	   following	   complete	   vagotomies	   [251].	   Altogether,	   the	   combination	   of	  both	  approaches	  allowed	  us	  to	  dissociate	  the	  contribution	  of	  the	  AP	  from	  vagal	  afferents	  in	  a	  model	  that	  mimics	  better	  the	  situation	  in	  human	  cancer	  patients.	  In	   conclusion,	  our	   findings	  demonstrate	   the	   importance	  of	   the	  AP	   in	   the	  mediation	  of	  cancer-­‐dependent	   anorexia	   and	   body	   weight	   loss.	   The	   underlying	   local	   neuronal	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signaling	   within	   the	   AP/NTS	   region	   (e.g.	   GLP-­‐1)	   represents	   promising	   therapeutic	  targets	  for	  the	  treatment	  of	  CACS.	  	  	  	  	  	  
8.2.2  GLP-1 expressing neurons in NTS mediate CACS 	  The	  overall	  aim	  of	  the	  second	  set	  of	  studies	  (i.e.	  chapter	  6)	  was	  to	  identify	  the	  putative	  neuronal	  mechanism	  responsible	   for	   the	  previously	  observed	  AP-­‐dependent	  effects	   in	  this	  model	   for	  CACS.	  These	   studies	  provided	   the	   first	   evidence	   that	   the	   central	  GLP-­‐1	  system	   is	   required	   for	   cancer	   anorexia	   and	   body	   weight	   loss	   in	   hepatoma	   TB	   rats.	  Specifically,	  a	  pharmacological	  blockade	  of	  the	  brainstem	  GLP-­‐1R	  signaling,	  as	  well	  as	  a	  genetic	  inhibition	  of	  the	  NTS	  GLP-­‐1	  production,	  attenuated	  anorexia,	  body	  weight	  loss,	  muscle	  mass	  loss	  and	  fat	  mass	  wasting	  induced	  by	  tumor	  growth.	  Both	  approaches	  did	  not	  affect	   food	   intake	  and	  body	  weight	  under	  non-­‐pathological	   conditions,	  underlying	  the	   specific	   role	   of	   GLP-­‐1	   in	   the	   etiology	   of	   CACS	   in	   this	   model.	   These	   results	  complement	  our	  findings	  of	  the	  involvement	  of	  the	  AP	  in	  CACS	  and	  also	  support	  the	  role	  of	  GLP-­‐1	  signaling	  within	   the	  AP/NTS	   for	   the	  mediation	  of	  CACS	   in	   this	  model.	   In	   line	  with	  the	  importance	  of	  GLP-­‐1	  signaling	  in	  the	  mediation	  of	  aversion,	  emesis	  and	  nausea,	  we	  also	  provided	  evidence	  demonstrating	  the	  presence	  of	  food	  aversion	  during	  CACS	  in	  hepatoma	  TB	  rats.	  	  	  The	   outcomes	   of	   the	   pharmacological	   and	   genetic	   blockade	   of	   brainstem	   GLP-­‐1	  signaling	   were	   similar.	   In	   both	   studies,	   tumor-­‐induced	   anorexia	   was	   markedly	  attenuated.	  Moreover,	  either	  a	  positive	  treatment	  effect	  on	  lean	  mass	  or	  muscle	  mass	  in	  addition	  to	  a	  preservation	  of	  fat	  mass	  was	  observed.	  	  Ex-­‐9	  did	  not	  alter	  metabolic	  rate	  in	  TB	   rats.	   The	   anti-­‐CACS	   effect	   of	   GLP-­‐1	   blockade	   is	   primarily	   based	   on	   higher	   food	  intake,	   which	   consequently	   leads	   to	   a	   preservation	   of	   fat	   mass	   and	   lean	   mass.	  Collectively,	   the	   use	   of	   pharmacological	   and	   genetic	   approaches	   strengthened	   the	  relevance	  of	  GLP-­‐1	  signaling	   in	   the	  etiology	  of	  CACS.	  Furthermore,	   the	  outcome	  of	   the	  PPG	  knockdown	   (PPG-­‐KD)	   study	   confirmed	   the	   contribution	  of	  NTS-­‐derived	  GLP-­‐1	   in	  the	   central	   mediation	   of	   CACS,	   further	   supporting	   the	   crucial	   role	   of	   brainstem	  structures	  in	  the	  pathophysiology	  of	  CACS.	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At	   least	   in	   lean	   ad	   libitum	   fed	   rats,	   the	   blockade	   of	   brainstem	   GLP-­‐1R	   did	   not	   affect	  energy	  intake	  or	  body	  weight	  development	  [144,	  224,	  225].	  Our	  findings	  are	  consistent	  with	   these	   studies	   since	   neither	   Ex-­‐9	   treatment	   nor	   PPG-­‐KD	   affected	   food	   intake	   or	  body	  weight	   in	   healthy	   rats.	   Based	   on	   these	   observations,	   brainstem	   GLP-­‐1	   does	   not	  seem	   to	   be	   required	   for	   the	   maintenance	   of	   energy	   balance	   in	   healthy	   animals	  maintained	  under	   normal	   conditions.	  Hence,	   the	   anti-­‐CACS	   effects	   described	  here	   are	  due	   to	  a	   specific	  blockade	  of	  a	  pathological	  activation	  of	   the	  brainstem	  GLP-­‐1	  system,	  and	   not	   secondary	   to	   alterations	   in	   eating	   behavior	   unrelated	   to	   CACS	   per	   se.	   	   The	  central	   GLP-­‐1	   inhibition	   does	   not	   compromise	   the	   normal	   control	   of	   eating	   but	  selectively	   blocks	   the	   tumor-­‐dependent	   anorectic	   mechanisms	   that	   override	  physiological	  signaling.	  	  	  
8.2.3  Central GLP-1 signaling in cancer-related malaise  
	  Previous	   studies	   conducted	   in	   rodents	   demonstrated	   the	   development	   of	   CTA	   as	   a	  consequence	  of	  cancer	   [236,	  252].	  Our	  results	  are	   in	   line	  with	   these	  previous	  reports.	  TB	   rats	   avoided	   the	   flavour	   that	  was	   preferred	   before	   tumour	   growth	   and	   presented	  during	   the	   conditioning	   phase,	   clearly	   showing	   the	   development	   of	   CTA.	   	   Evidence	  suggests	   that	   the	   central	   GLP-­‐1	   system	   is	   implicated	   in	   malaise,	   nausea	   and	   in	   the	  mediation	  of	  aversion,	  which	  contribute	  to	  the	  reduction	  of	  appetite	  and	  energy	  intake	  induced	   by	   different	   toxic	   agents	   [141,	   142,	   144].	   Whether	   the	   suppression	   of	   food	  intake	   that	   occurred	   in	   TB	   animals	   is	   due	   to	   CTA	   is	   difficult	   to	   examine	   under	   our	  experimental	   conditions.	   The	   severity	   of	   the	   anorectic	   response	   was	   not	   decreased	  when	  the	  diet	  was	  changed	  or	  an	  additional	  diet	  was	  offered,	  indicating	  that	  changes	  in	  the	  diet’s	  flavour	  did	  not	  attenuate	  anorexia.	  Nevertheless,	  our	  results	  point	  to	  a	  GLP-­‐1	  dependent	  mediation	  of	  CTA,	  which	  could	  be	  examined	  by	  combining	  GLP-­‐1	  blockade	  with	  a	  CTA	  paradigm.	  Food	  aversion	  following	  malaise	  is	  a	  known	  phenomenon,	  which	  not	  only	  occurs	  under	  experimental	  conditions	  but	  also	  in	  cancer	  patients	  and	  may	  act	  together	  with	  anorexia	  to	  suppress	  appetite	  and	  energy	  intake	  [106,	  234].	  The	  development	  of	  CTA,	  nausea	  and	  emesis	   can	   be	   a	   consequence	   of	   the	   cancer	   itself	   but	   also	   secondary	   to	   anti-­‐cancer	  treatments	  [234-­‐239].	  For	  instance,	  chemotherapeutic	  agents	  are	  often	  accompanied	  by	  
	   89	  
these	  severe	  side	  effects,	  which	  reduce	  quality	  of	  life	  and	  may	  lead	  to	  treatment	  delays	  or	   even	   treatment	   abortion	   [253].	   Chemotherapy-­‐induced	   nausea,	   food	   aversion	   and	  vomiting	  are	  ranked	  as	  the	  biggest	  patients	  concerns	  in	  anticipation	  of	  cancer	  treatment	  [254].	   More	   than	   90%	   of	   patients	   treated	   with	   cisplatin	   suffer	   from	   chemotherapy-­‐induced	  nausea,	  food	  aversion	  and	  vomiting,	  and	  approximately	  50%	  develop	  profound	  anorexia,	   which	   still	   persists	   despite	   anti-­‐emetic	   pharmacological	   treatments	   [255,	  256].	   Indeed,	   both	   serotonin	   and	   neurokinin-­‐1	   receptor	   antagonists,	   two	   classes	   of	  antiemetic	  medications,	  reduce	  acute	  chemotherapy-­‐induced	  emesis	  and	  nausea	  but	  fail	  to	   effectively	   suppress	   the	   delayed	   malaise	   phase	   that	   persist	   up	   to	   7	   days	   after	  chemotherapy	  [257-­‐260].	  	  	  The	   central	   GLP-­‐1	   system	   is	   activated	   by	   cisplatin,	   and	   brainstem	   GLP-­‐1R	   signaling	  partially	   mediates	   the	   delayed	   malaise	   phase	   [142].	   Our	   findings	   complement	   the	  outcomes	   of	   this	   study	   and	   highlight	   the	   possibility	   that	   brainstem	   GLP-­‐1	   might	   be	  common	   mediator	   of	   anorexia	   and	   malaise	   in	   different	   chronic	   disease	   models,	  including	  chemotherapy-­‐induced	  malaise	  and	  CACS.	  	  
8.2.4  Translation of GLP-1-based approaches to human cancer patients  	  The	  surgical	  removal	  of	  the	  AP	  in	  human	  cancer	  patients	  is	  not	  an	  option.	  	  Although	  AP	  lesions	  in	  humans	  were	  performed	  in	  the	  past	  to	  treat	  continuous	  nausea	  and	  vomiting,	  the	   side	   effects	   were	   severe	   [96].	   A	   pharmacological	   inhibition	   of	   the	   neuronal	  population	  that	  is	  activated	  during	  cancer	  (i.e.	  GLP-­‐1R-­‐expressing	  neurons)	  obviously	  is	  a	   better	   approach.	   Although	   we	   did	   not	   perform	   peripheral	   Ex-­‐9	   treatments	   in	   our	  current	   studies,	   GLP-­‐1	   and	   its	   agonists	   can	   target	   GLP-­‐1R	   located	   in	   the	   AP	   after	  peripheral	   administration	   [94,	   125,	   261,	   262].	   Therefore,	   one	   can	   assume	   that	   Ex-­‐9	  would	   exert	   its	   central	   effects	   after	   peripheral	   administration	   as	   well.	   Furthermore,	  systemic	  administration	  of	  Ex-­‐9	  could	  have	  additional	  peripheral	  effects	  that	  were	  not	  engaged	  after	   central	  delivery.	   Increased	  expression	  of	  uncoupling	  proteins	   (UCPs)	   in	  white	   and	   brown	   adipose	   tissues	   as	  well	   in	  muscles	   has	   been	   suggested	   as	   potential	  contributing	   factors	   to	   CACS	   [263-­‐265].	   Although	   the	   physiological	   and	   pathological	  relevance	  of	  UCPs	   in	  muscles	   still	   requires	  deeper	   investigation,	  peripheral	   treatment	  with	   Ex-­‐4	   increased	   energy	   expenditure	   by	   upregulating	   UCP-­‐1	   expression	   in	  muscle	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likely	  via	  a	  direct	  mechanism	  [233].	  Therefore,	  inhibition	  of	  peripheral	  GLP-­‐1	  signaling	  could	   potentially	   counteract	   muscle	   mass	   loss	   by	   decreasing	   energy	   expenditure	   in	  CACS	  patients.	  Importantly,	  GLP-­‐1-­‐based	  approaches	   could	  be	  more	   specific	   and	  may	  have	   less	   side-­‐effects	   compared	   to	   the	   current	   therapeutic	   options.	   For	   instance,	   megestrol	   acetate	  treatment,	   the	  most	  used	  drug	   for	   the	   treatment	  of	  CACS,	   is	   linked	  with	   serious	   side-­‐effects	   that	  may	  compromise	   life	  quality,	   such	  as	  nausea,	   vomiting	  and	  confusion,	  but	  also	  many	  severe	   life	   threatening	  side	  effects	   including	  pulmonary	  edema,	   thrombosis	  and	   heart	   failure	   [17].	   In	   contrast,	   the	   only	   potential	   side	   effect	   noticed	   during	   Ex-­‐9	  treatment	  in	  healthy	  and	  obese	  humans	  so	  far	  was	  a	  mild	  hyperglycemic	  state,	  which	  it	  can	   be	   easily	   be	   prevented	   by	   insulin	   co-­‐administration	   [266-­‐268].	   While	   more	   pre-­‐clinical	  and	  clinical	  studies	  in	  the	  context	  of	  cancer	  are	  required	  to	  shed	  more	  light	  on	  the	  beneficial	  effects	  of	  Ex-­‐9	  peripheral	  treatment	  as	  well	  as	   its	  safety	  and	  its	  efficacy,	  our	   findings	   suggest	   that	   GLP-­‐1R	   antagonists	   may	   be	   therapeutically	   useful	   for	   the	  treatment	  of	  CACS	  in	  humans.	  	  
8.2.5  Downstream projection sites of tumor-activated AP/NTS neurons as 
potential therapeutic targets for the treatment of CACS 
	  The	  PBN	  is	  an	  important	  downstream	  target	  of	  signals	  originated	  in	  the	  AP/NTS	  region	  following	   different	   anorectic	   stimuli	   (e.g.	   amylin,	   CCK,	   LiCl,	   LPS)	   and	   its	   role	   in	   the	  regulation	  of	  eating	  and	  in	  the	  mediation	  of	  anorexia	  and	  CTA	  is	  well	  established	  [269-­‐272].	  c-­‐Fos	  expression	   in	  the	  PBN	  was	  observed	  in	  hepatoma	  TB	  rats.	   In	  particular,	  c-­‐Fos	  labeling	  was	  located	  in	  the	  external	  lateral	  nucleus	  (i.e.	  LPBN),	  corresponding	  to	  the	  main	   ascending	   terminal	   target	   of	   the	  medial	   part	   of	   the	  NTS	   and	   the	  AP	   [111].	   This	  strongly	  suggests	  that	  activated	  AP/NTS	  neurons	  are	  directly	  involved	  in	  the	  activation	  of	   LPBN	   neurons.	   Thus,	   the	   LPBN	   is	   a	   potential	   site	   where	   neuronal	   signals	   may	  converge	  and	  trigger	  reduced	  eating.	  	  A	   population	   of	   LPBN	   neurons	   expresses	   the	   calcitonin	   related	   peptide	   (CGRP)	   and	  sends	   projections	   to	   different	   brain	   areas	   including	   the	   central	   amygdala.	   Central	  injection	  of	  CGRP	  in	  the	  amygdala	  reduced	  food	  intake,	  while	  inhibition	  of	  LPBN	  CGRP	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neurons	  blunted	  anorexia	  induced	  by	  the	  satiation	  hormone	  CCK	  as	  well	  other	  anorectic	  substances	  such	  as	  LiCl	  [273].	  Conversely,	  activation	  of	  CGRP	  LPBN	  neurons	  decreases	  feeding	   [271].	   Surgical,	   pharmacological	   and	  genetic	   apporaches	   such	  as	  LPBN	   lesion,	  selective	  LPBN	  CGRP	  knockdown	  and	  central	  CGRP	  receptor	  antagonist	   treatment	  can	  be	  use	  to	  investigate	  the	  involvement	  of	  LPBN	  CGRP	  signaling	  in	  hepatoma	  TB	  rats	  and	  possibly	  link	  the	  signals	  originating	  in	  the	  AP/NTS	  with	  the	  CGRP	  signaling	  in	  the	  LPBN.	  If	   this	   hypothesis	   is	   correct,	   pharmacological	   approaches	   targeting	   CGRP	   signaling	  might	  represent	  another	  potential	  therapeutic	  option	  for	  the	  treatment	  of	  CACS.	  	  
8.2.6   MIC-1 as the putative humoral factor mediating CACS 	  The	   inflammatory	  peripheral	  mediator	   responsible	   for	   the	  neuropathological	   changes	  following	   tumor	   growth	   was	   unknown	   in	   this	   model,	   as	   no	   “classical”	   inflammatory	  cytokine	   was	   increased	   in	   the	   circulation	   [111].	   We	   identified	   MIC-­‐1	   as	   a	   potential	  mediator	   of	   CACS	   in	   hepatoma	   TB	   rats	   by	   showing	   that	   MIC-­‐1	   levels	   were	   elevated	  during	   cancer.	   Moreover,	   its	   levels	   correlated	   with	   the	   severity	   of	   the	   anorectic	  response,	   tumor	   progression	   and	   tumor	   weight.	   Further	   studies	   are	   still	   required	   to	  demonstrate	   a	   direct	   involvement	   of	   MIC-­‐1	   in	   the	   pathophysiology	   of	   CACS	   in	   this	  model.	  Unfortunately,	  MIC-­‐1	  binds	  to	  an	  orphan	  receptor.	  Hence	  its	  receptor	  cannot	  be	  targeted	  by	  antagonists	  to	  confirm	  that	  endogenous	  MIC-­‐1	  signaling	  is	  required	  for	  the	  central	   mediation	   of	   CACS	   in	   our	   model	   [39].	   At	   present,	   gene-­‐targeting	   approaches	  appear	   to	   be	   the	   only	   practicable	   method	   to	   chronically	   disrupt	   MIC-­‐1	   signaling	   in	  rodents.	   While	   such	   studies	   have	   not	   yet	   been	   conducted,	   our	   results	   are	   consistent	  with	  previous	   findings	  showing	   that	   the	  anorectic	  effect	  of	  exogenous	  MIC-­‐1	  required	  an	  intact	  AP/NTS	  [101].	  	  	  
8.2.7  Proposed mechanism for CACS in hepatoma TB rats  	  The	   results	   obtained	   following	   genetic	   or	  pharmacological	   inhibition	  of	   central	  GLP-­‐1	  signaling	  are	  similar	  to	  those	  of	  our	  AP-­‐lesion	  study	  in	  respect	  to	  many	  of	  the	  measured	  parameters.	   Consequently,	   the	   comparable	   outcomes	   of	   these	   studies	   are	   consistent	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with	   the	   hypothesis	   that	   CACS	   in	   this	   model	   is	   mediated	   by	   GLP-­‐1-­‐ergic	   projections	  from	  the	  NTS	  to	  the	  AP.	  One	  could	  speculate	  that	  other	  brain	  areas	  that	  are	  targeted	  by	  NTS	   GLP-­‐ergic	   projections	  might	   also	   contribute	   to	   the	  mediation	   of	   CACS.	   However,	  due	  to	  the	  rostral-­‐to-­‐caudal	  flow	  of	  the	  cerebrospinal	  fluid,	  Ex-­‐9	  infused	  into	  the	  fourth	  ventricle	  is	  unlikely	  to	  efficiently	  block	  GLP-­‐1R	  signaling	  in	  forebrain	  structures.	  Although	  GLP-­‐1	  signaling	  in	  the	  AP/NTS	  region	  was	  identified	  as	  crucial	  for	  the	  central	  mediation	  of	  CACS	  in	  this	  model,	  the	  underlying	  mechanism	  that	  stimulates	  NTS	  GLP-­‐1	  neurons	  and	  that,	  leads	  to	  the	  activation	  of	  the	  AP/NTS	  region,	  still	  remains	  unknown.	  As	   mentioned	   in	   the	   introduction,	   growing	   evidence	   suggests	   a	   role	   of	   MIC-­‐1	   in	   the	  central	   mediation	   of	   CACS	   via	   AP/NTS	   signaling.	   Direct	   conclusive	   evidence	   is	   still	  lacking.	  MIC-­‐1	  responsive	  neurons	  in	  the	  NTS	  are	  mostly	  non-­‐catecholaminergic	  [101].	  Interestingly,	   NTS	   GLP-­‐1	   neurons	   do	   not	   co-­‐express	   catecholaminergic	  neurotransmitters	  [222].	  These	  observations	  suggest	  a	  possible	  functional	  link	  between	  MIC-­‐1,	   AP/NTS	   activation	   and	   brainstem	   GLP-­‐1-­‐mediated	   mediation	   of	   CACS.	   	   The	  dendrites	  of	  NTS	  GLP-­‐1	  neurons	  extend	   into	   the	  AP	   [131].	  Thus,	  MIC-­‐1	   could	  directly	  activate	  GLP-­‐1	  expressing	  neurons	   in	   the	  NTS.	  This	  may	  then	   lead	  to	   the	  activation	  of	  GLP-­‐1R	  expressing	  neurons	  in	  the	  AP	  and	  in	  its	  downstream	  projection	  sites	  (e.g.	  LPBN)	  that	  are	  involved	  in	  the	  control	  of	  food	  intake	  (Fig.	  1).	  	  	  	  
	  
Fig.	  1.	  Proposed	  mechanism	  for	  CACS	   in	  hepatoma	  TB	  rats:	  MIC-­‐1	  directly	  activates	  GLP-­‐1	  expressing	  
neurons	   located	   in	   the	  NTS.	   This	   leads	   to	  GLP-­‐1	   release	   in	   the	  AP	  and	  a	   subsequent	   activation	   of	  GLP-­‐1R	  
neurons.	  The	  signal	   is	   then	  transmitted	  to	  downstream	  target	  areas	   involved	   in	  the	  control	  of	   food	   intake,	  





Nucleus	  tractus	  solitarii 
Area	  postrema Downstream	  targets (e.g.	  LPBN) 
Anorexia 
Body	  weight	  loss	   
Aversion 
	  
Bloodborne	  mediators (e.g.	  MIC-­‐1) 	   	  
	  
	   	  GLP-­‐1	   
GLP-­‐1R	   
	   93	  
8.3  The evaluation of the ghrelin analog HM01 for the treatment of 
CACS 
	  Ghrelin-­‐based	   approaches	   represent	   a	   promising	   strategy	   for	   the	   treatment	   of	   CACS.	  The	  positive	  effects	  of	  ghrelin	  treatments	  have	  been	  demonstrated	  in	  different	  models	  for	  CACS,	  as	  well	  as	  in	  human	  cancer	  patients	  (see	  table	  1).	  Unfortunately,	  however,	  the	  clinical	  use	  of	  ghrelin	  is	  limited	  due	  to	  its	  short	  halftime	  and	  its	  peptidergic	  nature	  that	  excludes	  its	  oral	  delivery.	  	  Our	  manuscript	  (i.e.	  chapter	  7)	  provided	  the	  first	  characterization	  of	  the	  synthetic	  GHSR	  agonist	  HM01	  in	  the	  context	  of	  CACS.	  Our	  major	  aim	  was	  to	  evaluate	  the	  ability	  of	  the	  novel	   ghrelin	   agonist	   HM01	   to	   counteract	   tumor-­‐induced	   anorexia	   and	   body	   weight	  loss.	   	  We	  demonstrated	   that	  HM01	   increased	   food	   intake	   and	  body	  weight	   in	  healthy	  rats.	  Moreover,	  HM01	  also	  improved	  both	  total	  fat	  and	  lean	  volumes	  and	  gastrocnemius	  mass.	  More	  importantly,	  HM01	  was	  proven	  effective	  in	  preventing	  tumor-­‐induced	  body	  weight	   loss	   and	  muscle	   degradation	   by	   attenuating	   anorexia	   and	   by	   reducing	   energy	  expenditure.	  	  	  
8.3.1  HM01 attenuated tumor-induced anorexia and reduced energy 
expenditure  	  There	   is	   some	   evidence	   for	   a	   decreased	   responsiveness	   to	   ghrelin	   treatment	   under	  tumor	   conditions.	   In	   fact,	   systemic	   and	   central	   ghrelin	   administration	   in	   different	  rodent	  models	  for	  CACS	  failed	  to	  stimulate	  eating	  if	  compared	  to	  healthy	  controls	  [166,	  274].	   This	   lack	   of	   ghrelin	   responsiveness	  was	   also	   observed	   in	   cancer	   patients	   [275].	  Furthermore,	   in	   some	   models	   for	   CACS,	   which	   are	   characterized	   by	   higher	   levels	   of	  ghrelin,	   increased	   endogenous	   serum	   ghrelin	   levels	   accompanied	   this	   reduced	  effectiveness	  [166,	  274,	  276].	  These	  findings	  might	  indicate	  a	  state	  of	  ghrelin	  resistance	  or	   at	   least	   reduced	   ghrelin	   responsiveness	   under	   tumor	   conditions.	   However,	   in	  contrast	   to	   what	   has	   been	   observed	   in	   these	   studies,	   the	   relative	   increase	   in	   eating	  observed	  in	  HM01-­‐treated	  TB	  rats	  was	  comparable	  to	  the	  increase	  observed	  in	  healthy	  animals.	  Further,	  under	  our	  testing	  conditions,	  the	  effects	  of	  HM01	  on	  eating	  and	  body	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weight	  persisted	  until	   the	  end	  of	   the	  experiment.	  For	   these	  reasons,	  or	   results	  do	  not	  suggest	  the	  presence	  of	  a	  profound	  ghrelin	  resistance.	  Interestingly,	  HM01-­‐treatment	  reduced	  energy	  expenditure.	  While	  the	  ghrelin	  effects	  on	  energy	   expenditure	   are	   known,	   our	   study	   is	   the	   first	   showing	   a	   beneficial	   effect	   of	   a	  ghrelin-­‐based	   therapy	   on	   energy	   expenditure	   in	   the	   context	   of	   CACS.	   Therefore,	   the	  observed	   preservation	   of	   body	  weight	   following	   tumor-­‐induction	   could	   be	   partly	   the	  consequence	  of	  both	  higher	  food	  intake	  and	  reduced	  energy	  metabolism.	  	  
8.3.2   HM01 prevents muscle mass degradation 	  HM01	   not	   only	   stimulated	   muscle	   growth	   in	   healthy	   animals	   but	   it	   also	   increased	  muscle	   mass	   in	   TB	   rats.	   As	   mentioned	   in	   the	   introduction,	   ghrelin	   exerts	   anabolic	  actions	   via	   GH/IGF-­‐1	   signaling.	   Since	   HM01	   is	   a	   potent	   stimulator	   of	   GH	   release	  (Helsinn	  Healthcare	  SA,	  unpublished	  findings),	  the	  beneficial	  effect	  of	  HM01	  on	  muscle	  mass	   is	   likely	   to	   be	   at	   least	   be	   partly	   mediated	   by	   increased	   GH/IGF-­‐1	   signaling,	  although	  future	  studies	  are	  required	  to	  confirm	  this.	  	  In	  addition	  to	  its	  orexigenic	  and	  anabolic	  actions,	  ghrelin-­‐based	  approaches	  might	  have	  additional	   anti-­‐CACS	   properties	   due	   to	   ghrelin’s	   anti-­‐inflammatory	   properties	   [277].	  Hence,	   HM01-­‐induced	   inhibition	   of	   central	   and	   peripheral	   inflammatory	   signaling	  cascades	  might	   not	   only	   indirectly	   blunt	  muscle	   degradation	  by	   attenuating	   anorexia,	  but	  also	  prevent	  direct	  cytokine-­‐mediated	  muscle	  wasting.	  The	  only	  circulating	  cytokine	  that	  was	  found	  evaluated	  in	  this	  model	  was	  MIC-­‐1.	  No	  increase	  in	  systemic	  levels	  of	  IL-­‐6,	  TNF-­‐α,	  IL-­‐1β	  and	  IFN-­‐γ,	  IL-­‐6	  has	  been	  reported	  [111].	  Therefore,	  it	  is	  unlikely	  that	  the	  effects	  observed	  in	  our	  study	  are	  due	  to	  HM01	  anti-­‐inflammatory	  actions.	  Other	  models,	  characterized	  by	   systemic	   cytokine	   release,	   are	  more	  appropriate	   for	   testing	   the	  anti-­‐inflammatory	  properties	  of	  HM01.	  Similar	  studies	  using	  the	  mouse	  C26	  model,	  which	  is	  characterized	   by	   systemic	   cytokine	   release,	   showed	   a	   reduction	   of	   TNF-­‐α,	   and	   IL-­‐1β	  levels	   after	   ghrelin	   administration	   [79].	   HM01	   treatment	   in	   those	   animals	   increased	  food	   intake,	  body	  weight,	   fat	  and	  muscle	  mass	  while	   it	  decreased	  energy	  expenditure.	  These	  effects	  appeared	  to	  be	  independent	  of	  the	  potential	  anti-­‐inflammatory	  effects	  of	  HM01	  as	  IL-­‐6,	  MIC-­‐1,	  MuRF-­‐1	  or	  MAFbx	  levels	  were	  not	  affected	  by	  the	  treatment	  [278].	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8.3.3  The efficacy of ghrelin-based therapies was recently confirmed in phase 
III studies 	  The	  use	  of	  ghrelin-­‐based	  therapies	  to	  effectively	  prevent	  and	  reverse	  CACS	  in	  humans	  was	   substantiated	   by	   two	   randomized,	   double-­‐blind	   phase	   III	   clinical	   trials	   (i.e.	  ROMANA	  1	  and	  ROMANA	  2)	  [205].	  In	  these	  studies,	  which	  are	  so	  far	  the	  largest	  and	  the	  longest	   trial	   conducted	   in	   the	   context	   of	   CACS,	   the	   novel,	   orally	   available,	   peptide-­‐derived	  ghrelin	  mimetic	  anamorelin	  was	  tested.	  Anamorelin	  was	  administered	  daily	  for	  12	   weeks	   in	   patients	   with	   inoperable	   non-­‐small-­‐cell	   lung	   cancer	   and	   CACS.	   Patients	  receiving	   anamorelin	   increased	   body	   weight	   and	   lean	   mass	   but	   also	   had	   an	  improvement	   in	   their	   anorexia	   symptoms	   (e.g.	   appetite,	   nausea	   and	   food	   aversion),	  which	   were	   evaluated	   using	   the	   Functional	   Assessment	   of	   Cancer	   Therapy	   (FACT)	  questionnaire	   [279].	   Unfortunately,	   anamorelin	   failed	   to	   show	   significant	  improvements	   in	  muscle	   strength	   and	   fatigue,	   probably	   as	   a	   consequence	   of	   the	   high	  degree	  of	  subject	  variability	  and	  cancer	  treatments.	  Although	  HM01	  was	  not	   tested	   in	  humans	  yet,	   pre-­‐clinical	   studies	   anticipate	  a	  higher	  brain	   permeability	   and	   bioavailability	   of	   HM01	   compared	   to	   anamorelin	   (Helsinn	  Healthcare	  SA,	  unpublished	  results).	  Hence,	  one	  could	  assume	  that	  HM01	  would	  have	  a	  greater	   impact	   on	   increasing	   eating	   and	   GH-­‐release	   and	   on	   decreasing	   energy	  expenditure.	   If	   this	  were	   confirmed	   in	  humans,	  HM01	  might	   represent	  a	   fundamental	  step	  toward	  a	  more	  efficient	  clinical	  management	  of	  CACS.	  	  
8.3.4  Ghrelin and ghrelin mimetics are safe and well tolerated in humans 	  One	   of	   the	   major	   concerns	   regarding	   ghrelin-­‐based	   approaches	   is	   the	   possibility	   to	  promote	  tumor	  growth	  via	  GH/IGF-­‐1	  signaling.	  Nevertheless,	  all	  experiments	  conducted	  in	   different	   rodent	   models	   have	   so	   far	   demonstrated	   the	   safety	   of	   ghrelin-­‐based	  therapeutic	  approaches	  without	  evidence	  of	   increased	  tumor	  progression	   following	  1-­‐14	  days	  of	  treatment	  [280-­‐283].	  The	  lack	  of	  differences	  in	  tumor	  weight	  in	  our	  study	  is	  in	  line	  with	  these	  findings.	  Even	  more	  significant	  are	  recent	  clinical	  data	  revealing	  that	  the	  overall	  survival,	  tumor	  size	  or	  tumor	  progression	  markers	  were	  not	  increased	  after	  sustained	   and	   prolonged	   treatment	   with	   ghrelin	   or	   ghrelin	   mimetics	   [284,	   285].	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Additionally,	  in	  all	  clinical	  studies,	  no	  severe	  side	  effects	  were	  induced	  by	  ghrelin-­‐based	  treatments	   [205,	   275,	   284-­‐287].	   In	   healthy	   subjects	   side	   effects	  were	   extremely	   rare,	  with	  most	  common	  adverse	  events	  being	  mild	  headache	  and	  stomachache,	  which	  both	  regressed	  spontaneously	  [288-­‐291].	  A	  recent	  meta-­‐analysis	  of	  all	  published	  anamorelin	  phase	  II	  and	  phase	  III	  randomized	  trials	  demonstrated	  that	  anamorelin	   induced	  fewer	  adverse	   events	   compared	   to	   placebo	   [292].	   This	   outcome	   confirms	   the	   safety	   and	  tolerability	  of	  anamorelin	  for	  long-­‐term	  applications	  in	  humans.	  One	  can	  speculate	  that	  other	  GHSR	  analogs,	  including	  HM01,	  would	  be	  safe	  and	  tolerated	  in	  cancer	  patients	  as	  well.	  	  
8.4  Significance of these studies for other form of anorexia-cachexia 	  While	  this	  thesis	  focused	  specifically	  on	  CACS,	  it	  needs	  to	  be	  mentioned	  that	  anorexia-­‐cachexia	   syndrome	   (ACS)	   is	   also	   associated	   with	   other	   chronic	   diseases	   such	   as	  bacterial	  and	  parasitic	  infection,	  acquired	  immune	  deficiency	  syndrome	  (AIDS),	  chronic	  obstructive	   pulmonary	   disease	   (COPD),	   chronic	   inflammatory	   bowel	   disease,	   chronic	  liver	   disease,	   chronic	   cardiovascular	   disease,	   rheumatoid	   arthritis	   and	   many	   others.	  Between	  10%	  and	  40%	  of	  patients	  affected	  by	  these	  disorders	  experience	  malnutrition	  and	  loss	  of	  body	  weight	  requiring	  medical	  treatment.	  Altogether,	  in	  the	  US	  alone,	  more	  than	   30	   million	   of	   people	   suffer	   from	   ACS	   [293].	   Moreover,	   anorexia,	   nausea	   and	  vomiting	   are	   caused	   by	   a	   wide	   variety	   of	   pharmacotherapies	   (e.g.	   lithium-­‐based	  psychoactive	  agents	  and	  chemotherapeutic	  drugs).	  The	  GLP-­‐1	  antagonism	  and	  ghrelin-­‐based	   treatment	   approaches	   examined	   here	   focused	   on	   anorexia,	   malaise	   and	   body	  weight	  loss	  in	  the	  context	  of	  cancer.	  However,	  the	  neuronal	  pathways	  investigated	  may	  have	  broader	   implications	   for	   all	   these	  diseases	   and	   treatments	   that	   cause	   these	   side	  effects.	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8.5  Overall conclusions 	  CACS	   severely	   deteriorates	   the	   clinical	   status	   and	   promotes	  morbidity	   and	  mortality	  with	  a	  very	  high	  prevalence	  in	  particular	  types	  of	  cancers	  [1,	  4].	  Importantly,	  CACS	  has	  been	  reported	  by	  cancer	  patients	  to	  be	  the	  major	  detrimental	  factor	  affecting	  quality	  of	  life	  [7].	  Unfortunately,	  the	  clinical	  management	  of	  CACS	  is	  still	  inadequate	  and	  currently	  available	   therapies	  are	   insufficient.	  The	  most	  widely	  used	  drugs	  such	  as	  progesterone	  and	   corticoid-­‐based	   agents	   cause	   only	   a	   transient	   stimulation	   of	   food	   intake	   and	   a	  moderate	   increase	   body	   weight	   and	   failed	   to	   show	   an	   improvement	   in	   the	   general	  quality	  of	  life.	  Unfortunately,	  other	  treatment	  approaches	  have	  not	  yet	  been	  developed	  into	  effective	  therapies	  [8].	  A	  better	  understanding	  of	  the	  pathophysiology	  of	  CACS	  is	  a	  crucial	  step	  towards	  the	  development	  of	  effective	  and	  specific	  therapeutic	  approaches.	  	  In	   this	   dissertation,	   we	   provided	   new	   insight	   on	   the	   pathophysiology	   of	   CACS	   and	  proposed	  different	  strategies	  for	  its	  treatment.	  We	  substantiated	  the	  fundamental	  role	  of	  the	  AP	  in	  the	  mediation	  of	  CACS	  and	  we	  provided	  evidence	  for	  a	  role	  of	  central	  GLP-­‐1	  signaling	  in	  hepatoma	  TB	  rats.	  Furthermore,	  we	  demonstrated	  the	  therapeutic	  efficacy	  of	  the	  novel	  ghrelin	  analog	  HM01	  in	  the	  context	  of	  CACS.	  Both	  ghrelin	  and	  GLP-­‐1-­‐based	  approaches	  represent	  promising	  options	  for	  the	  treatment	  of	  CACS	  and	  possibly	  other	  forms	  of	  disease-­‐related	  anorexia.	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9 List of abbreviations 	  	   AgRP	  
	  
Neuropeptides	  agouti-­‐related	  peptide	  AP	  	  
	  
Area	  postrema	  
	   	  APX	  
	  
Area	  postrema	  lesion	  
	   	  Arc	  
	  
Arcuate	  nucleus	  
	   	  BAT	  
	  
Brown	  adipose	  tissue	  
	   	  BBB	  
	  
Blood-­‐brain	  barrier	  
	   	  CACS	  
	  
Cancer	  anorexia-­‐cachexia	  syndrome	  
	  CART	  	  
	  
cocaine-­‐	  and	  amphetamine-­‐regulated	  transcript	  CCK	  
	  
Cholecystokinin	  
	   	  CGRP	  
	  
Calcitonin	  related	  peptide	  
	  CNS	  
	  
Central	  nervous	  system	  
	   	  CTA	  
	  
Conditioned	  taste	  aversion	  
	  DMN	  
	  




	   	   	  Ex-­‐9	  
	  
Exendin-­‐9	  
	   	   	  GDF15	  
	  




	   	  GHSR	  
	  
Growth	  hormone	  secretagouge	  receptor	  GLP-­‐1	  
	  
Glucagon-­‐like	  peptide-­‐1	  
	   	  GLP-­‐1R	  
	  




	   	  IGF-­‐1	  
	  




	   	  IL-­‐6	  
	  
Interleukin	  6	  
	   	  LiCl	  
	  
Lithium	  chloride	  
	   	  LPBN	  
	  




	   	  MAFbx/atrogin-­‐1	   Muscle	  atrophy	  F-­‐box	  protein	  
	  MC4R	  
	  
Melanocortin	  4	  receptor	  
	   	  MIC-­‐1	  
	  
Macrophage	  inhibitory	  cytokine-­‐1	  
	  
	   99	  
MURF-­‐1	  
	  




	   	   	  NPY	  
	  
Neuropeptide	  Y	  
	   	  NTB	  
	  
Non-­‐tumor-­‐bearing	  
	   	  NTS	  
	  
Nucleus	  tractus	  solitarii	  
	   	  POMC	  
	  
Pro-­‐opiomelanocortin	  
	   	  PPG	  
	  
Pre-­‐pro-­‐glucagon	  
	   	  PVN	  
	  
Paraventricular	  nucleus	  
	   	  RER	  
	  
Respiratory	  exchange	  ration	  
	  sCVO	  
	  
Sensory	  circumventricular	  organs	  
	  SDA	  
	  
Subdiaphragmatic	  vagal	  deafferentation	  STAT	  
	  
Signal	  transducers	  and	  activators	  of	  transcription	  TB	  
	  
Tumor-­‐bearing	  
	   	  TNF-­‐α	  
	  
Tumor	  necrosis	  factor	  α	  
	   	  UCP-­‐1	  
	  
Uncoupling	  protein-­‐1	  
	   	  αMSH	  
	  
α	  melanocyte	  stimulating	  hormone	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